Tokushima University / Educator and Researcher Directory --- Takahashi, Masayuki

Personal Web Page

https://researchmap.jp/read0088068 (researchmap)

Field of Study

○	Medicine

Subject of Study

○

Book / Paper

Book:

1.	Masayuki Takahashi and Hiro-omi Kanayama : 海外のガイドラインと本邦の腎癌診療ガイドライン, NIPPONRINSHOSHA Co.,Ltd., Tokyo, May 2021.
2.	Masayuki Takahashi and Hiro-omi Kanayama : II RCC long-term prognosis RCC薬物療法のリスク分類別長期成績改善の変遷」1. Favorable risk, Dec. 2020.
3.	Masayuki Takahashi and Hiro-omi Kanayama : 腎癌の薬物療法のクリニカル・パール, Oct. 2020. (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413207032 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413207032 (DOI: 10.11477/mf.1413207032)
4.	Masayuki Takahashi and Hiro-omi Kanayama : 高齢者に対する手術の適応と限界高齢者の腎癌に対する手術, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413206934 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413206934 (DOI: 10.11477/mf.1413206934)
5.	Masayuki Takahashi and Hiro-omi Kanayama : 腎癌診療ガイドライン2019年度小改訂のポイント, 科学評論社, Mar. 2020.
6.	Masayuki Takahashi and Hiro-omi Kanayama : II Topics of RCC 「Yes or No ―cytoreductive nephrectomy―」 1.Overview: 転移性RCCに対するcytoreductive nephrectomyの歴史的変遷, Dec. 2019.
7.	Masayuki Takahashi and Hiro-omi Kanayama : 【これ一冊でパーフェクト!!泌尿器科薬物療法】腎癌ソラフェニブ, Apr. 2019.
8.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱への穿通胎盤にて帝王切開，子宮全摘，膀胱部分切除術施行後に骨盤内尿腫を形成し，真性尿失禁をきたした1例, Oct. 2018.
9.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 間質性膀胱炎が疑われ，膀胱水圧拡張術が診断の契機となった膀胱アミロイドーシスの1例, Dec. 2017.
10.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器科処方のすべてーすぐに使える実践ガイド 9腫瘍転移性腎細胞癌, IGAKU-SHOIN Ltd.Tokyo,Japan, Apr. 2016.
11.	Yoshito Kusuhara, Masayuki Takahashi and Hiro-omi Kanayama : 【骨盤部感染症の画像診断-迅速な診断と治療のストラテジー-】泌尿器領域の感染症の臨床像と治療戦略, Dec. 2015.
12.	Masayuki Takahashi and Hiro-omi Kanayama : 長期投与を目指したAEマネジメント 4) アキシチニブ, Medical Review Co.,Ltd, 大阪市, Dec. 2015.
13.	Masayuki Takahashi and Hiro-omi Kanayama : II What's New in RCC 1 Immune Checkpoint阻害剤 3) 抗PD-L1抗体，抗CTLA-4抗体の開発状況, Medical Review Co.,Ltd, Osaka, Feb. 2015.
14.	Masayuki Takahashi, 横田三樹 and Hiro-omi Kanayama : 【レジメンから理解する泌尿器科の化学療法副作用症状コントロール】患者さんへの説明に使える!腎がんの化学療法レジメン, Medicus SHUPPAN, Osaka, Jul. 2014.
15.	Masayuki Takahashi and Hiro-omi Kanayama : 根治的腎摘除術後のadjuvant治療の現状と展望, 医学図書出版, Tokyo, May 2014.
16.	Masayuki Takahashi and Hiro-omi Kanayama : 第17章泌尿器科腫瘍:進行性腎細胞癌の治療 III.手術, 放射線治療等, 日本泌尿器科学会, Mar. 2014.
17.	Masayuki Takahashi and Hiro-omi Kanayama : II.Topics of RCC―分子標的治療の最前線― 2.分子標的治療の実際―診療の現場から:私はこう使っている― スニチニブ③, Oct. 2011.
18.	Masayuki Takahashi and Hiro-omi Kanayama : 前治療歴によるセカンドライン治療のアルゴリズムを探る, SENTAN IGAKU-SHA, Jul. 2011.
19.	Masayuki Takahashi, Hiro-omi Kanayama, 野口京子, 柴山純子 and 谷口啓子 : 【見ること・することリストで一目瞭然!術式別泌尿器科の術前・術後ケア】泌尿器科手術の術前・術後ケア腎臓の手術腎瘻造設術, 2011. (Keyword) 留置カテーテル
20.	Masayuki Takahashi and Bin Teams Teh : Expression Profiling of Human Tumors : Diagnostic and Research Applications, --- 13 Gene Expression Profiling of Renal Cell Carcinoma and its Clinical Implications ---, Humana Press, Totowa, NJ USA, May 2003. (Link to Publication Site) ● Publication site (DOI): 10.1226/1588291227 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1226/1588291227 (DOI: 10.1226/1588291227)

Academic Paper (Judged Full Paper):

1.	Kyotaro Fukuta, Tomoya Fukawa, Saki Kobayashi, Keito Shiozaki, Yutaro Sasaki, Kosuke Seto, Ryoichi Nakanishi, Hirofumi Izaki, Masayuki Takahashi, Kazuya Kanda, Hiro-omi Kanayama and Junya Furukawa : Efficacy of educational stepwise robot-assisted radical prostatectomy procedure for urology residents., Asian Journal of Endoscopic Surgery, Vol.17, No.3, e13334, 2024. (Summary) To evaluate the effectiveness of an educational stepwise robot-assisted radical prostatectomy (RARP) procedure for urology residents. We performed a detailed evaluation of 42 RARP procedures performed by a single urology resident from July 2019 to February 2022. The RARP procedures were divided into the following nine steps: (1) bladder dissection, (2) endopelvic fascia dissection, (3) bladder neck dissection, (4) seminal vesicle dissection, (5) Denonvilliers' fascia dissection, (6) dorsal vascular complex ligation, (7) dissection of the prostatic apex, (8) posterior anastomosis, and (9) urethro-vesical anastomosis. The procedures were further subcategorized as anatomical understanding, spatial recognition, and technical skills for evaluation of resident training. The surgeries were divided into first and second halves, and patient characteristics and operative outcomes were statistically analyzed. The operative time of each of the nine steps and the reasons for proctor intervention were compared. Among 42 patients, there were no significant differences in operative outcomes between the two groups. The median operative time was 169 min (164 vs. 179 min, p = .12), and the median console time was 128 min (127 vs. 130 min, p = .74). Although there were no significant differences in the time of the nine steps, the resident significantly overcame (7) dissection of the prostatic apex and (8) posterior anastomosis based on the evaluation of the proctored reasons for intervention. Urology residents can safely perform and efficiently learn RARP with this stepwise educational system. This educational stepwise RARP procedure can effectively help residents to develop their skills. (Keyword) Humans / Prostatectomy / Internship and Residency / Robotic Surgical Procedures / male / Middle Aged / urology / Clinical Competence / Aged / Operative Time / Prostatic Neoplasms / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.13334 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38830638 ● Summary page in Scopus @ Elsevier: 2-s2.0-85195016027 (DOI: 10.1111/ases.13334, PubMed: 38830638, Elsevier: Scopus)
2.	Yutaro Sasaki, Yoshito Kusuhara, Takuro Oyama, Mitsuki Nishiyama, Saki Kobayashi, Kei Daizumoto, Ryotaro Tomida, Yoshiteru Ueno, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi, Hiroomi Kanayama and Junya Furukawa : Radical prostatectomy using the Hinotori robot-assisted surgical system: Docking-free design may contribute to reduction in postoperative pain., The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS, Vol.20, No.3, e2648, 2024. (Summary) The docking-free design of the Japanese Hinotori surgical robotic system allows the robotic arm to avoid trocar grasping, thereby minimising excessive abdominal wall stress. The aim of this study was to evaluate the safety and efficacy of robotic-assisted radical prostatectomy (RARP) using the Hinotori system and to explore the potential contribution of its docking-free design to postoperative pain reduction. This study reviewed the clinical records of 94 patients who underwent RARP: 48 patients in the Hinotori group and 46 in the da Vinci Xi group. Hinotori group had significantly longer operative and console times (p = 0.030 and p = 0.029, respectively). Perioperative complications and oncologic outcomes did not differ between the two groups. On postoperative day 4, the rate of decline from the maximum visual analogue scale score was marginally significant in the Hinotori group (p = 0.062). The docking-free design may contribute to reducing postoperative pain. (Keyword) Humans / Prostatectomy / Robotic Surgical Procedures / Male / Pain, Postoperative / Middle Aged / Aged / Prostatic Neoplasms / Treatment Outcome / Retrospective Studies / Operative Time (Link to Publication Site) ● Publication site (DOI): 10.1002/rcs.2648 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38824454 ● Summary page in Scopus @ Elsevier: 2-s2.0-85195016810 (DOI: 10.1002/rcs.2648, PubMed: 38824454, Elsevier: Scopus)
3.	Yutaro Sasaki, Masayuki Takahashi, Mitsuki Nishiyama, Saki Kobayashi, Yoshiteru Ueno, Junya Furukawa and Kenji Shimada : A novel treatment strategy for bladder hypoplasia: A case of megaureter in a functional solitary kidney., IJU Case Reports, Vol.7, No.3, 243-246, 2024. (Summary) We report a case of megaureter in a functional solitary kidney in which surgery was performed after bladder capacity was increased by home bladder cycling. A 6-day-old girl with a left megaureter, a right multicystic dysplastic kidney, and bladder hypoplasia underwent percutaneous left nephrostomy for obstructive renal failure. At 8 months, home bladder cycling was initiated to increase bladder capacity before the planned ureterocystoneostomy. Surgery was performed after bladder capacity increased. The left ureter was compressed by the left umbilical ligament, so ureteral end-to-end anastomosis was performed at 1 year and 4 months. At 2 years and 8 months, cystometry showed age-appropriate bladder capacity and improved bladder compliance. To the best of our knowledge, this is the first report of bladder hypoplasia treated by home bladder cycling. (Link to Publication Site) ● Publication site (DOI): 10.1002/iju5.12713 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38686067 ● Summary page in Scopus @ Elsevier: 2-s2.0-85186572590 (DOI: 10.1002/iju5.12713, PubMed: 38686067, Elsevier: Scopus)
4.	Yutaro Sasaki, Katsuhito Hori, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa and Masayuki Takahashi : A new trick for scrotal surgery using Doyen intestinal forceps., International Journal of Urology, Vol.31, No.4, 446-447, 2024. (Keyword) Humans / Anastomosis, Surgical / Surgical Instruments (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.15366 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38116859 ● Summary page in Scopus @ Elsevier: 2-s2.0-85180170927 (DOI: 10.1111/iju.15366, PubMed: 38116859, Elsevier: Scopus)
5.	Fumiya Kadoriku, Yutaro Sasaki, Kyotaro Fukuta, Mitsuki Nishiyama, Seiya Utsunomiya, Saki Kobayashi, Keito Shiozaki, Kei Daizumoto, Yoshiteru Ueno, Kosuke Seto, Ryotaro Tomida, Yoshito Kusuhara, Tomoya Fukawa, Ryoichi Nakanishi, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi and Junya Furukawa : Robot-assisted intracorporeal ileal conduit urinary diversion: A two-center comparative study of Bricker versus Wallace ureteroileal anastomosis, Asian Journal of Endoscopic Surgery, Vol.17, No.2, e13307, 2024. (Summary) This study was performed to evaluate the differences in the perioperative results, renal function, and incidence of hydronephrosis over time between the use of Bricker anastomosis and Wallace anastomosis for robot-assisted intracorporeal ileal conduit urinary diversion (RICIC). Fifty-five patients who underwent RICIC at two institutions were evaluated (Bricker, n = 23; Wallace, n = 32). We investigated changes in estimated glomerular filtration rate and hydronephrosis before surgery and at 3, 6, and 12 months after surgery. The patients in the Bricker group were significantly older than those in the Wallace group. The urinary diversion time was significantly longer in the Bricker group. No significant difference in postoperative renal function was observed. Additionally, no significant difference was observed in the incidence of postoperative hydronephrosis. However, the incidence of right hydronephrosis tended to be high overall, especially in the Wallace group. No patients in either group required repair surgery or ureteral stent placement. In patients undergoing RICIC, there was no difference in postoperative renal function or the incidence of hydronephrosis between Wallace and Bricker anastomosis. Symptomatic hydronephrosis was not observed in either group. The present study showed that each method was equally effective and safe. (Keyword) Humans / Robotics / Ileum / Urinary Diversion / Cystectomy / Hydronephrosis / Anastomosis, Surgical / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.13307 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38561598 ● Summary page in Scopus @ Elsevier: 2-s2.0-85189310851 (DOI: 10.1111/ases.13307, PubMed: 38561598, Elsevier: Scopus)
6.	Yutaro Sasaki, Kazuyoshi Izumi, Kyotaro Fukuta, Fumiya Kadoriku, Yuichiro Atagi, Kei Daizumoto, Keito Shiozaki, Ryotaro Tomida, Yoshito Kusuhara, Tomoya Fukawa, Yutaka Yanagihara, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Kenjiro Okamoto, Masahito Yamanaka and Junya Furukawa : Impact of lymph node dissection on surgical and oncological outcomes in patients undergoing robot-assisted radical cystectomy for bladder cancer: a multicenter retrospective study, Journal of Robotic Surgery, Vol.18, No.1, 141, 2024. (Summary) This study was performed to clarify the therapeutic and diagnostic roles of lymph node dissection (LND) by examining the impact of LND and lymph node yield (LNY) on oncological outcomes in patients undergoing robot-assisted radical cystectomy (RARC). Between 2014 and 2021, 216 patients underwent LND during RARC at Tokushima University Hospital and affiliated hospitals. Among the 216 patients, we compared 115 patients with an LNY of ≥ 20 and 101 with an LNY of < 20 to investigate the impact of LNY on surgical and oncological outcomes. Furthermore, we investigated the impact of LNY and the extent of LND on oncological outcomes by dividing the extent of LND into two groups (standard and extended). The 3-year rates of overall survival (OS) (p = 0.256), cancer-specific survival (CSS) (p = 0.791), and recurrence-free survival (RFS) (p = 0.953) did not differ between the two groups divided by the LNY. A higher LNY was associated with a significantly higher lymph node positivity rate (p = 0.020). The incidence of LND-related major complications was not significantly different between the two groups (p = 0.910). The 3-year survival rates did not differ between the two groups divided by the extent of LND: OS (p = 0.366), CSS (p = 0.814), and RFS (p = 0.689). The LNY and extent of LND were not associated with oncological outcomes in patients undergoing LND during RARC, whereas a higher LNY was associated with lymph node positivity. In the era of adjuvant therapy with immune checkpoint inhibitors, LND during RARC has an important diagnostic role in the detection of pathological node positivity. (Keyword) Humans / Cystectomy / Lymph Node Excision / Retrospective Studies / Robotic Surgical Procedures / Treatment Outcome / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s11701-024-01893-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38554230 ● Summary page in Scopus @ Elsevier: 2-s2.0-85188969651 (DOI: 10.1007/s11701-024-01893-y, PubMed: 38554230, Elsevier: Scopus)
7.	Yutaro Sasaki, Yasuyo Yamamoto, Saki Kobayashi, Masaaki Nishi, Masayuki Takahashi and Junya Furukawa : A case of laparoscopically assisted transperineal repair of anterior enterocele dehiscence with small bowel evisceration after robot-assisted radical cystectomy, Urology Case Reports, Vol.52, 102629, 2024. (Summary) We herein report a case of successful laparoscopically assisted transperineal repair of anterior enterocele dehiscence with small bowel evisceration after robot-assisted radical cystectomy. A 75-year-old woman underwent robot-assisted radical cystectomy with anterior vaginectomy and urethrectomy for bladder cancer (pTisN0M0). Vaginal reconstruction was performed using the posterior vaginal wall. Four months after surgery, she presented with small bowel evisceration due to anterior enterocele dehiscence. She underwent laparoscopically assisted transperineal repair. The anterior enterocele dehiscence did not occur at the vaginal closure site but instead between the vaginal wall and posterior pubic bone. No recurrence had developed at 2 months postoperatively. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.eucr.2023.102629 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38146484 ● Summary page in Scopus @ Elsevier: 2-s2.0-85179006873 (DOI: 10.1016/j.eucr.2023.102629, PubMed: 38146484, Elsevier: Scopus)
8.	Tomokazu Sazuka, Yuto Matsushita, Hiroaki Sato, Takahiro Osawa, Nobuyuki Hinata, Shingo Hatakeyama, Kazuyuki Numakura, Kosuke Ueda, Takahiro Kimura, Masayuki Takahashi, Hajime Tanaka, Yoshihide Kawasaki, Toshifumi Kurahashi, Takuma Kato, Kazutoshi Fujita, Makito Miyake, Takahiro Kojima, Hiroshi Kitamura, Hideaki Miyake and Tomohiko Ichikawa : Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study., Scientific Reports, Vol.13, No.1, 2023. (Summary) Immuno-oncology (IO) combination therapy is utilized as a first-line systemic treatment for advanced renal cell carcinoma. However, evidence supporting the use of cabozantinib after IO combination therapy is lacking. We retrospectively analyzed patients who received second-line cabozantinib after IO combination therapy using the Japanese Urological Oncology Group (JUOG) database. In total, 254 patients were enrolled in the JUOG global study, and 118 patients who received second-line cabozantinib comprised the study cohort. The objective response rate, disease control rate, second-line cabozantinib progression-free survival (PFS), and overall survival from second-line for overall were 32%, 75%, 10.5months, and not reached, respectively, for first-line IO-IO therapy were 37%, 77%, 11.1months, and not reached, respectively, versus 24%, 71%, 8.3months, and not reached, respectively, for first-line IO-tyrosine kinase inhibitor therapy. In univariate and multivariate analyses, discontinuation of first-line treatment because of progressive disease and liver metastasis were independent risk factors for PFS. All-grade adverse events occurred in 72% of patients, and grade 3 or higher adverse events occurred in 28% of patients. Second line-cabozantinib after first-line IO combination therapy for advanced renal cell carcinoma was expected to be effective after either IO-IO or IO-TKI treatment and feasible in real-world practice. (Keyword) Humans / Carcinoma, Renal Cell / Kidney Neoplasms / Retrospective Studies / East Asian People / Anilides (Tokushima University Institutional Repository) ● Metadata: 119522 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-48087-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37996622 ● CiNii @ National Institute of Informatics (CRID): 1050019668024826240 ● Search Scopus @ Elsevier (PMID): 37996622 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-48087-4 (Tokushima University Institutional Repository: 119522, DOI: 10.1038/s41598-023-48087-4, PubMed: 37996622, CiNii: 1050019668024826240)
9.	Yutaro Sasaki, Masayuki Takahashi, Keito Shiozaki, Katsuhito Hori, Fumiya Kadoriku, Kei Daizumoto, Ryotaro Tomida, Yoshiteru Ueno, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Koichi Tomita, Koichi Sairyo and Hiroomi Kanayama : The importance of laparoscopic surgery for young urologists remains unwavering even in the era of robot assisted surgery, Asian Journal of Endoscopic Surgery, Vol.17, No.1, e13254, 2023. (Summary) Robot-assisted surgery (RAS) cannot be achieved without the performance of laparoscopic surgical techniques by a patient-side surgeon (PSS). In many medical institutions in Japan, young urologists often take on the role of a PSS. Participating in RAS as a PSS provides a good opportunity to acquire not only the knowledge necessary for surgery, but also skills in laparoscopic surgical techniques. Learning laparoscopic surgery as a PSS may contribute to improving the quality of RAS. Furthermore, it will lead to skill improvement as an operator in laparoscopic surgery. However, notably, opportunities for young urologists to perform laparoscopic surgery are decreasing in the current era of RAS. Under these circumstances, we believe that cadaver surgical training will become increasingly important in the future. We believe that performance of cadaver surgical training will contribute to increased motivation, enhance the understanding of surgical procedures, and facilitate the acquisition of surgical techniques. (Keyword) Humans / Robotic Surgical Procedures / Urologists / Laparoscopy / Clinical Competence / Cadaver (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.13254 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37837342 ● Summary page in Scopus @ Elsevier: 2-s2.0-85173987092 (DOI: 10.1111/ases.13254, PubMed: 37837342, Elsevier: Scopus)
10.	Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori, Yoshiteru Ueno, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Hiro-omi Kanayama and Masayuki Takahashi : Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer., Anticancer Research, Vol.43, No.10, 4627-4635, 2023. (Summary) Positive core ratios observed on prostate biopsy correlated with higher recurrence rates after LDR-BT. This indicates that the proportion of positive cores in the biopsy may be an important factor in predicting the likelihood of recurrence, especially for patients with GG3 PCa. (Keyword) Male / Humans / Retrospective Studies / Brachytherapy / Prostatic Neoplasms / Neoplasm Grading / Biopsy / Prostate-Specific Antigen (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.16657 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37772553 ● Search Scopus @ Elsevier (PMID): 37772553 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.16657 (DOI: 10.21873/anticanres.16657, PubMed: 37772553)
11.	Yutaro Sasaki, Masayuki Takahashi, Kei Daizumoto, Keito Shiozaki, Tomoya Fukawa and Hiroomi Kanayama : Assistent guide short: A new device for facilitating ureteric stenting in women., International Journal of Urology, 2023. (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.15252 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37504506 ● Summary page in Scopus @ Elsevier: 2-s2.0-85165960914 (DOI: 10.1111/iju.15252, PubMed: 37504506, Elsevier: Scopus)
12.	Yutaro Sasaki, Kei Daizumoto, Kyotaro Fukuta, Keito Shiozaki, Mitsuki Nishiyama, Seiya Utsunomiya, Saki Kobayashi, Kosuke Seto, Yoshiteru Ueno, Ryotaro Tomida, Yoshito Kusuhara, Tomoya Fukawa, Ryoichi Nakanishi, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki and Masayuki Takahashi : Lymph node dissection during radical cystectomy for bladder cancer: A two-center comparative study of robotic versus open surgery., Asian Journal of Endoscopic Surgery, 2023. (Summary) This study was performed to evaluate the safety and efficacy of lymph node dissection (LND) during robot-assisted radical cystectomy (RARC) compared with open radical cystectomy (ORC). From October 2003 to December 2021, 122 patients underwent LND during RARC and 103 patients underwent LND during ORC at Tokushima University Hospital and Tokushima Prefectural Central Hospital. We investigated the safety and efficacy of LND during RARC by comparing the surgical and oncological outcomes between the two groups. The patients were significantly older in the RARC than the ORC group. The operative time was significantly shorter and the estimated blood loss was significantly lower in the RARC than the ORC group. Although the lymph node yield was significantly higher in the RARC than the ORC group, there was no significant difference in lymph node positivity between the groups. There was no significant difference in the incidence of local recurrence or distant metastasis between the two groups. The 5-year survival rates (overall survival, cancer-specific survival, and recurrence-free survival) were not different between the RARC and ORC groups. This study suggests that the surgical and oncological safety and efficacy of LND during RARC are greater than those of LND during ORC. We believe that LND during RARC is a higher-quality procedure than LND during ORC. (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.13234 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37489628 ● Summary page in Scopus @ Elsevier: 2-s2.0-85165549223 (DOI: 10.1111/ases.13234, PubMed: 37489628, Elsevier: Scopus)
13.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa, Yayoi Fukuhara, Yoshimi Bando, Minoru Kowada, Tsogt-Ochir Dondoo, Yutaro Sasaki, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hisanori Uehara and Hiroomi Kanayama : Insulin receptor expression to predict resistance to axitinib and elucidation of the underlying molecular mechanism in metastatic renal cell carcinoma., British Journal of Cancer, 2023. (Summary) Decreased INSR in RCC could be a biomarker to predict axitinib resistance. Regarding the resistant mechanism, vascular endothelial cells with decreased INSR in RCC may secrete interferon-β and induce PD-L1. (Link to Publication Site) ● Publication site (DOI): 10.1038/s41416-023-02325-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37355721 ● Search Scopus @ Elsevier (PMID): 37355721 ● Search Scopus @ Elsevier (DOI): 10.1038/s41416-023-02325-8 (DOI: 10.1038/s41416-023-02325-8, PubMed: 37355721)
14.	Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 尿失禁手術で女性の健康長寿を目指す, The Nishinihon Journal of Urology, Vol.85, No.5, 277-283, 2023. (Summary) 尿失禁は女性の約50%が一生のうちに一度は経験するとされ，その半数は腹圧性尿失禁(SUI: Stress Urinary Incontinence)である．骨盤底筋トレーニングが第一選択であるが，中等症以上や軽症でもQOLが低下している場合には，中部尿道スリング手術(MUS: Mid Urethral Sling)がゴールドスタンダードとなる．MUSには，恥骨後式のTVT(Tension-free vaginal Tape)と経閉鎖孔式のTOT(Transobturator Tape)があり，ともに成功率は高い．手術手技は比較的容易だが，テープ張力の調整は手術の成否に関わり，注意を要する．QOL疾患であり，手術に対する患者の期待も大きく，術前からの適切な症例の選択，十分な説明が必要である．難治性の切迫性尿失禁(UUI: Urge Urinary Incontinence)に対しては，ボツリヌス毒素の膀胱壁内注入療法が2019年より保険適用となった．外来で実施可能であり，安全性も高く，治療成績も良好である．内因性括約筋不全(ISD: Intrinsic Sphincter Deficiency)症例に対する尿道周囲注入術は有効であるが，本邦では使用可能なbulking agent がない．海外で認可されているシリコン粒子やポリアクリルアミドゲル，男性患者に承認がある自己皮下脂肪組織由来再生幹細胞の実用化が期待される．今後10年で尿失禁患者の治療の選択肢が増加し，さらに高齢女性の健康長寿に貢献できることを切に願っている． (Keyword) 腹圧性尿失禁 / 尿道スリング手術 / 切迫性尿失禁 / ボツリヌス毒素膀胱壁内注入療法 / stress urinary incontinence / mid-urethral sling / urge urinary incontinence / intravesical botulinum toxin injection (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050579134193026560 (CiNii: 1050579134193026560)
15.	Kei Daizumoto, Saki Minato, 小居浩之, Tomoteru Kishimoto, Takeshi Iwasa, Masayuki Takahashi and Hiro-omi Kanayama : 徳島大学病院における不妊治療の取り組み, The Nishinihon Journal of Urology, Vol.85, 317-323, 2023.
16.	Katsuhito Hori, Yutaro Sasaki, Keito Shiozaki, Fumiya Kadoriku, Kei Daizumoto, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi, Yoshihiro Tsuruo and Hiroomi Kanayama : Efficacy of fresh-frozen cadaveric surgical training for arteriovenous fistula in vascular access., The Journal of Vascular Access, 2023. (Summary) CST for AVF creation is useful for surgical education because it enables learning of surgical techniques that are almost equivalent to those in living bodies. In addition, this study suggested that CST not only contributes to the improvement of surgical skills of young surgeons but also promotes the reduction of anxiety and stress about AVF creation. (Link to Publication Site) ● Publication site (DOI): 10.1177/11297298231169056 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37070175 ● Search Scopus @ Elsevier (PMID): 37070175 ● Search Scopus @ Elsevier (DOI): 10.1177/11297298231169056 (DOI: 10.1177/11297298231169056, PubMed: 37070175)
17.	Masayuki Takahashi, Kei Daizumoto, Yutaro Sasaki, 冨田諒太郎, 上野恵輝, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto and Hiro-omi Kanayama : 有転移腎細胞癌に対する薬物療法のNext 10 Years, The Nishinihon Journal of Urology, Vol.85, 145-152, 2023.
18.	Yutaro Sasaki, Masayuki Takahashi, Kyotaro Fukuta, Keito Shiozaki, Kei Daizumoto, Yoshiteru Ueno, Ryotaro Tomida, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki and Hiroomi Kanayama : Assistent guide: A novel device for ureteral stent placement in robot-assisted intracorporeal ileal conduit., The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS, Vol.19, No.4, 2023. (Summary) We showed the safety and efficacy of the Assistent guide for ureteral stent placement in RICIC. (Keyword) Humans / Cystectomy / robotics / Urinary Diversion / Stents / Ureteral Obstruction / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1002/rcs.2513 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36840720 ● Summary page in Scopus @ Elsevier: 2-s2.0-85149381419 (DOI: 10.1002/rcs.2513, PubMed: 36840720, Elsevier: Scopus)
19.	Masaki Shiota, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara, Nobuo Shinohara, Kiyohide Fujimoto, Masahiro Nozawa, Kojiro Ohba, Chikara Ohyama, Katsuyoshi Hashine, Shusuke Akamatsu, Tomomi Kamba, Koji Mita, Momokazu Gotoh, Shuichi Tatarano, Masato Fujisawa, Yoshihiko Tomita, Shoichiro Mukai, Keiichi Ito, Tokiyoshi Tanegashima, Shoji Tokunaga and Masatoshi Eto : Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial., Cancer Immunology, Immunotherapy, Vol.72, No.6, 1903-1915, 2023. (Summary) Anti-PD-1 antibodies are widely used for cancer treatment including advanced renal cell carcinoma (RCC). However, their therapeutic and adverse effects vary among patients. This study aimed to identify genetic markers that predict outcome after nivolumab anti-PD-1 antibody treatment for advanced RCC. This study was registered on the website of the University Hospital Medical Information Network (protocol ID, UMIN000037739). Patient enrollment was conducted at 23 institutions in Japan between August 19, 2019, and September 30, 2020. Patient follow-up ended on March 31, 2021. Patients were treated with nivolumab for advanced clear cell RCC. A genome-wide association study was performed in the development set, while genotyping of target regions in the validation set was undertaken. Single nucleotide polymorphisms (SNPs) in genes of interest CD274, PDCD1LG2 and PDCD1 were genotyped in the combined set. The primary endpoint was the association of SNPs with objective response following nivolumab treatment. As secondary endpoints, the associations of SNPs with radiographic progression-free survival (rPFS) and treatment-related grade ≥ 3 adverse events (AEs) were evaluated. A genome-wide association study followed by a validation study identified that SNPs in FARP1 (rs643896 and rs685736) were associated with objective response and rPFS but not AEs following nivolumab treatment. Furthermore, SNPs in PDCD1LG2 (rs822339 and rs1411262) were associated with objective response, rPFS, and AEs following nivolumab treatment. Genetic risk category determined according to the number of risk alleles in SNPs (rs643896 in FARP1 and rs4527932 in PDCD1LG2) excellently predicted objective response and rPFS in nivolumab treatment. This study revealed that SNPs in FARP1 and PDCD1LG2 were correlated with outcome in nivolumab treatment. The use of these SNPs may be beneficial in selecting appropriate treatment for individual patients and may contribute to personalized medicine. (Keyword) Humans / Nivolumab / Carcinoma, Renal Cell / Genome-Wide Association Study / Progression-Free Survival / Polymorphism, Single Nucleotide / Kidney Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s00262-023-03367-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36729213 ● Search Scopus @ Elsevier (PMID): 36729213 ● Search Scopus @ Elsevier (DOI): 10.1007/s00262-023-03367-w (DOI: 10.1007/s00262-023-03367-w, PubMed: 36729213)
20.	Megumi Tsuda, Tomoya Fukawa, Yasuyo Yamamoto, Kei Daizumoto, Yutaro Sasaki, Yoshiteru Ueno, Ryotaro Tomida, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Impact of early urinary catheter removal on successful voiding and physical function in stroke patients., The Journal of Medical Investigation : JMI, Vol.70, No.3.4, 436-442, 2023. (Summary) The aim of the present study was to identify factors related to the success of trial without catheter (TWOC) in patients with stroke and to examine the effect of the timing of urinary catheter removal on the course of stroke. Patients who were admitted to the Stroke Care Unit of our institution between March 2018 and October 2021 were included. To identify factors related to success of TWOC, a multivariate analysis was performed on the patient's condition at admission and catheter indwelling time. The patients were divided into two groups by the timing of catheter removal, and we assessed the relationship between the timing of catheter removal successful TWOC and recovery of physical function. A total of 118 patients were included. The presence of comorbidities and scores of severity and function at admission were not predictors of successful voiding. The time to achieve voiding sussess was significantly shorter in the early catheter removal group than in the later group (p<0.005). Interestingly, the early group also showed better improvements in physical function. Early removal of catheters may lead to early recovery of bladder function, improvement of physical function, and lower risk of complications in patients with stroke. J. Med. Invest. 70 : 436-442, August, 2023. (Keyword) Humans / Urinary Catheterization / Urinary Catheters / Catheters, Indwelling / Stroke / Device Removal (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.436 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940529 ● CiNii @ National Institute of Informatics (CRID): 1390298068225662720 ● Summary page in Scopus @ Elsevier: 2-s2.0-85176414269 (DOI: 10.2152/jmi.70.436, PubMed: 37940529, CiNii: 1390298068225662720, Elsevier: Scopus)
21.	Keisuke Ozaki, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Yoshiteru Ueno, Megumi Tsuda, Takayuki Uchida, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : The impact of nutritional status and changes of body composition on the prognosis of metastatic renal cell carcinoma patients., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 80-87, 2023. (Summary) Nutritional status of mRCC patients may predict changes in body composition and be associated with their prognosis. J. Med. Invest. 70 : 80-87, February, 2023. (Keyword) Humans / Carcinoma, Renal Cell / Kidney Neoplasms / Nutritional Status / Prognosis / Body Composition / Retrospective Studies / Protein Kinase Inhibitors (Tokushima University Institutional Repository) ● Metadata: 118311 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.80 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164748 ● Search Scopus @ Elsevier (PMID): 37164748 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.80 (Tokushima University Institutional Repository: 118311, DOI: 10.2152/jmi.70.80, PubMed: 37164748)
22.	Yoshiteru Ueno, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Masayuki Takahashi and Hiro-omi Kanayama : Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer., In Vivo, Vol.37, No.2, 738-746, 2023. (Summary) PSA levels at 5 years post-treatment were associated with long-term recurrence of localized prostate cancer, which can help alleviate patient anxiety concerning prostate cancer recurrence if PSA levels remain low at 5 years after LDR-BT. (Keyword) Male / Humans / Prostate-Specific Antigen / Brachytherapy / Cohort Studies / East Asian People / Prostatic Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.13136 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36881090 ● Search Scopus @ Elsevier (PMID): 36881090 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.13136 (DOI: 10.21873/invivo.13136, PubMed: 36881090)
23.	尾﨑啓介, Kunihisa Yamaguchi, 多田亜沙香, Tomoya Fukawa, Yutaro Sasaki, Yoshito Kusuhara, Yasuyo Yamamoto, 林秀樹, Masayuki Takahashi, Yoshihiro Tsuruo, 橋本寛文 and Hiro-omi Kanayama : 未固定凍結遺体を用いた心停止下献腎摘出教育の試み, Journal of Japanese Society for Clinical Renal Transplantation, Vol.10, No.2, 259-261, 2022. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520576215060551680 (CiNii: 1520576215060551680)
24.	Keito Shiozaki, Kazuyoshi Izumi, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Yasuo Kawanishi and Hiroomi Kanayama : Comparison of robot-assisted partial nephrectomy with soft coagulation and double-layer technique for complex and non-complex tumors., International Journal of Urology, Vol.30, No.3, 281-288, 2022. (Summary) Single-layer suturing with soft coagulation achieves renal function and perioperative outcomes comparable to those of double-layer suturing regardless of complexity. (Keyword) Humans / Robotics / Retrospective Studies / Nephrectomy / Kidney / Kidney Neoplasms / Robotic Surgical Procedures / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 118156 (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.15112 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36448456 ● Search Scopus @ Elsevier (PMID): 36448456 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.15112 (Tokushima University Institutional Repository: 118156, DOI: 10.1111/iju.15112, PubMed: 36448456)
25.	Fumiya Kadoriku, Yutaro Sasaki, Kyotaro Fukuta, Yuichiro Atagi, Keito Shiozaki, Kei Daizumoto, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yutaka Yanagihara, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Sadamu Yamashi, Masaharu Kan and Hiroomi Kanayama : A propensity score matching study on robot-assisted radical cystectomy for older patients: comparison of intracorporeal ileal conduit and cutaneous ureterostomy., BMC Urology, Vol.22, No.1, 2022. (Summary) In older patients, the ICIC group showed non-inferior surgical and oncological outcomes compared with the CUS group. Urinary diversion following RARC in older patients should be carefully selected by considering not only the age but also the general condition (including comorbidities) of the patient. (Keyword) Aged / Humans / Cystectomy / Postoperative Complications / Propensity Score / Retrospective Studies / Robotic Surgical Procedures / robotics / Treatment Outcome / Ureterostomy / Urinary Bladder Neoplasms / Urinary Diversion (Tokushima University Institutional Repository) ● Metadata: 118559 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12894-022-01123-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36344965 ● Summary page in Scopus @ Elsevier: 2-s2.0-85141380657 (Tokushima University Institutional Repository: 118559, DOI: 10.1186/s12894-022-01123-3, PubMed: 36344965, Elsevier: Scopus)
26.	Kouki Tada, Kei Daizumoto, Masayuki Takahashi, Hisanori Uehara, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment., IJU Case Reports, Vol.6, No.1, 41-44, 2022. (Summary) Sunitinib after an IO-drug showed a significant effect in spite of only slight efficacy with other VEGFR-TKIs, which may have occurred through the alteration of the immunological microenvironment. (Tokushima University Institutional Repository) ● Metadata: 118791 (Link to Publication Site) ● Publication site (DOI): 10.1002/iju5.12545 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36605682 ● Search Scopus @ Elsevier (PMID): 36605682 ● Search Scopus @ Elsevier (DOI): 10.1002/iju5.12545 (Tokushima University Institutional Repository: 118791, DOI: 10.1002/iju5.12545, PubMed: 36605682)
27.	Yutaro Sasaki, Masayuki Takahashi, Mitsuki Nishiyama, Saki Kobayashi, Keito Shiozaki and Hiroomi Kanayama : A case of laparoscopic adhesiotomy for urodynia caused by bladder wall adhesion to the anterior abdominal wall after vesicoscopic ureteral reimplantation for vesicoureteral reflux., Urology Case Reports, Vol.45, 102216, 2022. (Summary) We herein report an extremely rare case of urodynia caused by bladder wall adhesion to the anterior abdominal wall after vesicoscopic ureteral reimplantation for vesicoureteral reflux with resolution of the urodynia by laparoscopic adhesiotomy. A 13-year-old girl who had undergone vesicoscopic cross-trigonal ureteral reimplantation for bilateral grade IV vesicoureteral reflux subsequently experienced severe urodynia for 5 years until her self-report to the attending physician. Magnetic resonance imaging suggested that bladder wall adhesion to the anterior abdominal wall may have caused the urodynia. Therefore, laparoscopic adhesiotomy of the bladder was performed. Notably, her urodynia disappeared immediately after surgery. (Tokushima University Institutional Repository) ● Metadata: 119493 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.eucr.2022.102216 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36160066 ● Summary page in Scopus @ Elsevier: 2-s2.0-85139230936 (Tokushima University Institutional Repository: 119493, DOI: 10.1016/j.eucr.2022.102216, PubMed: 36160066, Elsevier: Scopus)
28.	Kyotaro Fukuta, Keito Shiozaki, Ryoichi Nakanishi, Hirofumi Izaki, Eiji Kudo, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Leptomeningeal carcinomatosis in small cell carcinoma of the prostate., IJU Case Reports, Vol.5, No.6, 493-496, 2022. (Summary) Careful monitoring of the central nervous system should be considered in small cell carcinoma of the prostate patients. (Tokushima University Institutional Repository) ● Metadata: 118792 (Link to Publication Site) ● Publication site (DOI): 10.1002/iju5.12524 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36341201 ● Search Scopus @ Elsevier (PMID): 36341201 ● Search Scopus @ Elsevier (DOI): 10.1002/iju5.12524 (Tokushima University Institutional Repository: 118792, DOI: 10.1002/iju5.12524, PubMed: 36341201)
29.	K. Ozaki, Takashi Kawanaka, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Megumi Tsuda, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Appropriate management reduces radiation exposure in daily urological practice, International Journal of Urology, 2022. (Summary) To identify and raise awareness of the radiation exposure of urologists due to X-ray fluoroscopic procedures in daily practice. This was a single-center, cohort study of 30 consecutive patients who underwent periodic percutaneous or transurethral replacements of urinary tract catheters. A total of 55 replacements every 3 months with cases aligned were performed by a single urologist. The urologist's radiation exposure and the incident dose to patients per case were measured with thermoluminescent dosimeters. In the latter 3-month period, the pulse fluoroscopy condition was changed from 15 to 7.5 pulses per second, and collimation was added to the field of view. In the analysis of all patients, the use of a modified pulse rate and collimation did not affect the fluoroscopy time, but it did significantly reduce the air kerma and dose area product; in addition, with respect to the medical exposure dose during percutaneous catheter replacement, fluoroscopy time was longer, but air kerma and dose area product showed significant decreases. As with decreases in medical exposure of patients, the equivalent dose for eye lenses of the urologist decreased from 1.2 mSv in the first 3-month period to 0.2 mSv in the second 3-month period. Similarly, the exposure dose for the extremities also decreased significantly, from 33.9 mSv to 8.1 mSv. Urologists are exposed to non-negligible amounts of radiation due to fluoroscopy. Appropriate management such as modified pulse fluoroscopy condition and precautions are required. (Tokushima University Institutional Repository) ● Metadata: 118219 (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.14971 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35851694 ● Search Scopus @ Elsevier (PMID): 35851694 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.14971 (Tokushima University Institutional Repository: 118219, DOI: 10.1111/iju.14971, PubMed: 35851694)
30.	Kyotaro Fukuta, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : High-Grade Renal Mucinous Tubular and Spindle Cell Carcinoma, Case Reports in Oncology, Vol.15, No.2, 580-585, 2022. (Summary) Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare subtype of renal cell carcinoma. Although usually indolent, high-grade MTSCC has been reported to exhibit an aggressive clinical course. Herein, we report a case of high-grade renal MTSCC. An 86-year-old man visited our hospital with fever and fatigue. Based on contrast-enhanced computed tomography findings, the patient was diagnosed with clinical stage T2aN0M0 right renal cell carcinoma and underwent laparoscopic radical nephrectomy. Histological examination showed tubular to tubulopapillary structures accompanied by mucinous stroma, suggesting high-grade renal MTSCC. He remained recurrence- and metastasis-free 6 months after nephrectomy. Since high-grade renal MTSCC may have an aggressive clinical course, such patients should be observed carefully after radical nephrectomy. (Tokushima University Institutional Repository) ● Metadata: 117428 (Link to Publication Site) ● Publication site (DOI): 10.1159/000524897 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35813692 ● Search Scopus @ Elsevier (PMID): 35813692 ● Search Scopus @ Elsevier (DOI): 10.1159/000524897 (Tokushima University Institutional Repository: 117428, DOI: 10.1159/000524897, PubMed: 35813692)
31.	Yusuke Fukatani, Kei Daizumoto, Fumiya Kadoriku, 山本拓, Yutaro Sasaki, 尾﨑啓介, 上野恵輝, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Mariko Niki and Hisanori Uehara : A Case of Pappilary Renal Cell Caircinoma which Responded Well to the Combination Therapy of Ipilimumab and Nivolumab --A CASE REPORT--, Acta Urologica Japonica, Vol.68, No.4, 107-111, 2022. (Summary) We report a case of papillary renal cell carcinoma that responded well to the combination of ipilimumab and nivolumab. The patient was a 68-year-old male who was being followed up for a small left renal mass without treatment. Two years later, computed tomography (CT) showed enlarged cervical and para-aortic lymph nodes, and lymph node biopsy suggested metastases of the cancer. After resection of the renal tumor, we performed pararenal aortic lymph node biopsy, and we diagnosed the case as papillary renal cell carcinoma type 1 with lymph node metastasis. The combination of ipilimumab and nivolumab each metastatic site showed regression on CT. Since immune-related adverse events occurred during the therapy nivolumab was discontinued, but partial response of the metastases was maintained. (Keyword) Papillary renal cell carcinoma / Ipilimumab and nivolumab / 494.9 (Link to Publication Site) ● Publication site (DOI): 10.14989/actauroljap_68_4_107 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390573715168780160 ● Search Scopus @ Elsevier (DOI): 10.14989/actauroljap_68_4_107 (DOI: 10.14989/actauroljap_68_4_107, CiNii: 1390573715168780160)
32.	Kyotaro Fukuta, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Micropapillary Variant of Urothelial Carcinoma in a Hemodialysis Patient, Case Reports in Oncology, Vol.15, No.1, 462-468, 2022. (Summary) The micropapillary variant of urothelial carcinoma (MPUC) is an aggressive form of urothelial carcinoma with high metastatic potential and a poor prognosis. Although various therapies have been reported, there is still no established treatment strategy for MPUC due to its rarity. The incidence of urinary tract malignancies is higher in patients undergoing hemodialysis (HD) than in healthy individuals. Here, we report the case of an 82-year-old man on HD with end-stage kidney disease who visited our hospital for macrohematuria. Cystoscopy followed by computed tomography and urine cytology revealed a sessile papillary tumor around the left bladder wall. We performed transurethral resection of the bladder tumor. Based on histopathological and imaging findings indicative of clinical-stage T3N0M0 MPUC, we performed radical cystectomy. Histopathology revealed a pathological stage T4aN0M0 MPUC. Two months after the cystectomy, the patient complained of constipation and painful defecation due to local recurrence and rectal invasion. While colostomy was performed to improve defecation 3 months after cystectomy, he did not receive any chemotherapy due to his progressively worsening general condition. Six months after cystectomy, he died following rapid metastases. Our findings, in this case, confirm that bladder cancer in HD patients tends to be pathologically more advanced. Therefore, regular screening is recommended for its early detection in HD patients. (Tokushima University Institutional Repository) ● Metadata: 117427 (Link to Publication Site) ● Publication site (DOI): 10.1159/000524430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35702563 ● Search Scopus @ Elsevier (PMID): 35702563 ● Search Scopus @ Elsevier (DOI): 10.1159/000524430 (Tokushima University Institutional Repository: 117427, DOI: 10.1159/000524430, PubMed: 35702563)
33.	Yutaro Sasaki, Masayuki Takahashi, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : The patient-side surgeon plays a key role in facilitating robot-assisted intracorporeal ileal conduit urinary diversion in men, Journal of Robotic Surgery, Vol.16, No.2, 437-444, 2022. (Summary) The influence of the console surgeon on the feasibility and outcome of various robot-assisted surgeries has been evaluated. These variables may be partially affected by the skills of the patient-side surgeon (PSS), but this has not been evaluated using objective data. This study aimed to describe the surgical techniques of the PSS in robot-assisted radical cystectomy (RARC) and intracorporeal ileal conduit (ICIC) urinary diversion and objectively examine the changes in surgical outcomes with increasing PSS experience. During a 3-year period, 28 men underwent RARC and ICIC urinary diversion. Clinical characteristics and surgical outcomes were compared between patients who underwent surgery early (first half group) or late in the study period (second half group). The pre-docking incision enabled easy specimen removal. The glove port technique widened the working space of the PSS. The stay suture allowed the PSS to control the distal portion of the conduit, facilitating the passage of the ureteral stents. During stoma creation, pneumoperitoneum pressure was lost by opening the abdominal cavity. To overcome this problem, the robotic arm was used to lift the abdominal wall to maintain the surgical field and facilitate the PSS procedure. Compared with the first half group, the second half group had significantly shorter times for urinary diversion (202 min vs 148 min, p < 0.001), ileal isolation and anastomosis (73 min vs 45 min, p < 0.001), and stenting (23.0 min vs 6.5 min, p < 0.001). As the experience of the PSS increased, the time of the PSS procedures decreased. (Keyword) Cystectomy / Humans / Male / Robotic Surgical Procedures / Robotics / Surgeons / Treatment Outcome / Urinary Bladder Neoplasms / Urinary Diversion (Tokushima University Institutional Repository) ● Metadata: 116363 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11701-021-01256-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34081290 ● Search Scopus @ Elsevier (PMID): 34081290 ● Search Scopus @ Elsevier (DOI): 10.1007/s11701-021-01256-x (Tokushima University Institutional Repository: 116363, DOI: 10.1007/s11701-021-01256-x, PubMed: 34081290)
34.	Kyotaro Fukuta, Keito Shiozaki, Saki Kobayashi, Ryoichi Nakanishi, Hirofumi Izaki, Kazuya Kanda, Tohru Inai, Eiji Kudo, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Poor Outcome due to the Plasmacytoid Variant of Urothelial Carcinoma, Case Reports in Oncology, Vol.15, No.1, 369-375, 2022. (Summary) A 72-year-old man visited our hospital due to pollakiuria and lower abdominal pain. Urinary cytology was positive, and cystoscopy revealed diffuse edematous nonpapillary tumor. We performed transurethral biopsy, and clinical stage T3 plasmacytoid variant of urothelial carcinoma (PUC) was diagnosed. Although we planned for radical cystectomy, peritoneal dissemination and lung and pelvic lymph node metastases appeared 3 weeks after the initial visit. We also planned for chemotherapy; however, the metastases rapidly progressed, and he died 7 weeks after the biopsy. PUC is rare and shows an aggressive clinical course and poor prognosis. (Tokushima University Institutional Repository) ● Metadata: 117426 (Link to Publication Site) ● Publication site (DOI): 10.1159/000524038 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35529298 ● Search Scopus @ Elsevier (PMID): 35529298 ● Search Scopus @ Elsevier (DOI): 10.1159/000524038 (Tokushima University Institutional Repository: 117426, DOI: 10.1159/000524038, PubMed: 35529298)
35.	Keito Shiozaki, Yasuo Kawanishi, Yutaro Sasaki, Kei Daizumoto, Megumi Tsuda, Kazuyoshi Izumi, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiroomi Kanayama : Clinical application of virtual imaging guided Robot-assisted partial nephrectomy., The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 237-243, 2022. (Summary) Objectives : To evaluate whether virtual partial nephrectomy images could help surgeons identify vascular and collecting system around tumors during actual surgery. Materials & methods : We retrospectively analyzed 36 patients who underwent robot-assisted partial nephrectomy (RAPN) between 2016 and 2017. Virtual partial nephrectomy images were created from preoperative CT images using computer software, and then analyzed. For analysis, blood vessels and collecting system portions within a 5-mm-thick safety margin around the tumor were examined. During analysis, we predicted whether targeted vasculature around the tumor would require clipping or suturing during surgery, and also whether the collecting system would require opening during resection. Surgical outcomes for virtual partial nephrectomy analyses and actual RAPNs were compared and analyzed for sensitivity and specificity. Results : In 36 cases, 119 arteries and 100 veins were targeted on virtual partial nephrectomy images. Arterial suturing or clipping for hemostasis showed a sensitivity and specificity of 83.3% and 84.5%, respectively. For veins, the sensitivity and specificity were 39.1% and 92.2%, respectively. Collecting system opening prediction sensitivity was 85.7%, and specificity was 65.2%. Conclusion : Virtual partial nephrectomy imaging is useful for RAPN planning, particularly regarding arteries and the collecting system. It is hoped that techniques for visualizing veins will improve. J. Med. Invest. 69 : 237-243, August, 2022. (Keyword) Humans / Kidney Neoplasms / Nephrectomy / Retrospective Studies / Robotic Surgical Procedures / Robotics / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.237 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244775 ● CiNii @ National Institute of Informatics (CRID): 1390293788341771136 ● Search Scopus @ Elsevier (PMID): 36244775 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.237 (DOI: 10.2152/jmi.69.237, PubMed: 36244775, CiNii: 1390293788341771136)
36.	Kunihisa Yamaguchi, Yutaro Sasaki, Tomoya Fukawa, Masayuki Takahashi and Hiro-omi Kanayama : 腎移植後のリンパ漏にリンパ管造影が効果的であった3例, 日本臨床腎移植学会雑誌, Vol.1, No.19, 118-121, 2021. (Keyword) 腎移植 / リンパ漏 / リンパ管造影 / ジンイショク / リンパロウ / リンパカンゾウエイ (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388081028360448 (CiNii: 1523388081028360448)
37.	Yutaro Sasaki, 安宅真利花, 多田航生, 中西亮太, 橋本啓佑, 吉岡拓哉, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Hideya Kashihara and Takuya Tokunaga : Two Cases of Robot-Assisted Total Pelvic Exenteration and Intracorporeal Ileal Conduit for Locally Advanced Rectal Cancer, Acta Urologica Japonica, Vol.68, No.5, 155-159, 2021. (Summary) We describe two cases of locally advanced rectal cancer (LARC) treated with robot-assisted total pelvic exenteration (Ra-TPE) and intracorporeal ileal conduit (ICIC). The first case was in a 71-year-old man with LARC (RbP, T4bN2bM0, cStage IIIc). He was started on bevacizumab+S-1/oxaliplatin therapy in July 2019. In April 2020, he developed Fournier's gangrene due to subcutaneous penetration of rectal cancer. Emergency drainage and colostomy were performed simultaneously, and a percutaneous vesical fistula was created. In May 2020, Ra-TPE and ICIC were performed. Histopathological analysis revealed moderately differentiated tubular adenocarcinoma (ypT3N0, RM0). At postoperative 9 months, thoracoscopic right upper lobectomy was performed for a right metastatic lung tumor. At present, ie, at postoperative 12 months, the patient has been free of recurrence and metastasis, with a carcinoembryonic antigen (CEA) level of 1.4 ng/ml and carcinoma antigen (CA) 19-9 level of 11 U/ml. The second case was in a 61-year-old man with fistula-associated anal cancer (PRb, T4N3M1b, cStage IVb). In April 2019, he was started on FOLFOXIRI+cetuximab therapy. In August 2020, Ra-TPE, ICIC, and transperineal total mesenteric excision were performed. Histopathological analysis revealed adenocarcinoma (ypT4N0, RM0). At postoperative 11 months, thoracoscopic left lower lobectomy was performed for a left metastatic lung tumor. At present, ie, at postoperative 12 months, the patient remains free of recurrence and metastasis, with a CEA level of 7.3 ng/ml and CA19-9 level of 12 U/ml. Ra-TPE, which allows transperineal removal of a specimen, can be performed as a minimally invasive surgery in combination with ICIC. (Keyword) Robot-assisted total pelvic exenteration / Intracorporeal urinary diversion / Intracorporeal ileal conduit (Link to Publication Site) ● Publication site (DOI): 10.14989/actauroljap_68_5_155 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390855656035011840 ● Search Scopus @ Elsevier (DOI): 10.14989/actauroljap_68_5_155 (DOI: 10.14989/actauroljap_68_5_155, CiNii: 1390855656035011840)
38.	Yutaro Sasaki, 角陸文哉, 深谷友祐, 山本拓, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : A Case of Robot-Assisted Radical Cystoprostatectomy for Locally Advanced Prostate Cancer with Bladder Infiltration, Acta Urologica Japonica, Vol.67, No.4, 163-166, 2021. (Summary) While robot-assisted radical cystoprostatectomy (RARC) for locally advanced prostate cancer (LAPC) may sometimes prove to be excessive treatment, it can significantly reduce the risk of positive surgical margins and lower urinary tract obstruction in some cases. Here, we report a case of LAPC treated with RARC in a patient with right hydronephrosis due to bladder infiltration and left hypoplastic kidney. A 71-year-old man presented with frequent urination in August 2019. Prostate-specific antigen (PSA) level was 8.633 ng/ml, and magnetic resonance imaging led to the suspicion that the prostate cancer extended beyond the prostate capsule without distant metastasis. Prostatic biopsy revealed Gleason score 10 (5+5) adenocarcinoma in 8 out of 8 specimens. We diagnosed left hypoplastic kidney and LAPC with right hydronephrosis due to bladder infiltration. We performed percutaneous right nephrostomy and started neoadjuvant hormone therapy. RARC and intracorporeal ileal conduit were performed in March 2020. The prostate was adherent to the anterior surface of the rectum and was difficult to remove. At present, five months after the surgery, the patient remains free of recurrence and metastasis with PSA level <0.003 ng/ml. RARC for LAPC with bladder infiltration can be an effective therapeutic strategy in some cases. (Keyword) Locally advanced prostate cancer / Bladder Invasion / Robot-assisted radical cystoprostatectomy (Link to Publication Site) ● Publication site (DOI): 10.14989/ActaUrolJap_67_4_163 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34107613 ● Summary page in Scopus @ Elsevier: 2-s2.0-85108011497 (DOI: 10.14989/ActaUrolJap_67_4_163, PubMed: 34107613, Elsevier: Scopus)
39.	Yutaro Sasaki, Masayuki Takahashi, Keisuke Ozaki, Kei Daizumoto, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Efficacy of the direct grasping technique using pean forceps under fluoroscopy to replace ureteral stents in women, The Journal of Medical Investigation : JMI, Vol.3.4, No.68, 326-329, 2021. (Summary) Purpose : To evaluate the efficacy of the direct grasping technique using pean forceps under fluoroscopic guidance for ureteral stent replacement in women. Methods : Between April 2018 and September 2020, 28 female patients underwent ureteral stent replacements at our facility, and 184 stent replacement procedures were performed. A total of 127 stents were replaced using pean forceps under fluoroscopic guidance (pean forceps group), and 57 stents were replaced using the cystoscope (cystoscopy group). Clinical characteristics and surgical outcomes were compared between the groups. Results : All stents were successfully replaced. There was a statistically significant difference in the procedure time between the two groups (median [interquartile range], pean forceps group : 10.8 [8.2-13.9] minutes vs. cystoscopy group : 15.8 [11.1-20.9] minutes, P < 0.001). There were no intraoperative complications in either group and no difference in the incidence of postoperative complications (pean forceps group : 1.6% vs. cystoscopy group : 1.8%, P = 1.000). Fluoroscopy time was longer in the pean forceps group, although this difference was not statistically significant (pean forceps group : 38.9 [22.6-60.1] seconds vs. cystoscopy group : 33.0 [20.0-48.9] seconds, P = 0.0558). Conclusion : The direct grasping technique using pean forceps under fluoroscopy may be a beneficial alternative to cystoscopy for ureteral stent replacement in women. J. Med. Invest. 68 : 326-329, August, 2021. (Keyword) female / Fluoroscopy / Humans / Stents / Surgical Instruments / Ureter / Ureteral Obstruction (Tokushima University Institutional Repository) ● Metadata: 116511 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.326 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759153 ● Search Scopus @ Elsevier (PMID): 34759153 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.326 (Tokushima University Institutional Repository: 116511, DOI: 10.2152/jmi.68.326, PubMed: 34759153)
40.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Tetsuhiro Yano, Kei Daizumoto, Yutaro Sasaki, Keisuke Ozaki, Yoshiteru Ueno, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : [A Case of Pelvic Organ Prolapse and Bladder Diverticulum Surgically Treated at the Same Time]., Acta Urologica Japonica, Vol.66, No.8, 269-272, 2020. (Summary) We report a case of bladder diverticulum presumably caused by lower urinary tract dysfunction due to pelvic organ prolapse (POP) simultaneously treated with transurethral coagulation (TUC) of the bladder diverticulum and laparoscopic sacrocolpopexy (LSC). A literature search showed this is the first report of bladder diverticulum and POP surgically treated at the same time. A 71-year-old woman was referred to our hospital for the treatment of cystocele. She had both storage and voiding symptoms. She had a POPQ stage III cystocele and stage I uterine prolapse. Ultrasonography and computed tomographic scan showed a large volume of residual urine along with a bladder diverticulum. Since urodynamic studies revealed a low compliance bladder and obstruction, we opined that the lower urinary tract symptoms were induced by the cystocele. TUC of the bladder diverticulum and LSC were performed at the same time. After the operation, clean intermittent catheterization (CIC) was needed once a day for one month. Gradually, residual urine decreased and CIC became unnecessary. The bladder diverticulum disappeared, and there has been no recurrence of POP. (Keyword) Aged / Diverticulum / female / Humans / Lower Urinary Tract Symptoms / Pelvic Organ Prolapse / Urinary Bladder / Urinary Bladder, Overactive (Link to Publication Site) ● Publication site (DOI): 10.14989/ActaUrolJap_66_8_269 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32882124 ● Summary page in Scopus @ Elsevier: 2-s2.0-85090318500 (DOI: 10.14989/ActaUrolJap_66_8_269, PubMed: 32882124, Elsevier: Scopus)
41.	Yoshito Kusuhara, Kei Daizumoto, Kaichi Kawai, Kento Hirayama, Minoru Kowada, Terumichi Shintani, Yayoi Fukuhara, Tsogt-Ochir Dondoo, Keisuke Ozaki, Megumi Tsuda, Tomoya Fukawa, Hiroyoshi Nakatsuji, Yoshimi Bando, Hisanori Uehara, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer., Anticancer Research, Vol.39, No.2, 703-711, 2019. (Summary) Low TLR4 expression was correlated with tumor progression. (Keyword) Aged / Biomarkers, Tumor / Cell Differentiation / Cell Line, Tumor / Computational Biology / Disease Progression / Female / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Male / Middle Aged / Neoplasm Invasiveness / Oligonucleotide Array Sequence Analysis / Prognosis / RNA, Small Interfering / Toll-Like Receptor 4 / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13166 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30711948 ● Search Scopus @ Elsevier (PMID): 30711948 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13166 (DOI: 10.21873/anticanres.13166, PubMed: 30711948)
42.	Yoshito Kusuhara, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 腎摘除術, 副腎摘除術における血管処理のポイント, Japanese Journal of Endourology, Vol.32, No.1, 62-65, 2019. (Summary) <p> 腹腔鏡下腎摘除術や副腎摘除術は, 簡便な低侵襲手術として標準化され普及している. 本項では, 腎茎の血管処理を安全に遂行するための術前準備, 血管処理の基本について述べた. 術前に血管走行などの作図を行い, 手術手順を確認する準備が重要である. 術前に把握されていない構造物に遭遇した際には, 手技を中断し, 画像を見直すことで安全に手術を遂行できる. また, 手術後に手術動画を省みることで, 画像読影力や作図能力は向上していく.</p><p> 血管処理は, 「血管以外の組織を凝固切離した結果, 血管だけが残った」という考えで, 丁寧に基本に忠実に行う. 助手の術野展開と鏡の選定を行い, 処理に適した角度から良好な視野を得る. 血管は把持せず, 血管に垂直に鉗子を動かし剥離を行う. 微量な出血も放置せず, その都度止血し無血野を保つ. 各種デバイスの特性を理解し, 処理に最適なデバイスを選択する.</p> (Tokushima University Institutional Repository) ● Metadata: 115193 (Link to Publication Site) ● Publication site (DOI): 10.11302/jsejje.32.62 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390564238108124416 ● Search Scopus @ Elsevier (DOI): 10.11302/jsejje.32.62 (Tokushima University Institutional Repository: 115193, DOI: 10.11302/jsejje.32.62, CiNii: 1390564238108124416)
43.	Satoru Shimochi, Kei Daizumoto, Keisuke Ozaki, Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : [Renal Angiomyolipoma Extending into the Renal Vein --A Case Report-]., Acta Urologica Japonica, Vol.64, No.5, 213-217, 2018. (Summary) We report a case of left renal angiomyolipoma extending into the renal vein. A 67-year-old woman showed a left renal tumor which was 6 cm in diameter and had density equal to fat tissue in computed tomography. We suspected liposarcoma and performed radical nephrectomy and resection of thrombus. The pathological diagnosis was angiomyolipoma with no malignancy. To our knowledge, renal angiomyolipoma with tumor thrombus has been reported in 62 cases, and pulmonary embolism developed in 9 of these cases. We conclude that surgical treatment is effective in treating angiomyolipoma with tumor thrombus. (Keyword) Aged / Angiomyolipoma / Female / Humans / Kidney Neoplasms / Nephrectomy / Renal Veins / Thrombosis / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.14989/ActaUrolJap_64_5_213 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30064160 ● Search Scopus @ Elsevier (PMID): 30064160 ● Search Scopus @ Elsevier (DOI): 10.14989/ActaUrolJap_64_5_213 (DOI: 10.14989/ActaUrolJap_64_5_213, PubMed: 30064160)
44.	Masayuki Takahashi and Hiro-omi Kanayama : 【小児腹腔内精巣-どう扱うか?】腹腔内精巣に対する腹腔鏡下二期的Fowler-Stephens法, Japanese Journal of Endourology, Vol.31, No.1, 51-54, 2018. (Link to Publication Site) ● Publication site (DOI): 10.11302/jsejje.31.51 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11302/jsejje.31.51 (DOI: 10.11302/jsejje.31.51)
45.	Hidehisa Mori, Tomoharu Fukumori, KEI DAIZUMOTO, MEGUMI TSUDA, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Predictive Factors for Prolonged Urination Disorder After Permanent 125I Brachytherapy for Localized Prostate Cancer, In Vivo, Vol.31, No.4, 755-761, 2017. (Summary) We assessed the change in LUTS after prostate brachytherapy to reveal factors for prolonged urination disorder. Four hundred and four patients received prostate brachytherapy at our institution and were followed-up for at least 2 years. We evaluated the correlation of mean IPSS changes and clinical factors. Using multivariate analysis, we also evaluated clinical factors with potential to delay IPSS resolution. In cases with prostate volume more than 30 cm, radiation dose to 90% of prostate volume (D90) more than 160 Gy, and radiation dose to 30% of the urethral volume (UD30) more than 240 Gy, mean IPSS levels were significantly higher, even 30 months after treatment. On multivariate analysis, baseline IPSS more than 8 points and D90 more than 160 Gy were significant predictors for delayed IPSS resolution. Our data suggest that higher baseline IPSS and higher D90 were predictors for prolonged urination disorder. (Keyword) Aged / Aged, 80 and over / Brachytherapy / Humans / Iodine Radioisotopes / male / Middle Aged / Prostate / Prostate-Specific Antigen / Prostatic Neoplasms / Urination Disorders (Tokushima University Institutional Repository) ● Metadata: 113626 (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28652453 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028539877 (Tokushima University Institutional Repository: 113626, DOI: 10.21873/invivo.11127, PubMed: 28652453, Elsevier: Scopus)
46.	Terumichi Shintani, Yoshito Kusuhara, Kei Daizumoto, Tsogt-Ochir Dondoo, Yasuyo Yamamoto, Hidehisa Mori, Tomoya Fukawa, Hiroyoshi Nakatsuji, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells., Urology, Vol.101, 169.e7-169.e13, 2017. (Summary) To clarify the invasive mechanisms of muscle-invasive bladder cancer (BCa) would be useful for the determination of appropriate treatment strategies. We previously showed that hepatocyte growth factor (HGF)-MET signaling is correlated with invasiveness of BCa cells. Here, we investigated the effects of the MET inhibitor, cabozantinib (XL184), on BCa cells. We first conducted Western blot analysis to investigate MET expression in BCa cell lines. Next, we examined the effect of cabozantinib on their proliferation and invasive abilities using MTT and Matrigel invasion assays, respectively. Invasion assays were performed using the xCELLigence system. Additionally, to investigate the biological function of HGF-MET signaling, we analyzed gene expression profiles and performed real-time polymerase chain reaction analyses of 5637 cells that were cultivated with or without HGF stimulation, with or without cabozantinib. MET was highly expressed in 4 of 5 BCa cell lines, and 5637 and T24 cells showed especially high protein expression of MET. Cabozantinib suppressed cell proliferation and invasion (cell index; mock, 1.49 vs HGF, 2.26 vs HGF + XL184, 1.47, P < .05). Gene expression profile analysis indicated that matrix metalloproteinase 1 (MMP1) was significantly elevated at the mRNA level with addition of HGF. Moreover, cabozantinib suppressed HGF-induced MMP1 expression in 5637 T24 cells. These data indicate that cabozantinib suppressed MMP1 expression by blocking HGF-MET signaling and that HGF-MET-MMP1 signaling is involved in the invasiveness and proliferation of BCa cells. These results suggest that cabozantinib might prove useful for future treatment of muscle-invasive BCa. (Keyword) Anilides / Blotting, Western / Cell Count / Cell Line, Tumor / Cell Proliferation / Gene Expression Regulation, Neoplastic / Hepatocyte Growth Factor / Humans / Matrix Metalloproteinase 1 / Neoplasm Invasiveness / Protein Array Analysis / Proto-Oncogene Proteins c-met / Pyridines / RNA, Neoplasm / Receptor Protein-Tyrosine Kinases / Reverse Transcriptase Polymerase Chain Reaction / signal transduction / Urinary Bladder / Urinary Bladder Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110112 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2016.12.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28013036 ● Summary page in Scopus @ Elsevier: 2-s2.0-85009932260 (Tokushima University Institutional Repository: 110112, DOI: 10.1016/j.urology.2016.12.006, PubMed: 28013036, Elsevier: Scopus)
47.	Masayuki Takahashi and Hiro-omi Kanayama : LAPAROSCOPIC PYELOPLASTY IN CHILDREN-ADVANCEMENT OF NEW TECHNIQUES, The Nishinihon Journal of Urology, Vol.78, No.4, 172-177, 2016. (Keyword) 腹腔鏡下腎盂形成術 / 経腹膜 / 後腹膜 / 経腸間膜 / 単孔式腹腔鏡下手術 / laparoscopic pyeloplasty / transperitoneal / retroperitoneal / transmesenteric / laparoendoscopic single-site (LESS) (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572358445395200 ● Summary page in Scopus @ Elsevier: 2-s2.0-84973661387 (CiNii: 1520572358445395200, Elsevier: Scopus)
48.	Tomokazu Senzaki, Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy., Urologia Internationalis, Vol.95, No.4, 457-464, 2015. (Summary) The aim of this study is to clarify the clinical significance of neoadjuvant combined androgen blockade (CAB) for ≥ 6 months in patients with localized prostate cancer. A total of 431 patients with localized prostate cancer who underwent prostate brachytherapy (BT) with or without neoadjuvant CAB for ≥ 6 months with mean follow-up time of 64.6 months (range 24-108 months) were evaluated retrospectively. Of those 431, 232 patients received BT in combination with neoadjuvant CAB for ≥ 6 months. Biochemical recurrence-free rates (BRFRs) in 364 patients with at least 3 years of follow-up were evaluated by log-rank test. BRFR in patients with low-, intermediate- and high-risk prostate cancer were 98.1, 94.2 and 89.1%, respectively. In patients with intermediate-risk prostate cancer only, neoadjuvant CAB was significantly associated with BRFR (p = 0.0468). Especially in patients with intermediate-risk prostate cancer with radiation dose received by 90% of the prostate (D90) < 180 Gy, neoadjuvant CAB exerted a favorable impact on BRFR (p = 0.0429). On multivariate analyses, neoadjuvant CAB and D90 were independent predictors of BRFR (p = 0.0061 and p < 0.0001, respectively). Neoadjuvant CAB for ≥ 6 months has a favorable impact on BRFR in patients with intermediate-risk prostate cancer, particularly in patients with relatively low radiation doses of D90. (Link to Publication Site) ● Publication site (DOI): 10.1159/000439573 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26461847 ● Search Scopus @ Elsevier (PMID): 26461847 ● Search Scopus @ Elsevier (DOI): 10.1159/000439573 (DOI: 10.1159/000439573, PubMed: 26461847)
49.	小居浩之, 大豆本圭, Yasuyo Yamamoto, Jun-ichiro Kagawa, Masatsugu Komori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Hirofumi Izaki : RETROPERITONEAL SCHWANNOMA WITH INCREASED F18-FLUORODEOXYGLUCOSE UPTAKE ON POSITRON EMISSION TOMOGRAPHY : A CASE REPORT, The Nishinihon Journal of Urology, Vol.77, No.8, 297-301, 2015. (Keyword) 後腹膜神経鞘腫 / ¹⁸F-FDGPET-CT / retroperitoneal schwannoma (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853833143993344 ● Summary page in Scopus @ Elsevier: 2-s2.0-84941121427 (CiNii: 1520853833143993344, Elsevier: Scopus)
50.	Masayuki Takahashi, Yoshito Kusuhara, Hidehisa Mori, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer., Clinical Genitourinary Cancer, Vol.13, No.4, e337-40, 2015. (Keyword) Aged / Antineoplastic Agents / Bone Neoplasms / Drug Administration Schedule / Fatal Outcome / Humans / Maintenance Chemotherapy / Male / Middle Aged / Prostatic Neoplasms, Castration-Resistant / Taxoids (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clgc.2015.01.012 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25770768 ● Summary page in Scopus @ Elsevier: 2-s2.0-84936985299 (DOI: 10.1016/j.clgc.2015.01.012, PubMed: 25770768, Elsevier: Scopus)
51.	Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Masaaki Nishitani, Yasushi Sutou, Kenzou Uema, Akira Kawano, Takumi Hamao and Hiro-omi Kanayama : Changes in levels of prostate-specific antigen and testosterone following discontinuation of long-term hormone therapy for non-metastatic prostate cancer., The Journal of Medical Investigation : JMI, Vol.61, No.1-2, 35-40, 2014. (Summary) We evaluated changes in levels of prostate-specific antigen (PSA) and testosterone following discontinuation of long-term hormone therapy for non-metastatic prostate cancer. Treatment was discontinued in 31 patients with non-metastatic prostate cancer (clinical stage B-C) after ≥ 5 years of hormone therapy, during which time PSA level had been maintained less than 0.5 ng/ml. PSA and testosterone levels were measured after discontinuation of therapy. PSA > 4.0 ng/ml was defined as PSA relapse in this study. Mean age at discontinuation of hormone therapy was 78.7 years (range, 66-90). Mean duration of follow-up after discontinuation of therapy was 25.5 months. PSA non-relapse rate was quite high (87.1%). 4 of the 31 patients showed PSA relapse, after 12-24 months. Testosterone level exceeded castration level (< 1.0 ng/ml) in 3 patients, each of whom developed PSA relapse. During follow-up, the PSA relapse rate was relatively low. These results suggest that treatment may be safely discontinued in many prostate cancer patients. In addition, rate of testosterone recovery after treatment discontinuation may be associated with PSA relapse. When considered the adaptation of discontinued, or intermittent hormone therapy for aged people, these findings may be useful. (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.35 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705746 ● Summary page in Scopus @ Elsevier: 2-s2.0-84897929249 (DOI: 10.2152/jmi.61.35, PubMed: 24705746, Elsevier: Scopus)
52.	Masayuki Takahashi and Hiro-omi Kanayama : Updated systemic therapy for advanced/metastatic renal cell carcinoma and prostate cancer, Shikoku Acta Medica, Vol.69, No.5,6, 201-206, 2013. (Summary) As advanced renal cell carcinoma (RCC) shows resistance to anti-cancer drugs, immunotherapy had been the mainstay of systemic therapy. Recently, molecular targeted agents including VEGF and mTOR inhibitors have been introduced, and so systemic therapy for advanced RCC has been significantly altered. VEGF inhibitors show marked efficacy in regard to tumor size reduction, and the representative adverse events include hypertension, hand-foot syndrome, and hypothyroidism. mTOR inhibitors have modest effects for tumor size reduction, and the specific adverse events include stomatitis, hyperglycemia, hyperlipidemia, and interstitial pneumonia. The introduction of molecular targeted agents has improved survival in advanced RCC patients. Hormonal therapy is at the center of systemic therapy for advanced prostate cancer patients. Castration or LH-RH analogues suppress the proliferation of prostate cancer cells by decreasing androgen production in the testes. Anti-androgens inhibit the binding of testosterone to androgen receptors, and combination therapy of castration or LH-RH analogues and anti-androgens, called maximum androgen blockade, shows enhanced efficacy for advanced prostate cancer. Docetaxel is administered for castration-resistant prostate cancer, and prolongs survival compared to previously used anti-cancer drugs. Regarding new drugs for prostate cancer, an LH-RH antagonist, a CYP17 inhibitor of androgen production in the adrenal glands, and new anti-androgens with a higher affinity for androgen receptors have been developed for clinical use. (Keyword) renal cell carcinoma / prostate cancer / molecular targeted therapy / hormonal therapy / docetaxel (Tokushima University Institutional Repository) ● Metadata: 109726 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050564287418406400 (Tokushima University Institutional Repository: 109726, CiNii: 1050564287418406400)
53.	Masanori Hirono, Mikio Kobayashi, Tomoyasu Tsushima, Wataru Obara, Nobuo Shinohara, Keiichi Ito, Masatoshi Eto, Tatsuya Takayama, Yasuhisa Fujii, Masaharu Nishikido, Go Kimura, Takeshi Kishida, Masayuki Takahashi, Noriomi Miyao, Yukio Naya, Takashige Abe, Tomoaki Fujioka, Kazuto Ito and Seiji Naito : Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan., BMC Cancer, Vol.13, 447, 2013. (Summary) Although the percentage of patients with renal cell carcinoma (RCC) extending into venous systems is unexpectedly high, the prognostic impact and independency of venous tumor thrombus-related factors on overall survival (OS) remain controversial. Furthermore, the prognostic impact of various clinicopathologic factors including tumor thrombus-related factors on OS may change with elapsed years after the intervention and also with follow-up duration of participants. The aim of the study is to explore independent and universal predictive preoperative and intraoperative clinicopathologic factors on OS in patients with RCC extending into venous systems using subgroup analysis in terms of restricted follow-up duration and yearly-based survivors. Between 1980 and 2009, 292 patients diagnosed with RCC with venous tumor thrombus were retrospectively registered for this study. The prognostic impacts of various clinicopathologic and surgical treatment factors including levels of venous thrombus, venous wall invasion status and likelihood of aggressive cytoreductive operation, were investigated using Kaplan-Meier method and following multivariate Cox proportional hazards model for all patients and those still alive at 1, 2, and 3 years of follow-up. To investigate the impact of follow-up duration on the statistical analyses, multivariate logistic regression analyses were used to explore prognostic factors using restricted data until 1, 2, and 3 years of follow-up. The median follow-up duration was 40.4 months. The 5-year OS was 47.6%. Several independent predictive factors were identified in each subgroup analysis in terms of yearly-based survival and restricted follow-up duration. The presence of tumor thrombus invading to venous wall was independently related to OS in the full-range follow-up data and in survivors at 2 and 3 years of follow-up. Using restricted follow-up data until 1, 2, and 3 years of follow-up, many independent predictive factors changed with follow-up duration, but surgical category could be universal and independent predictive factors. The most universal factors affecting improvement both in short-term and long-term survivals could be cytoreductive surgery and absence of venous wall invasion. It may mean that feasible aggressive cytoreductive operation following more reliable preoperative imaging for predicting venous wall invasion status would improve OS for patients with RCC extending into venous systems. (Keyword) Aged / Carcinoma, Renal Cell / Female / Follow-Up Studies / Humans / Japan / Kidney Neoplasms / Male / Middle Aged / Neoplasm Grading / Neoplasm Metastasis / Neoplastic Cells, Circulating / Nephrectomy / Proportional Hazards Models / Retrospective Studies / Treatment Outcome / Tumor Burden / Venous Thrombosis (Link to Publication Site) ● Publication site (DOI): 10.1186/1471-2407-13-447 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24083566 ● Search Scopus @ Elsevier (PMID): 24083566 ● Search Scopus @ Elsevier (DOI): 10.1186/1471-2407-13-447 (DOI: 10.1186/1471-2407-13-447, PubMed: 24083566)
54.	佐々木雄太郎, 小居浩之, 大山拓郎, Jun-ichiro Kagawa, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Hisaya Takahashi, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : NON-MUSCLE INVASIVE BLADDER CANCER WITH MULTIPLE BONE METASTASIS WITHOUT LOCAL INVASION : A CASE REPORT, Acta Urologica Japonica, Vol.59, No.10, 669-672, 2013. (Summary) A 66-year-old man with superficial bladder cancer was treated with transurethral resection (TURBT) in October 2011. The pathological diagnosis was urothelial carcinoma (UC), grade 2, T1. A second TURBT was performed one month later. The pathological diagnosis was UC, grade 3, T1. He was treated with intravesical bacillus Calmette-Guerin (BCG) after TURBT. His progress was satisfactory, but a small superficial bladder cancer was found on cystoscopy in August 2012. He was going to be treated with TURBT, but the serum alkaline phosphatase level was abnormally high on preoperative evaluation. Bone scintigraphy showed multiple bone metastases from non-muscle invasive bladder cancer (NMIBC) without local invasion. He was started on combined chemotherapy with 1,000 mg/m2 gemcitabine on days 1, 8 and 15 and 70 mg/m2 cisplatin on day 2 every four weeks. He received denosumab for multiple bone metastases at the same time. Although he subsequently developed severe hypocalcemia, treatment was continued, and he completed four courses of chemotherapy. Bone scintigraphy and contrast-enhanced computed tomography showed reduction of the multiple bone metastases, and alkaline phosphatase decreased to the normal range. It is rare for NMIBC without local invasion to metastasize to other organs. Thus, it is necessary to consider distant metastases in patients with NMIBC. (Keyword) Non-muscle invasive / Bladder cancer / Bone metastasis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24262709 ● CiNii @ National Institute of Informatics (CRID): 1050845760708113920 ● Summary page in Scopus @ Elsevier: 2-s2.0-84888314282 (PubMed: 24262709, CiNii: 1050845760708113920, Elsevier: Scopus)
55.	Sei Naito, Hidefumi Kinoshita, Tsunenori Kondo, Nobuo Shinohara, Takashi Kasahara, Kazutaka Saito, Tatsuya Takayama, Naoya Masumori, Wataru Takahashi, Masayuki Takahashi, Toshiro Terachi, Seiichiro Ozono, Seiji Naito and Yoshihiko Tomita : Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients., Urology, Vol.82, No.4, 846-851, 2013. (Summary) To investigate the prognosis and prognostic factors of patients with metastatic renal cell carcinoma who underwent metastasectomy. We sent questionnaires to Japanese hospitals. The questionnaires included data of patients with metastatic renal cell carcinoma who had their metastatic lesions removed between January 1988 and December 2009. We collected them and retrospectively analyzed these data and calculated the overall survival from the first metastasectomy until death or last follow-up. We also analyzed the relationship between survival and clinico-pathologic features and determined adverse prognostic factors. Furthermore, we identified a poor prognostic group by counting the number of prognostic factors. A sample size of 556 patients from 48 institutions was studied. The median overall survival was 80 months. Four adverse prognostic factors were detected: incomplete resection by metastasectomy (hazard ratio [HR], 2.15), brain metastasis (HR, 3.73), >1.0 mg/dL C-reactive protein (HR, 2.45), and the highest histologic grade in Japanese classification (nuclei of tumor cells are larger than nuclei of normal tubular cells; HR, 1.88). The median overall survivals of patients with 3 or 4 prognostic factors, 2 factors, and 0 and 1 factors were 10 months, 42 months, and 105 months, respectively. Four adverse prognostic factors for predicting the survival of patients with removed metastases were identified. Patients with 3 or 4 of these adverse prognostic factors had a worse prognosis. (Keyword) Adult / Aged / Aged, 80 and over / Asian Continental Ancestry Group / Carcinoma, Renal Cell / Female / Humans / Kidney Neoplasms / Male / Metastasectomy / Middle Aged / Prognosis / Retrospective Studies / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2013.06.035 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24074981 ● Search Scopus @ Elsevier (PMID): 24074981 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2013.06.035 (DOI: 10.1016/j.urology.2013.06.035, PubMed: 24074981)
56.	Masayuki Takahashi, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 小児低形成腎/機能低下腎に対する腹腔鏡下腎摘除術の臨床的検討, Japanese Journal of Endourology, Vol.26, No.2, 263-269, 2013. (Summary) We reviewed the results of laparoscopic nephrectomy for children with a hypoplastic or poorly functioning kidney in our department. Laparoscopic nephrectomy was performed in 10 patients including 1 boy and 9 girls. The patients' median age was 5.5 years old. There were 8 patients with a hypoplastic kidney and an ectopic ureter, and 2 patients with a poorly functioning kidney and a megaureter or vesicoureteral reflux. Laparoscopic nephrectomy was conducted transperitoneally in 5 and retroperitoneally in 5 patients. The median operative time was 167 minutes. There was no intraoperative complication. Postoperatively, subcutaneous emphysema and fever developed in one patient each. 7 patients used an analgesic suppository once or several times, and 3 patients received no analgesics. Oral intake was started at a median of 1 day postoperatively. The median hospital stay after surgery was 4.5 days. Laparoscopic nephrectomy for a hypoplastic and poorly functioning kidney in children is a minimally invasive surgery. (Keyword) 小児 / 鏡視下腎摘除術 / 尿管異所開口 (Link to Publication Site) ● Publication site (DOI): 10.11302/jsejje.26.263 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205509695360 ● Search Scopus @ Elsevier (DOI): 10.11302/jsejje.26.263 (DOI: 10.11302/jsejje.26.263, CiNii: 1390001205509695360)
57.	Masayuki Takahashi, Kawabata Rumi, Kawano Akira, Murakami Yoshihide, Sutou Yasushi, Inai Tohru, Akazawa Seiji, Hamao Takumi, Hayashi Hideki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : Substitution of antiandrogens and tegafur-uracil combination therapy for castration-resistant prostate cancer: results of a multi-center randomized phase II study, International Journal of Oncology, Vol.43, No.3, 713-720, 2013. (Summary) We conducted this study to determine whether substitution with anti-androgen (SOA) and tegafur-uracil (a pro-drug of 5-FU) combination therapy is more effective than SOA alone after relapse from initial hormonal therapy. Patients who were histologically confirmed and relapsed after initial hormonal therapy were included. All patients were randomly allocated into two groups: SOA alone (group A) or SOA combined with tegafur-uracil (group B). The mRNA expression of four enzymes, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phospho-ribosyltransferase (OPRT) and thymidine phosphorylase (TP), in prostate cancer cells was analyzed by quantitative reverse-transcription polymerase chain reaction. Fifty-two patients were enrolled in this study. The median age was 77 (range: 47-92) years. The PSA response rate in group B (61.5%) tended to be higher compared to that in group A (34.6%) (p=0.095). Group B (median: 15.9 months) had a significantly longer time to PSA progression (TTP) compared to group A (6.4 months) (p=0.014). In patients with a lower TS expression or a higher OPRT expression, group B demonstrated a higher PSA response rate compared to group A (p=0.019 and p=0.041, respectively). In addition, in the patients with a lower TS expression, group B demonstrated a significantly longer TTP compared to group A (p=0.018). There were no severe adverse events in either treatment group. After relapse from initial hormonal therapy, SOA combined with tegafur-uracil is effective and well tolerated. The TS mRNA expression level may be a predictive factor for this combination therapy. (Keyword) Aged / Aged, 80 and over / Androgen Antagonists / Antineoplastic Combined Chemotherapy Protocols / Dihydrouracil Dehydrogenase (NADP) / Gene Expression Regulation, Neoplastic / Humans / Male / Middle Aged / Orotate Phosphoribosyltransferase / Prostatic Neoplasms, Castration-Resistant / RNA, Messenger / Tegafur / Thymidine Phosphorylase / Thymidylate Synthase / Uracil (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2013.1997 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23817692 ● Summary page in Scopus @ Elsevier: 2-s2.0-84880578556 (DOI: 10.3892/ijo.2013.1997, PubMed: 23817692, Elsevier: Scopus)
58.	Hisaya Takahashi, Yasuyo Yamamoto, 小居浩之, 大山拓郎, 佐々木雄太郎, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL EXPERIENCE OF INTERSTITIAL CYSTITIS TREATED WITH HYDRODISTENSION, The Nishinihon Journal of Urology, Vol.75, No.8, 413-417, 2013. (Keyword) 間質性膀胱炎 / 水圧拡張術 / interstitial cystitis (IC) hydrodistension (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290882119498752 ● Summary page in Scopus @ Elsevier: 2-s2.0-84884299458 (CiNii: 1520290882119498752, Elsevier: Scopus)
59.	Masayuki Takahashi and Hiro-omi Kanayama : TREATMENT ALGORITHM FOR ADVANCED/METASTATIC RENAL CELL CARCINOMA : AVAILABILITY OF NEW CANDIDATE AGENTS FOR USE IN THE NEAR FUTURE, The Nishinihon Journal of Urology, Vol.75, No.5, 218-224, 2013. (Keyword) renal cell carcinoma / molecular targeted agent / treatment algorithm / near future (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572358200310272 ● Summary page in Scopus @ Elsevier: 2-s2.0-84879205280 (CiNii: 1520572358200310272, Elsevier: Scopus)
60.	Tomoteru Kishimoto, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : Mineralocorticoid receptor expression in human penile corpus cavernosum, The Journal of Medical Investigation : JMI, Vol.60, 21-26, 2013. (Summary) Mineralocorticoid receptor (MR) is known to play physiological and pathophysiological roles in the cardiovascular system, and MR activation directly damages these organs. The aim of this study was to evaluate the expression of MR and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in the human penile corpus cavernosum. MR and 11β-HSD2 expression was assayed in human penile tissues, and also in human renal tissues as a positive control. Expressions of MR mRNA and 11β-HSD2 mRNA were evaluated using reverse transcription polymerase chain reaction (RT-PCR). MR and 11β-HSD2 were visually identified using immunofluorescence analysis. MR mRNA expression in human penis was confirmed by RT-PCR. On quantitative RT-PCR analysis, 11β-HSD2 mRNA expression was detected at minimal levels in penile tissue. Immunofluorescence analysis revealed positive staining for MR and negative staining for 11β-HSD2 in smooth muscle cells of the corpus cavernosum. This study demonstrated the presence of MR and the absence of 11β-HSD2 in human penile corpus cavernosum. Considering that MR activation causes various organ damages, MR blockade in human penile corpus cavernosum may have therapeutic benefits. Investigations for the penile effects of MR activation have the potential to provide new treatment approaches for erectile dysfunction. (Keyword) 11-beta-Hydroxysteroid Dehydrogenase Type 2 / Adult / Aged / Erectile Dysfunction / Fluorescent Antibody Technique / Humans / Male / Middle Aged / Mineralocorticoid Receptor Antagonists / Penis / RNA, Messenger / Receptors, Mineralocorticoid (Tokushima University Institutional Repository) ● Metadata: 106037 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614907 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876057957 (Tokushima University Institutional Repository: 106037, DOI: 10.2152/jmi.60.21, PubMed: 23614907, Elsevier: Scopus)
61.	Hisaya Takahashi, 津田恵, 大豆本圭, 三宅毅志, 塩﨑啓登, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL EXPERIENCE OF REITER'S SYNDROME FOLLOWING BCG INTRAVESICAL THERAPY, The Nishinihon Journal of Urology, Vol.76, 10-14, 2013. (Keyword) Reiter症候群 / BCG膀胱内注入療法 / 膀胱癌 / Reiter's syndrome / intravesical BCG therapy / bladder cancer (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853832090604416 ● Summary page in Scopus @ Elsevier: 2-s2.0-84894647903 (CiNii: 1520853832090604416, Elsevier: Scopus)
62.	Masayuki Takahashi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 分子標的薬投与中に腸管穿孔をきたした2例, 泌尿器外科, Vol.26, 106-108, 2013.
63.	Takuya Tsujioka, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : BCG膀胱内注入療法後に発症した結核性精巣上体炎の1例, 泌尿器外科, Vol.25, No.11, 2217-2220, 2012.
64.	Nobuo Shinohara, Katsuya Nonomura, Takashige Abe, Satoru Maruyama, Takao Kamai, Masayuki Takahashi, Katsunori Tatsugami, Shigeaki Yokoi, Takashi Deguchi, Hiroomi Kanayama, Koji Oba and Seiji Naito : A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma, Cancer Science, Vol.103, No.9, 1695-1700, 2012. (Summary) The aims of the present study were to: (i) develop a clinically useful prognostic classification in Asian patients with metastatic renal cell carcinoma (RCC) by combining metastatic features with several pretreatment parameters; and (ii) evaluate the validity of this prognostic classification. Baseline characteristics and outcomes were collected for 361 patients who underwent interferon-α-based therapy between 1995 and 2005. Relationships between overall survival (OS) and potential prognostic factors were assessed using Cox's proportional hazard model. The predictive performance of the model was evaluated using bootstrap resampling procedures and by using an independent dataset obtained from randomly selected institutions. The predictive accuracy was measured using the concordance index (c-index). Four factors were identified as independent prognostic factors: time from initial diagnosis to treatment, anemia, elevated lactate dehydrogenase (LDH), and poor prognostic metastatic group (liver only, bone only, or multiple organ metastases). Each patient was assigned to one of three risk groups: favorable risk (none or one factor; n = 120), in which median OS was 51 months; intermediate risk (two factors; n = 101), in which median OS was 21 months; and poor risk (three or four factors; n = 102), in which median OS was 10 months. The c-index was 0.72 in the original dataset and 0.72 in 500 random bootstrap samples. In the independent dataset for external validation, the c-index was 0.73. Thus, the new prognostic classification is easily applicable for Asian patients with previously untreated metastatic RCC and should be incorporated into patient care, as well as clinical trials performed in Asia. (Keyword) Adult / Aged / Aged, 80 and over / Asian Continental Ancestry Group / Carcinoma, Renal Cell / Female / Humans / Interferon-alpha / Kidney Neoplasms / Male / Metastasectomy / Middle Aged / Neoplasm Metastasis / Prognosis / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1349-7006.2012.02351.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22642767 ● Search Scopus @ Elsevier (PMID): 22642767 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.2012.02351.x (DOI: 10.1111/j.1349-7006.2012.02351.x, PubMed: 22642767)
65.	Masayuki Takahashi, Kosuke Seto, Takuya Tsujioka, Ryotaro Tomita, Megumi Tsuda, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : SEQUENTIAL THERAPY WITH MOLECULAR TARGETED AGENTS FOR ADVANCED RENAL CELL CARCINOMA, The Nishinihon Journal of Urology, Vol.74, No.5, 258-263, 2012. (Keyword) renal cell carcinoma / molecular targeted agent / sequential therapy (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572357422341632 ● Summary page in Scopus @ Elsevier: 2-s2.0-84861809136 (CiNii: 1520572357422341632, Elsevier: Scopus)
66.	Hisaya Takahashi, Hiroyoshi Nakatsuji, Masayuki Takahashi, Avirmed Shiirevnyamba, Tomoya Fukawa, Masahiko Takemura, Tomoharu Fukumori and Hiro-omi Kanayama : Up-regulation of Plakophilin-2 and Down-regulation of Plakophilin-3 are Correlated With Invasiveness in Bladder Cancer, Urology, Vol.79, No.1, 240e1-240e8, 2012. (Summary) To examine plakophilin proteins (Pkp) and 3 expression levels in bladder cancer, in particular their levels during cellular growth and invasion. Pkp is associated with the binding of cadherin to intermediate filaments of the cytoskeleton. The relative mRNA and protein expression levels of Pkp2 and 3 in bladder cancer cell lines were determined using quantitative real-time polymerase chain reaction and Western blot analyses. The cellular localization of Pkp2 and 3 proteins in bladder cancer cells was also assayed using immunohistochemistry. The proliferation and invasive activities of bladder cancer cells were evaluated using cell growth and in vitro cell invasion assays, and were compared with those of bladder cancer cells treated with Pkp2 and 3 small interfering RNAs. Pkp2 mRNA and protein levels were elevated, and those of Pkp3 were reduced, in bladder cancer cells that are known to exhibit increased proliferation and invasive activity. Pkp2/3 protein expression was predominantly observed in the cytoplasm of invasive bladder cancer cells and tissues. Pkp2 knockdown inhibited, and Pkp3 knockdown enhanced, invasion of bladder cancer cells, but these knockdowns did not alter cell proliferation. We conclude that high Pkp2, and low Pkp3, expression is associated with bladder cancer cell invasion and that neither Pkp2 nor Pkp3 is associated with cell proliferation. We further hypothesize that accumulation of Pkp2 and 3 in the cell cytoplasm, rather than their recruitment to the cell membrane, is related to an increased ability of the tumor to invade and metastasize. (Keyword) Blotting, Western / Cell Line, Tumor / Cell Proliferation / Down-Regulation / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Microscopy, Fluorescence / Neoplasm Invasiveness / Plakophilins / RNA, Messenger / Real-Time Polymerase Chain Reaction / Sensitivity and Specificity / Up-Regulation / Urinary Bladder Neoplasms (Tokushima University Institutional Repository) ● Metadata: 106137 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2011.08.049 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22119253 ● Search Scopus @ Elsevier (PMID): 22119253 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2011.08.049 (Tokushima University Institutional Repository: 106137, DOI: 10.1016/j.urology.2011.08.049, PubMed: 22119253)
67.	Rumi Kawabata, Shinji Oie, Masayuki Takahashi, Hiro-omi Kanayama, Toshinori Oka and Kouji Itou : Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines., International Journal of Oncology, Vol.38, No.6, 1489-1500, 2011. (Summary) In this study, we investigated the synergistic mechanism of anti-androgen and 5-fluorouracil (5-FU) combination therapy against castration-resistant prostate cancer (CRPC). Four prostate cancer cell lines, LNCaP, 22Rv1, DU145 and PC3, were examined for their growth dependency on androgens and the insulin-like growth factor 1 (IGF1). We assessed the expression changes of certain growth factor receptors and regulating proteins when treated with 5-FU, and found that 5-FU increased the expression of the IGF-binding protein 3 (IGFBP3). Furthermore, 5-FU inhibited the phosphorylation of Akt and p70 S6K, while the knockdown of IGFBP3 reduced the levels of poly (ADP-ribose) polymerase cleaved by 5-FU in PC3 cells. Therefore, the up-regulation of IGFBP3 by 5-FU not only inhibits cell growth by reducing the IGF1 signal but also induces apoptosis in PC3 cells. The synergistic effect of bicalutamide and 5-FU on 22Rv1 cells was reduced by IGFBP3 gene silencing using small-interfering RNA. These results suggest that the up-regulation of IGFBP3 induced by 5-FU plays an important role in the potent anti-tumor effect of 5-FU combined with anti-androgens on CRPC. Androgen-deprivation therapy combined with 5-FU could therefore be an appropriate therapy for CRPC patients. (Keyword) Androgen Antagonists / Androgens / Anilides / Antineoplastic Agents / apoptosis / Cell Line, Tumor / Cell Proliferation / Drug Synergism / Fluorouracil / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Insulin-Like Growth Factor Binding Protein 3 / Insulin-Like Growth Factor I / Male / Nitriles / Prostatic Neoplasms / RNA Interference / Receptors, Growth Factor / Signal Transduction / Tosyl Compounds / Up-Regulation (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2011.991 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21455575 ● Search Scopus @ Elsevier (PMID): 21455575 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2011.991 (DOI: 10.3892/ijo.2011.991, PubMed: 21455575)
68.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Shunsuke Furutani, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 中間リスク群，高リスク群前立腺癌に対するI-125密封小線源療法の治療成績, Japanese Journal of Endourology, Vol.24, No.1, 131-135, 2011. (Keyword) prostate cancer / brachytherapy / risk group classification (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205509858560 (CiNii: 1390001205509858560)
69.	Rumi Kawabata, Shinji Oie, Toshinori Oka, Masayuki Takahashi, Hiro-omi Kanayama and Kouji Itou : Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells, International Journal of Oncology, Vol.38, No.3, 665-676, 2011. (Summary) We investigated the antitumor effects of combination therapy with anti-androgens and 5-fluorouracil (5-FU), and examined the underlying mechanism of the treatment. Initially, we established the bicalutamide-resistant subline CDX25R from the androgen receptor (AR)-positive human prostate cancer cell line LNCaP through continuous exposure to bicalutamide. CDX25R cells lost the ability to respond to androgens, but still expressed AR. They showed significant resistance to bicalutamide, but had high sensitivity to hydroxyflutamide (OH-flutamide) compared with LNCaP cells. The CDX25R subline was thus considered to be a suitable model for prostate cancer that has developed resistance to first-line hormonal therapy but shows sensitivity to an alternative approach. Combined treatment with 5-FU and OH-flutamide had a synergistic effect on CDX25R cells. OH-flutamide decreased expression of the transcription factor E2F1, and subsequently of thymidylate synthase (TS), in CDX25R cells but not in AR-negative DU145 cells. This suggested that OH-flutamide enhanced the growth-inhibitory activity of 5-FU in CDX25R cells by reducing TS expression through the AR pathway. Combined therapy with 5-FU and OH-flutamide may, therefore, be appropriate for patients with prostate cancer that has acquired resistance to initial hormone therapy including bicalutamide. (Keyword) Androgen Antagonists / Anilides / Antimetabolites, Antineoplastic / Carcinoma / Cell Line, Tumor / Drug Evaluation, Preclinical / Drug Resistance, Neoplasm / Drug Synergism / Fluorouracil / Flutamide / Gene Expression Regulation, Enzymologic / Gene Expression Regulation, Neoplastic / Humans / Male / Models, Biological / Neoplasms, Hormone-Dependent / Nitriles / Prostatic Neoplasms / Thymidylate Synthase / Tosyl Compounds (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2011.909 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21243325 ● Search Scopus @ Elsevier (PMID): 21243325 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2011.909 (DOI: 10.3892/ijo.2011.909, PubMed: 21243325)
70.	Nobuo Shinohara, Masayuki Takahashi and Hiro-omi Kanayama : The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma, British Journal of Cancer, Vol.104, No.2, 241-247, 2011. (Summary) To elucidate the incidence and mechanisms of sunitinib-induced thyroid atrophy, we investigated serial volumetric and functional changes, and evaluated histological changes of the thyroid gland in metastatic renal cell carcinoma patients who received sunitinib. Thyroid volume (by computed tomography volumetry) and thyroid function were measured at baseline, during the treatment, and at post-treatment periods. Histological evaluation of the thyroid gland was performed in four autopsied patients. The median reduction rate in thyroid volume at last evaluation during sunitinib treatment was 30% in all 17 patients. The incidence of hypothyroidism during sunitinib treatment was significantly higher in the high reduction rate group (n=8; more than 50% reduction in volume) than in the low reduction rate group (n=9; less than 50% reduction in volume). Half of the patients in the high reduction rate group exhibited a transient thyroid-stimulating hormone suppression, suggesting thyrotoxicosis during sunitinib treatment. Histological evaluation demonstrated atrophy of thyroid follicles and degeneration of follicular epithelial cells without critical diminution of vascular volume in the thyroid gland. Thyroid atrophy is frequently observed following sunitinib treatment and may be brought about by sunitinib-induced thyrotoxicosis or the direct effects of sunitinib that lead to degeneration of thyroid follicular cells. (Keyword) Adult / Aged / Antineoplastic Agents / Carcinoma, Renal Cell / Cohort Studies / Female / Humans / Indoles / Kidney Neoplasms / Male / Neoplasm Metastasis / Pyrroles / Thyroid Function Tests / Thyroid Gland / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1038/sj.bjc.6606029 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21157447 ● Search Scopus @ Elsevier (PMID): 21157447 ● Search Scopus @ Elsevier (DOI): 10.1038/sj.bjc.6606029 (DOI: 10.1038/sj.bjc.6606029, PubMed: 21157447)
71.	Masayuki Takahashi, HIROYUKI YAMAMOTO, AKIHITO YUASA, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL REVIEW OF ELDERLY PATIENTS WITH RENAL TUMORS IN OUR HOSPITAL, The Nishinihon Journal of Urology, Vol.72, No.7, 363-370, 2010. (Summary) 初診時80歳以上の腎腫瘍患者24例(男17例・女7例・中央値81.5歳)の成績を報告した．ECOG performance status(PS)は0:9例，1:7例，2:3例，3:1例，4:3例，不明:1例，臨床病期はstage I:11例，II:2例，III:5例，IV:6例であった．腎摘出術を施行したのは6例で，PSは0:4例，1:1例，2:1例，病期はstage I:4例，II:1例，III:1例であった．非手術の理由は，本人・家族が希望しない，手術適応外，合併症の存在などであった．全生存期間の中央値は25ヵ月で，stage I:44ヵ月，II:10ヵ月，III:9ヵ月，IV:25ヵ月であった．癌特異生存期間の中央値はstage I:44ヵ月，II:10ヵ月，III:15ヵ月，IV:18ヵ月であった．stage I・IIの13例を手術施行5例と非手術8例に分け比較したが，全生存率，癌特異生存率ともに有意差はなかった．また，stage III・IVを治療介入7例と無治療3例に分けて行った比較でも，同様に有意差はなかった． (Keyword) RCC / elderly patients / survival / 腎細胞癌 / 高齢者 / 生存率 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290883090281344 ● Summary page in Scopus @ Elsevier: 2-s2.0-77955855677 (CiNii: 1520290883090281344, Elsevier: Scopus)
72.	Masayuki Takahashi, X J Yang, S McWhinney, Nobuya Sano, C Eng, Susumu Kagawa, B T Teh and Hiro-omi Kanayama : cDNA microarray analysis assists in diagnosis of malignant intrarenal pheochromocytoma originally masquerading as a renal cell carcinoma, Journal of Medical Genetics, Vol.42, 48, 2005. (Summary) Intrarenal pheochromocytoma (paraganglioma) is a very rare tumour. Its diagnosis is often difficult to establish because of its rarity and its histological similarity to renal cell carcinoma (RCC). Recently, we examined the molecular signatures of different subtypes of kidney tumours by using cDNA microarray. The signature pattern for one tumour, which was originally diagnosed as granular cell RCC, was clearly distinct from that of any other subtype of kidney tumour, and led us to re-evaluate the case. Haematoxylin and eosin staining revealed histological features suggestive of pheochromocytoma, and immunohistochemical studies showed positive staining for neuroendocrine markers but not for keratin. A germline missense mutation, D119E, in the familial paraganglioma related gene succinate dehydrogenase subunit D (SDHD), was subsequently identified. The treatment modality was revised and radiotherapy was given, to which the patient responded, leading to a reduction in tumour size of 25% within the first month. To our knowledge, this is the first report of an intrarenal pheochromocytoma that was diagnosed with the assistance of cDNA microarray analysis. (Keyword) intrarenal pheochromocytoma / paraganglioma (Link to Publication Site) ● Publication site (DOI): 10.1136/jmg.2005.031708 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16061554 ● Search Scopus @ Elsevier (PMID): 16061554 ● Search Scopus @ Elsevier (DOI): 10.1136/jmg.2005.031708 (DOI: 10.1136/jmg.2005.031708, PubMed: 16061554)
73.	Ximing J. Yang, Min-Han Tan, Hyung L. Kim, Jonathon A. Ditlev, Mark W. Betten, Carolina E. Png, Eric J. Kort, Kunihiko Futami, Kyle A. Furge, Masayuki Takahashi, Hiro-omi Kanayama, Puay Hoon Tan, Bin Sing Teh, Chunyan Luan, Kim Wang, Michael Pins, Maria Tretiakova, John Anema, Richard Kahnoski, Theresa Nicol, Walter Stadler, Nicholas G. Vogelzang, Robert Amato, David Seligson, Robert Figlin, Arie Belldegrun, Craig G. Rogers and Bin Tean Teh : A Molecular Classification of Papillary Renal Cell Carcinoma, Cancer Research, Vol.65, No.13, 5628-5637, 2005. (Summary) Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphologic classification of PRCC into type 1 and 2 tumors has been recently proposed, but its biological relevance remains uncertain. We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analyses. Comparative genomic microarray analysis was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples with 15 independent tumors. We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histologic subtypes: type 1, low-grade type 2, and mixed type 1/low-grade type 2 tumors. The second class, with poor survival, corresponded to high-grade type 2 tumors (n = 11). Dysregulation of G1-S and G2-M checkpoint genes were found in class 1 and 2 tumors, respectively, alongside characteristic chromosomal aberrations. We identified a seven-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in class 1 tumors and of topoisomerase IIalpha in class 2 tumors. We report two molecular subclasses of PRCC, which are biologically and clinically distinct and may be readily distinguished in a clinical setting. (Keyword) Adult / Aged / Carcinoma, Papillary / Carcinoma, Renal Cell / Chromosome Aberrations / Female / Gene Expression Profiling / Humans / Immunohistochemistry / Kidney Neoplasms / Male / Middle Aged / Oligonucleotide Array Sequence Analysis (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-05-0533 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15994935 ● Search Scopus @ Elsevier (PMID): 15994935 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-05-0533 (DOI: 10.1158/0008-5472.CAN-05-0533, PubMed: 15994935)
74.	Masayuki Takahashi, VERONICA PAPAVERO, JASON YUHAS, ERIC KORT, Hiro-omi Kanayama, Susumu Kagawa, ROBERT C. BAXTER, XIMING J. YANG, STEVEN G. GRAY and BIN TEAN TEH : Altered expression of members of the IGF-axis in clear cell renal cell carcinoma, International Journal of Oncology, Vol.26, No.4, 923-931, 2005. (Summary) Renal cell carcinoma (RCC) is a heterogeneous disease and its biology is poorly understood. The commonest subtype identified is clear cell RCC. The insulin-like growth factor axis is intimately involved with many cellular roles including that of renal development. Dysregulation of this axis has frequently been demonstrated in cancer. In this study, we examine the expression of several IGF-axis components, including receptors, ligands, and binding proteins in clear cell renal cell carcinoma. A series of clear cell RCCs with matched normal kidney from the same individuals were obtained. Total RNA was extracted and expression levels of genes examined using RNase protection analysis. We confirm the dysregulation of the IGF-axis within clear cell renal cell carcinoma including the upregulation of IGFBP-3, which is further validated by immunohistochemical staining on a tissue array containing 50 RCC: positive staining in 29/30 clear cell; 1/10 papillary and 0/10 chromophobe. In addition, we demonstrate that the expression of the A isoform of the insulin receptor is significantly upregulated, while that of IGFBP-5 are significantly downregulated in this tumour subtype. (Keyword) Carcinoma, Renal Cell / Case-Control Studies / Down-Regulation / Female / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Insulin-Like Growth Factor Binding Protein 3 / Insulin-Like Growth Factor Binding Protein 5 / Male / RNA / Receptor, Insulin / Ribonucleases / Somatomedins / Up-Regulation (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15753986 ● Summary page in Scopus @ Elsevier: 2-s2.0-22844443822 (PubMed: 15753986, Elsevier: Scopus)
75.	Tomoharu Fukumori, Natsuo Oka, Toshinori Kasai, Tatsunori Tyubachi, Masayuki Takahashi, Masa-aki Nishitani, Susumu Kagawa and Hiro-omi Kanayama : Expression of galectin-3 is Associated With Resistance to Anticancer Drug-Induced Apoptosis in prostate Cancer, The Journal of Urology, Vol.173, No.4, 60, 2005.
76.	Natsuo Oka, Yasuyo Yamamoto, Masayuki Takahashi, Masaaki Nishitani, Hiro-omi Kanayama and Susumu Kagawa : Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer, BJU International, Vol.95, No.4, 660-663, 2005. (Summary) To investigate the relationship between angiopoietin-1 and -2 expression and the clinicopathological variables and clinical outcome in patients with bladder cancer treated by surgical resection, as both have been recently identified as antagonistic angiogenic factors which regulate tumour growth. The expression of angiopoietin-1 and -2 were assessed by immunohistochemistry in tissue sections from 52 transitional cell carcinomas of the bladder (33 grade 1, 15 grade 2, four grade 3, including two associated with carcinoma in situ; 22 were stage Ta, 19 T1 and 11 T2 tumours). Normal bladder specimens were also resected during each operation as controls. The expression angiopoietins were related to the clinicopathological variables of the tumours. Positive immunostaining was detected in 18 samples (35%) for angiopoietin-1 and in 23 (44) for angiopoietin-2. There was no significant difference in survival according to tumour angiopoietin-1 status in the patients, but in contrast the overall survival of patients with angiopoietin-2-positive tumours was significantly lower than for those with angiopoietin-2-negative tumours (P < 0.05). Positive angiopoietin-2 expression was significantly correlated with histological grade (P = 0.026), histological stage (P = 0.009) and poor prognosis (P < 0.05). On multivariate analysis, positive angiopoietin-2 expression was an independent negative predictor for survival (P = 0.042). These results suggest that angiopoietin-2 overexpression is associated with tumour progression, thereby indicating a poor prognosis for some patients treated by surgical resection for bladder carcinoma. (Keyword) Aged / Angiopoietin-1 / Carcinoma, Transitional Cell / Female / Humans / Immunohistochemistry / Male / Middle Aged / Prognosis / Survival Analysis / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1464-410X.2005.05358.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15705099 ● Search Scopus @ Elsevier (PMID): 15705099 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1464-410X.2005.05358.x (DOI: 10.1111/j.1464-410X.2005.05358.x, PubMed: 15705099)
77.	Carola J. Haven, Viive M. Howell, Paul C. H. Eilers, Robert Dunne, Masayuki Takahashi, Marjo van Puijenbroek, Kyle Furge, Job Kievit, Min-Han Tan, Gert Jan Fleuren, Bruce G. Robinson, Leigh W. Delbridge, Jeanette Philips, Anne E. Nelson, Ulf Krause, Henning Dralle, Cuong Hoang-Vu, Oliver Gimm, Hans Morreau, Deborah J. Marsh and Bin T. Teh : Gene Expression of Parathyroid Tumors, --- Molecular Subclassification and Identification of the Potential Malignant Phenotype ---, Cancer Research, Vol.64, No.20, 7405-7411, 2004. (Summary) Parathyroid tumors are heterogeneous, and diagnosis is often difficult using histologic and clinical features. We have undertaken expression profiling of 53 hereditary and sporadic parathyroid tumors to better define the molecular genetics of parathyroid tumors. A class discovery approach identified three distinct groups: (1) predominantly hyperplasia cluster, (2) HRPT2/carcinoma cluster consisting of sporadic carcinomas and benign and malignant tumors from Hyperparathyroidism-Jaw Tumor Syndrome patients, and (3) adenoma cluster consisting mainly of primary adenoma and MEN 1 tumors. Gene sets able to distinguish between the groups were identified and may serve as diagnostic biomarkers. We demonstrated, by both gene and protein expression, that Histone 1 Family 2, amyloid beta precursor protein, and E-cadherin are useful markers for parathyroid carcinoma and suggest that the presence of a HRPT2 mutation, whether germ-line or somatic, strongly influences the expression pattern of these 3 genes. Cluster 2, characterized by HRPT2 mutations, was the most striking, suggesting that parathyroid tumors with somatic HRPT2 mutation or tumors developing on a background of germ-line HRPT2 mutation follow pathways distinct from those involved in mutant MEN 1-related parathyroid tumors. Furthermore, our findings likely preclude an adenoma to carcinoma progression model for parathyroid tumorigenesis outside of the presence of either a germ-line or somatic HRPT2 mutation. These findings provide insights into the molecular pathways involved in parathyroid tumorigenesis and will contribute to a better understanding, diagnosis, and treatment of parathyroid tumors. (Keyword) Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Multigene Family / Neoplasm Proteins / Oligonucleotide Array Sequence Analysis / Parathyroid Neoplasms / Phenotype / Proto-Oncogene Proteins / Up-Regulation (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-04-2063 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15492263 ● Search Scopus @ Elsevier (PMID): 15492263 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-04-2063 (DOI: 10.1158/0008-5472.CAN-04-2063, PubMed: 15492263)
78.	Jun Sugimura, Ximing J. Yang, Maria S. Tretiakova, Masayuki Takahashi, Eric J. Kort, Barbara Fulton, Tomoaki Fujioka, Nicholas J. Vogelzang and Bin Tean Teh : Gene expression profiling of mesoblastic nephroma and Wilms tumors comparison and clinical implications, Urology, Vol.64, No.2, 362-368, 2004. (Summary) To better understand the molecular mechanisms in the tumorigenesis and progression of mesoblastic nephroma (MN), we studied its gene expression profiles. MN is the most common tumor of the neonatal kidney. It occurs in a younger age group than the Wilms tumor (WT). To date, very little is known about the etiology and pathogenesis of MN. Using microarrays containing 22,943 cDNA, we analyzed the expression profiles of MN and compared its expression profiles with those of several other types of kidney tumors, including WT. MN has a distinct molecular signature that clusters close to the WT, suggesting that both types of tumor share some similarity in gene expression and biology. When comparing the two profiles closely, we identified a number of genes that are commonly upregulated in both tumors, including insulin-like growth factor 2, thrombospondin 4, and mesenchyme homeo box 1. We also identified a set of genes that distinguish MN from WT, some of which may underlie the difference in their behaviors and can be used as diagnostic markers. Among this group of genes, topoisomerase II-alpha, highly expressed in WTs, is not overexpressed in MN. Immunohistochemical staining of topoisomerase II-alpha in additional cases of WTs and MNs confirmed this distinction further. The results of our study demonstrated that MN has a distinct gene expression profile and that some of the newly identified genes can be potentially used as novel diagnostic markers. (Keyword) GROWTH-FACTOR-II / MOLECULAR CHARACTERIZATION / breast cancer / CHEMOTHERAPY / FEATURES (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2004.04.052 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15302496 ● Search Scopus @ Elsevier (PMID): 15302496 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2004.04.052 (DOI: 10.1016/j.urology.2004.04.052, PubMed: 15302496)
79.	Kyle A. Furge, Kerry A. Lucas, Masayuki Takahashi, Jun Sugimura, Eric J. Kort, Hiro-omi Kanayama, Susumu Kagawa, Philip Hoekstra, John Curry, Ximing J. Yang and Bin T Teh : Robust Classification of Renal Cell Carcinoma Based on Gene Expression Data and Predicted Cytogenetic Profiles, Cancer Research, Vol.64, No.12, 4117-4121, 2004. (Summary) Renal cell carcinoma (RCC) is a heterogeneous disease that includes several histologically distinct subtypes. The most common RCC subtypes are clear cell, papillary, and chromophobe, and recent gene expression profiling studies suggest that classification of RCC based on transcriptional signatures could be beneficial. Traditionally, however, patterns of chromosomal alterations have been used to assist in the molecular classification of RCC. The purpose of this study was to determine whether it was possible to develop a classification model for the three major RCC subtypes that utilizes gene expression profiles as the bases for both molecular genetic and cytogenetic classification. Gene expression profiles were first used to build an expression-based RCC classifier. The RCC gene expression profiles were then examined for the presence of regional gene expression biases. Regional expression biases are genetic intervals that contain a disproportionate number of genes that are coordinately up- or down-regulated. The presence of a regional gene expression bias often indicates the presence of a chromosomal abnormality. In this study, we demonstrate an expression-based classifier can distinguish between the three most common RCC subtypes in 99% of cases (n = 73). We also demonstrate that detection of regional expression biases accurately identifies cytogenetic features common to RCC. Additionally, the in silico-derived cytogenetic profiles could be used to classify 81% of cases. Taken together, these data demonstrate that it is possible to construct a robust classification model for RCC using both transcriptional and cytogenetic features derived from a gene expression profile. (Keyword) Carcinoma, Renal Cell / Gene Expression Profiling / Humans / Kidney Neoplasms / Oligonucleotide Array Sequence Analysis / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-04-0534 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15205321 ● Search Scopus @ Elsevier (PMID): 15205321 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-04-0534 (DOI: 10.1158/0008-5472.CAN-04-0534, PubMed: 15205321)
80.	Jun Sugimura, Richard S. Foster, Oscar W. Cummings, Eric J. Kort, Masayuki Takahashi, Todd T. Lavery, Kyle A. Furge, Lawrence H. Einhorn and Bin Tean Teh : Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the Testis, Clinical Cancer Research, Vol.10, No.7, 2368-2378, 2004. (Summary) To better understand the molecular mechanisms that underlay the development and progression of nonseminomatous germ cell tumor of testis (NSGCTT) as well as malignant transformation of teratoma and primitive neuroectodermal tumor (PNET). We studied the gene expression profiles of 17 retroperitoneal NSGCTTs (10 yolk sac tumors, 3 embryonal carcinomas, 4 teratomas) and 2 PNETs obtained from patients with two clinical outcomes. Tissue samples were obtained from the Indiana University. One group of NSGCTT and PNET patients developed metastases within 2 years (early-relapse) of initial successful treatment, and the other group developed metastases after 2 years (late-relapse). Gene expression in these groups of patients was quantified using cDNA microarrays and real-time relative quantitative PCR. We demonstrate that the gene expression profiles of these tumors correlate with histological type. In addition, we identify type-specific genes that may serve as novel diagnostic markers. We also identify a gene set that can distinguish between early-relapse and late-relapse yolk sac tumors. The expression differences of these genes may underlie the differences in clinical outcome and drug response of these tumors. This is the first study that used gene expression profiling to examine the molecular characteristics of the NSGCTTs and drug response in early- and late-relapse tumors. These results suggest that two molecularly distinct forms of NSGCTTs exist and that the integration of expression profile data with clinical parameters could enhance the diagnosis and prognosis of NSGCTTs. More importantly, the identified genes provide insight into the molecular mechanisms of aggressive NSGCTTs and suggest intervention strategies. (Keyword) Cell Transformation, Neoplastic / Chromosome Aberrations / DNA, Complementary / Gene Expression Regulation, Neoplastic / Humans / Male / Neoplasm Metastasis / Neoplasms, Germ Cell and Embryonal / Neuroectodermal Tumors, Primitive, Peripheral / Oligonucleotide Array Sequence Analysis / Prognosis / Recurrence / Reverse Transcriptase Polymerase Chain Reaction / Teratoma / Testicular Neoplasms / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1158/1078-0432.CCR-03-0341 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15073113 ● Search Scopus @ Elsevier (PMID): 15073113 ● Search Scopus @ Elsevier (DOI): 10.1158/1078-0432.CCR-03-0341 (DOI: 10.1158/1078-0432.CCR-03-0341, PubMed: 15073113)
81.	Jindong Chen, Weng-Onn Lui, Michele D. Vos, Geoffrey J. Clark, Masayuki Takahashi, Jacqueline Schoumans, Sok Kean Khoo, David Petillo, Todd Lavery, Jun Sugimura, Dewi Astuti, Chun Zhang, Susumu Kagawa, Eamonn R. Maher, Catharina Larsson, Arthur S. Alberts, Hiro-omi Kanayama and Bin Tean Teh : The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas, Cancer Cell, Vol.4, No.5, 405-413, 2003. (Summary) By positional cloning, we identified two breakpoint-spanning genes in a familial clear cell renal cell carcinoma (CCRCC)-associated t(1;3)(q32.1;q13.3): LSAMP and NORE1 (RASSF1 homolog). Both genes are downregulated in 9 of 9 RCC cell lines. While the NORE1A promoter predominantly presents partial methylation in 6 of the cell lines and 17/53 (32%) primary tumors, the LSAMP promoter is completely methylated in 5 of 9 cell lines and in 14/53 (26%) sporadic and 4 familial CCRCCs. Expression of LSAMP and NORE1A proteins in CCRCC cell lines inhibited cell proliferation. These characteristics indicate that LSAMP and NORE1A may represent new candidate tumor suppressors for CCRCC. (Keyword) Adenocarcinoma, Clear Cell / Animals / Base Sequence / Carcinoma, Renal Cell / Cell Adhesion Molecules, Neuronal / Cell Division / Cells, Cultured / Cloning, Molecular / DNA Methylation / GPI-Linked Proteins / Gene Expression Regulation, Neoplastic / Humans / Molecular Sequence Data / Monomeric GTP-Binding Proteins (Link to Publication Site) ● Publication site (DOI): 10.1016/S1535-6108(03)00269-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14667507 ● Search Scopus @ Elsevier (PMID): 14667507 ● Search Scopus @ Elsevier (DOI): 10.1016/S1535-6108(03)00269-1 (DOI: 10.1016/S1535-6108(03)00269-1, PubMed: 14667507)
82.	Masayuki Takahashi, Ximing Yang, Hiro-omi Kanayama, Susumu Kagawa and Bin Teh : Molecular subclassification of kidney tumors and the discovery of new diagnostic markers, Oncogene, Vol.22, No.43, 6810-6818, 2003. (Summary) We analysed the expression profiles of 70 kidney tumors of different histological subtypes to determine if these subgroups can be distinguished by their gene expression profiles, and to gain insights into the molecular mechanisms underlying each subtype. In all, 39 clear cell renal cell carcinomas (RCC), seven primary and one metastatic papillary RCC, six granular RCC from old classification, five chromophobe RCC, five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of the renal pelvis and five Wilms' tumors were compared with noncancerous kidney tissues using microarrays containing 19,968 cDNAs. Based on global gene clustering of 3560 selected cDNAs, we found distinct molecular signatures in clear cell, papillary, chromophobe RCC/oncocytoma, TCC and Wilms' subtypes. The close clustering in each of these subtypes points to different tumorigenic pathways as reflected by their histological characteristics. In the clear cell RCC clustering, two subgroups emerged that correlated with clinical outcomes, confirming the potential use of gene expression signatures as a predictor of survival. In the so-called granular cell RCC (terminology for a subtype that is no longer preferred), none of the six cases clusters together, supporting the current view that they do not represent a single entity. Blinded histological re-evaluation of four cases of 'granular RCC' led to their reassignment to other existing histological subtypes, each compatible with our molecular classification. Finally, we found gene sets specific to each subtype. In order to establish the use of some of these genes as novel subtype markers, we selected four genes and performed immunohistochemical analysis on 40 cases of primary kidney tumors. The results were consistent with the gene expression microarray data: glutathione S-transferase alpha was highly expressed in clear cell RCC, alpha methylacyl racemase in papillary RCC, carbonic anhydrase II in chromophobe RCC and K19 in TCC. In conclusion, we demonstrated that molecular profiles of kidney cancers closely correlated with their histological subtypes. We have also identified in these subtypes differentially expressed genes that could have important diagnostic and therapeutic implications. (Keyword) Carcinoma, Renal Cell / Carcinoma, Transitional Cell / Cluster Analysis / DNA, Complementary / Gene Expression Regulation, Neoplastic / Glutathione Transferase / Humans / Immunohistochemistry / Kidney / Kidney Neoplasms / Multigene Family / Oligonucleotide Array Sequence Analysis / RNA / Tumor Markers, Biological / Wilms Tumor (Link to Publication Site) ● Publication site (DOI): 10.1038/sj.onc.1206869 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14555994 ● Search Scopus @ Elsevier (PMID): 14555994 ● Search Scopus @ Elsevier (DOI): 10.1038/sj.onc.1206869 (DOI: 10.1038/sj.onc.1206869, PubMed: 14555994)
83.	CHAO-NAN QIAN, Masayuki Takahashi, RICHARD J. KAHNOSKI and BIN TEAN TEH : Effect of Sildenafil Citrate on an Orthotopic Prostate Cancer Growth and Metastasis Model, The Journal of Urology, Vol.170, No.3, 994-997, 2003. (Summary) We characterized the effects of sildenafil citrate on the growth and metastasis of human prostate cancer cells in nude mice. The androgen independent human prostate cancer cell line PC-3 was inoculated into the prostate of nude mice to produce orthotopic primary prostate cancers and metastases. Sildenafil citrate gavage was started on day 31 after tumor cell inoculation and given every other day 15 times (30 days). The 7 mice in the low dose group received 25 mg/kg body weight sildenafil citrate per gavage, while the 7 in the high dose group received 50 mg/kg body weight sildenafil citrate and the 9 in the control group received water. Autopsy was performed on day 75 to evaluate primary tumor growth and metastasis. Plasma cyclic guanosine monophosphate concentrations were measured after the single dose of 50 mg/kg sildenafil citrate in the mice. Plasma cyclic guanosine monophosphate concentration increased 4-fold 1 hour after sildenafil citrate administration. The plasma concentration decreased rapidly and returned to normal after 8 hours. There was no significant difference in tumor weight between any of the 3 groups. The number of metastatic lymph nodes correlated significantly with primary tumor weight (p = 0.03) with a correlation coefficient of 0.454 but there was no significant correlation between the number of involved lymph nodes and sildenafil administration. Distant metastases were not significantly promoted by sildenafil administration. Incontinuous oral administration of sildenafil citrate did not promote primary tumor growth and metastasis in an orthotopic prostate cancer model. (Keyword) prostate / prostatic neoplasms / mice, nude / neoplasm metastasis (Link to Publication Site) ● Publication site (DOI): 10.1097/01.ju.0000080321.99119.df (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12913757 ● Search Scopus @ Elsevier (PMID): 12913757 ● Search Scopus @ Elsevier (DOI): 10.1097/01.ju.0000080321.99119.df (DOI: 10.1097/01.ju.0000080321.99119.df, PubMed: 12913757)
84.	Yasushi Kurokawa, Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : Strategy for treating pediatreic urological disease in the department of urology, The Nishinihon Journal of Urology, Vol.65, No.7, 433-436, 2003. (Keyword) strategy for pediatric disease / hypospadias / urethrocutaneous fistula / phimosis / undescended testis (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543025429482496 ● Summary page in Scopus @ Elsevier: 2-s2.0-0042155842 (CiNii: 1572543025429482496, Elsevier: Scopus)
85.	AHMED ANWAR, YASUSHI KUROKAWA, Masayuki Takahashi, YASUYO YAMAMOTO, Hiro-omi Kanayama and Susumu Kagawa : Functional evaluation of one-stage urethroplasty with parameatal foreskin flaps repair of hypospadias using uroflowmetry, International Journal of Urology, Vol.10, No.6, 297-301, 2003. (Summary) Uroflowmetry is a simple, accurate and non-invasive test. In the present study, we aimed to determine the role of uroflowmetry in the evaluation of the functional results of one-stage urethroplasty with parameatal foreskin flaps (OUPF) technique. Twenty-one children who had undergone OUPF repair at our clinic were selected. Selection criteria were that patients were toilet trained and had no fistula. Uroflowmetry was performed using a rotating disk sensor. The maximum flow rate (Qmax) and average flow rate (Qave) were plotted against body surface related flow rate nomograms. The upper 95% tolerance limits for the 5th, 10th, 15th, 20th and 25th percentiles of the normal population were used for comparison. The flow pattern was classified as bell ring, plateau or intermittent. The median age at the first uroflowmetry was 4.7 years (range 2.5-8.6) and the mean postoperative follow-up period was 25 months (range 1-58). Twelve children had Qmax above the 25th, six between the 5th and 25th and three less than the 5th percentiles of the normal population. A normal bell-shaped flow curve was obtained in 17 (80.6%) of the children. Of the three children with Qmax below the 5th percentile, two children had a plateau flow pattern and were found to have a urethal stricture. Dilation was performed successfully, after which the Qmax returned to the normal range and the symptoms disappeared. The OUPF technique provided satisfactory functional results for hypospadias repair. We advocate the use of uroflowmetry for routine postoperative follow-up. (Keyword) hypospadias / uroflowmetry / OUPF (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1442-2042.2003.00636.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12757597 ● Search Scopus @ Elsevier (PMID): 12757597 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1442-2042.2003.00636.x (DOI: 10.1046/j.1442-2042.2003.00636.x, PubMed: 12757597)
86.	Masayuki Takahashi, Jun Sugimura, Ximing Yang, Nicholas Vogelzang, Bin S. Teh, Kyle Furge and Bin T. Teh : Gene Expression Profiling of Renal Cell Carcinoma and Its Implications in Diagnosis, Prognosis, and Therapeutics, Advances in Cancer Research, Vol.89, 157-181, 2003. (Summary) Renal cell carcinoma (RCC) is the 10th most common cancer in the United States. It is a histologically heterogeneous disease with various histologic types being characterized by distinct genetic alterations. This chapter reviews advances in the gene expression profiling of RCC and discusses their clinical implications. Data are promising, and many more RCC-related microarray studies are currently underway or in planning. Undoubtedly these data will have an impact on the diagnosis, prognosis, and treatment of RCCs in the future. Finally, this chapter discusses what additional studies should be performed to help uncover the molecular mechanisms of RCC and to bring this new knowledge into use in the clinical arena. (Keyword) Carcinoma, Renal Cell / Gene Expression Regulation, Neoplastic / Humans / Kidney Neoplasms / Models, Genetic / Oligonucleotide Array Sequence Analysis / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1016/S0065-230X(03)01005-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14587873 ● Search Scopus @ Elsevier (PMID): 14587873 ● Search Scopus @ Elsevier (DOI): 10.1016/S0065-230X(03)01005-4 (DOI: 10.1016/S0065-230X(03)01005-4, PubMed: 14587873)
87.	Masayuki Takahashi, Ximing Yang, Todd Lavery, Susumu Kagawa and Bin Teh : Gene Expression Profiling of Favorable Histology Wilms Tumors and Its Correlation with Clinical Features, Cancer Research, Vol.62, No.22, 6598-6605, 2002. (Summary) The aims of this study were to understand the underlying molecular mechanisms of favorable histology Wilms tumors (WTs) and to classify them based on their molecular signatures. We studied a total of 15 favorable histology WTs using microarrays containing 19,968 cDNAs. First, we found commonly altered genes in WT. A total of 267 cDNAs were significantly overexpressed at least 3-fold in all of the tumors compared with noncancerous kidney and contained known WT-related genes such as IGF II and WT1. The gene with the highest expression change compared with noncancerous kidney was topoisomerase IIalpha. By hierarchical clustering, there was a clear distinction between high-stage and low-stage tumors. A total of 30 cDNAs were found differentially expressed between the high- and low-stage groups. One of them, Stathmin 1, which is involved in the microtubule system, was highly expressed in high-stage tumors compared with the low-stage tumors. The present chemotherapy regimens for WT consist mainly of topoisomerase II inhibitors (i.e., actinomycin D, doxorubicin, and etoposide) and antimicrotubule agents (i.e., vincristine and paclitaxel). Our data suggest that high expression of topoisomerase IIalpha and microtubule-related genes such as tubulin and stathmin 1 may be related to the high chemosensitivity of WT. In addition, retinol-related genes such as CRABP2 and retinol-binding protein 1 were overexpressed in WT, and CRABP2 was more highly expressed in the poor outcome patients, which suggests that retinoid acid may be a potential drug. In summary, our findings suggest that the integration of gene expression data and clinical parameters could aid in detecting aggressive tumors among favorable histology WT and lead to the discovery of new drugs for WT. (Keyword) Antigens, Neoplasm / Carcinoma, Renal Cell / Child, Preschool / Cluster Analysis / DNA Topoisomerases, Type II / DNA-Binding Proteins / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Infant / Insulin-Like Growth Factor II / Kidney Neoplasms / Neoplasm Staging / Oligonucleotide Array Sequence Analysis / Reverse Transcriptase Polymerase Chain Reaction / Treatment Outcome / WT1 Proteins / Wilms Tumor (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12438255 ● Search Scopus @ Elsevier (PMID): 12438255 (PubMed: 12438255)
88.	Yasushi Kurokawa, Hiro-omi Kanayama, Ahmed Anwar, Tomoharu Fukumori, Yasuyo Yamamoto, Masayuki Takahashi, Susumu Kagawa, Yosihide Murakami and Toshiro Terachi : Laparoscopic nephroureterectomy for dysplastic kidney in children: an initial experience, International Journal of Urology, Vol.9, No.11, 613-617, 2002. (Summary) Laparoscopic nephroureterectomy for dysplastic kidney is now becoming a widely accepted procedure. We report here our initial experience with laparoscopic nephroureterectomy in four girls. Between 1993 and 1999, laparoscopic nephroureterectomy was performed in four girls (mean age 5.3 years). Three patients had an ectopic dysplastic kidney with ectopic ureter, and one patient had hydronephrosis with megaureter due to distal ureteral atresia of the upper moiety in a duplicated dysplastic kidney. The transperitoneal approach was used in all cases. Mean operative time was 195 min (range 150-266). Blood loss was minimal. All operations were completed successfully and there were no intraoperative or postoperative complications except for subcutaneous emphysema in one patient (case 4). Postoperative analgesia was used in three patients and administered in the form of diclofenac sodium suppositories 12.5 mg (cases 1 and 2) or acetaminophen suppositories 50 mg (case 3) for 1-2 days. One patient did not require any analgesia (case 4). Oral fluid intake was resumed on the first postoperative day and ambulation began within 1-3 days (mean 1.6, cases 1, 2 and 3) and 6 days (case 4). All children returned to normal activity within 3-6 days of surgery. Mean postoperative hospital stay was 7.3 days. All cases had uneventful courses after discharge. Laparoscopic nephroureterectomy can be performed safely, with minimal postoperative pain, excellent cosmetic results and early ambulation. We advocate the use of laparoscopy for the diagnosis and treatment of dysplastic kidney with ectopic ureter. (Keyword) children / dysplastic kidney / laparoscopic nephroureterectomy (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1442-2042.2002.00534.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12534902 ● Search Scopus @ Elsevier (PMID): 12534902 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1442-2042.2002.00534.x (DOI: 10.1046/j.1442-2042.2002.00534.x, PubMed: 12534902)
89.	Masayuki Takahashi, Natsuo Oka, Takushi Naroda, Hiro-omi Kanayama and Susumu Kagawa : Prognostic Significance of matrix metalloproteinase-2 activation ratio in renal cell carcinoma, International Journal of Urology, Vol.9, No.10, 531-538, 2002. (Summary) Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases. MMP-2 and MMP-9 have been reported to be closely associated with tumor invasion and metastasis in various human carcinomas. Tissue samples were obtained from 57 patients with renal cell carcinoma (RCC) who underwent radical nephrectomy in our hospital. We examined the expression of MMPs by gelatin zymography and assessed correlations with clinico-pathological parameters and clinical outcomes. We detected bands corresponding to MMP-9, proMMP-2 and active MMP-2. The expression of active MMP-2 and MMP-2 activation ratio (active MMP-2/[proMMP-2 and active MMP-2]) were higher in T3 tumors than in T1 and T2 tumors. There were no significant differences in the expression of proMMP-2, active MMP-2 or MMP-9 for any of the clinico-pathological parameters. Patients with high MMP-2 activation ratio or high MMP-9 had significantly worse cause-specific survival. Interestingly, among patients with stage III RCC, those with high MMP-2 activation ratio or high active MMP-2 had significantly worse cause-specific survival. Univariate analysis showed that histological grade (P = 0.0001), histologic type (P = 0.0005), MMP-2 activation ratio (P = 0.0159), stage (P = 0.0001), MMP-9 (P = 0.0316), and T (primary tumor) category of TNM (primary tumor, lymph node, metastasis) classification (P = 0.0021) were significant predictors of clinical outcome. Multivariate analysis showed that only histological grade (P = 0.002) and stage (P = 0.0099) were independently significant predictors of clinical outcome. Activation of MMP-2 appears to play important roles in initiating metastasis, as shown by results obtained with stage III RCC patients. However, further study is needed to confirm this. (Keyword) Adult / Aged / Carcinoma, Renal Cell / Female / Humans / Kidney Neoplasms / Male / Matrix Metalloproteinase 2 / Matrix Metalloproteinases / Middle Aged / Neoplasm Invasiveness / Neoplasm Metastasis / Nephrectomy / Predictive Value of Tests / Prognosis / Survival Analysis / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1442-2042.2002.00516.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12445230 ● Search Scopus @ Elsevier (PMID): 12445230 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1442-2042.2002.00516.x (DOI: 10.1046/j.1442-2042.2002.00516.x, PubMed: 12445230)
90.	Masayuki Takahashi, Daniel R. Rhodes, Kyle A. Furge, Hiro-omi Kanayama, Susumu Kagawa, Brian B. Haab and Bin Tean Teh : Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification, Proceedings of the National Academy of Sciences of the United States of America, Vol.98, No.17, 9754-9759, 2001. (Summary) To better understand the molecular mechanisms that underlie the tumorigenesis and progression of clear cell renal cell carcinoma (ccRCC), we studied the gene expression profiles of 29 ccRCC tumors obtained from patients with diverse clinical outcomes by using 21,632 cDNA microarrays. We identified gene expression alterations that were both common to most of the ccRCC studied and unique to clinical subsets. There was a significant distinction in gene expression profile between patients with a relatively nonaggressive form of the disease [100% survival after 5 years with the majority (15/17 or 88%) having no clinical evidence of metastasis] versus patients with a relatively aggressive form of the disease (average survival time 25.4 months with a 0% 5-year survival rate). Approximately 40 genes most accurately make this distinction, some of which have previously been implicated in tumorigenesis and metastasis. To test the robustness and potential clinical usefulness of this molecular distinction, we simulated its use as a prognostic tool in the clinical setting. In 96% of the ccRCC cases tested, the prediction was compatible with the clinical outcome, exceeding the accuracy of prediction by staging. These results suggest that two molecularly distinct forms of ccRCC exist and that the integration of expression profile data with clinical parameters could serve to enhance the diagnosis and prognosis of ccRCC. Moreover, the identified genes provide insight into the molecular mechanisms of aggressive ccRCC and suggest intervention strategies. (Keyword) Adenocarcinoma, Clear Cell / Carcinoma, Renal Cell / Follow-Up Studies / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Image Processing, Computer-Assisted / Japan / Kidney Neoplasms / Neoplasm Proteins / Oligonucleotide Array Sequence Analysis / Prognosis / Risk / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1073/pnas.171209998 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11493696 ● Search Scopus @ Elsevier (PMID): 11493696 ● Search Scopus @ Elsevier (DOI): 10.1073/pnas.171209998 (DOI: 10.1073/pnas.171209998, PubMed: 11493696)
91.	Natsuo Oka, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : Secondary amyloidosis of the bladder causing macroscopic hematuria, International Journal of Urology, Vol.8, No.6, 330-332, 2001. (Summary) Bladder involvement in amyloidosis is unusual. The case of an 80-year-old man with macroscopic hematuria caused by secondary amyloidosis of the bladder is described. Cystoscopic examination revealed only a diffuse edematous area and bleeding. No tumor-like lesions were identified. Transurethral biopsy revealed amyloid deposits. Macroscopic hematuria disappeared spontaneously after cystoscopy and bladder biopsy. The patient has been followed up without treatment and is currently free of symptoms. (Keyword) Aged / Aged, 80 and over / Amyloidosis / Hematuria / Humans / Male / Urinary Bladder (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1442-2042.2001.00309.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11389752 ● Search Scopus @ Elsevier (PMID): 11389752 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1442-2042.2001.00309.x (DOI: 10.1046/j.1442-2042.2001.00309.x, PubMed: 11389752)
92.	Hiro-omi Kanayama, Weng-Onn Lui, Masayuki Takahashi, Takushi Naroda, Darek Kedra, Fung Ki Wong, Yoko Kuroki, Yutaka Nakahori, Catharina Larsson, Susumu Kagawa and Bin Tean Teh : Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma, Journal of Medical Genetics, Vol.38, No.3, 165-170, 2001. (Summary) Four cases of late onset clear cell renal cell carcinoma (RCC), a case of gastric cancer, and a case of exocrine pancreatic cancer were identified in a Japanese family. In order to elucidate the underlying mechanism for tumorigenesis in this family, extensive genetic studies were performed including routine and spectral karyotyping (SKY), fluorescence in situ hybridisation (FISH), comparative genomic hybridisation (CGH), loss of heterozygosity studies (LOH), and VHL mutation analysis. A germline translocation t(1;3)(q32-q41;q13-q21) was identified by karyotyping in five members of the family including all three RCC cases tested. The translocation was refined to t(1;3)(q32;q13.3) by FISH analysis using locus specific genomic clones, and the two breakpoints were mapped to a 5 cM region in 3q13.3 and a 3.6 cM region in 1q32. Both CGH and allelotyping using microsatellite markers showed loss of the derivative chromosome 3 carrying a 1q segment in the three familial RCCs analysed. Additional chromosomal imbalances were identified by CGH, including amplifications of chromosomes 5 and 7 and loss of 8p and 9. No germline VHL mutation was found but two different somatic mutations, a splice (IVS1-2A>C) and a frameshift (726delG), were identified in two RCCs from the same patient confirming their distinct origin. Taken together, these results firmly support a three step model for tumorigenesis in this family. A constitutional translocation t(1q;3q) increased the susceptibility to loss of the derivative chromosome 3 which is then followed by somatic mutations of the RCC related tumour suppressor gene VHL located in the remaining copy of chromosome 3. (Keyword) familial renal cell carcinoma / translocation / von Hippel-Lindau disease / loss of heterozygosity (Link to Publication Site) ● Publication site (DOI): 10.1136/jmg.38.3.165 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11238683 ● Search Scopus @ Elsevier (PMID): 11238683 ● Search Scopus @ Elsevier (DOI): 10.1136/jmg.38.3.165 (DOI: 10.1136/jmg.38.3.165, PubMed: 11238683)
93.	Yasushi Kurokawa, Ahmed Anwar, Masayuki Takahashi, Lee Kyung Soo, Yasuyo Yamamoto, Hiro-omi Kanayama, Susumu Kagawa, Tohru Inai and Masaharu Kan : De-epithelialized flap for closure of urethrocutaneous fistula after hypospadias repair, Japanese Journal of Pediatric Urology, Vol.10, No.2, 19(129)-23(133), 2001. (Keyword) urethrocutaneous fistula / de-epithelialized flap / hypospadias (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572261550132603776 (CiNii: 1572261550132603776)
94.	Hiro-omi Kanayama, Masayuki Takahashi, Masa-aki Nishitani and Susumu Kagawa : Analysis of serum soluble interferon α/β receptor levels in patients with urological diseases, The Japanese Journal of Urology, Vol.91, No.9, 630-636, 2000. (Summary) (Purpose)In order to define the clinical significance of serum soluble Interferon α/βreceptor(sIFN/α/βR)levels, we determined sIFNα/βR concentrations in serum of patients with urological benign and malignant diseases. (Materials and Methods)Serum sIFNα/βR levels were measured in normal control(n=22), patients with benign diseases(n=50)included urolithiasis(n=16), prostatic hypertrophy(n=13), and malignant diseases included bladder cancer(n=49), renal cell carcinoma(n=30)and prostate cancer(n=36)by the enzyme linked immunosolbent assay(ELISA)using monoclonal and pliyclonal antibodies. The levels of serum sIFNα/βR was correlated with the results of other hematoserological examinations, and clinical or pathological characters of each urological malignancies. (Results)The serum sIFNα/βR levels(pg/ml)of patients with urolithiasis(2,370.6±640.6, p=0.0002), benign prostatic hypertrophy(2,121.1±55.06, p=0.0103), bladder cancer(2,512.3±1,012.3,p=0.0006), renal cell carcinoma(2,686.4±1,510.9, p=0.0046), prostate cancer(3,188.7±1,788.0, P=0.0003)showed significantly higher values than those of controls(1,790.5±346.7). Moreover, we found statistically significant correlations among serum creatinine(Cr)levels and sIFNα/βR levels. However, there were no correlations between the sIFNα/βR levels and clinical stage, or histological grade in the patients with bladder cancer or prostate cancer, whenever the levels of sIFNα/βR were corrected by serum Cr levels. On the other hand, high level of corrected serum sIFNα/βR was observed in patients with high stage or high grade renal cell carcinoma, but not significant statistically. (Conclusion)Elevated serum sIFNα/βR was observed in patients with urological decease. Further examinations should be necessary to determine the clinical usefulness of serum sIFNα/βR. (Keyword) serum soluble Interferon α/β receptor / urological disease / clinical usefulness (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11068427 ● CiNii @ National Institute of Informatics (CRID): 1390001205057788288 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033792143 (PubMed: 11068427, CiNii: 1390001205057788288, Elsevier: Scopus)
95.	K Kanda, Masayuki Takahashi, Yoshihide Murakami, Hiro-omi Kanayama and Susumu Kagawa : The role of the activated form of matrix metalloproteinase-2 in urothelial cancer, BJU International, Vol.86, No.4, 553-557, 2000. (Summary) To investigate the expression of matrix metalloproteinase-2 (MMP-2, reportedly associated with cancer cell invasion and metastasis in many human cancers) in urothelial tumours and thus define its role in this disease. Materials and methods The expression of both the activated form of MMP-2 and total MMP-2 (activated + latent form) was measured using gelatine zymography in tissue obtained surgically from 61 patients with urothelial cancer. The correlation between the level of the activated form of MMP-2 and clinical and histological variables was assessed. The expression of activated and total MMP-2 were significantly higher in invasive tumour tissue and both levels were correlated with histological grade. In particular, the level of activated MMP-2 was more closely correlated than that of total MMP-2 in invasive tumour tissue. Moreover, high levels of activated MMP-2 were strongly associated with shorter disease-specific survival (P = 0.0016). These findings suggest that activated MMP-2 plays a significant role in invasion of urothelial cancer and that the level of activated MMP-2 expression is a useful prognostic indicator. (Keyword) Matrix metalloproteinase-2 / urothelial cancer / gelatine zymography / invasion / prognostic indicator (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1464-410X.2000.00734.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10971291 ● Search Scopus @ Elsevier (PMID): 10971291 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1464-410X.2000.00734.x (DOI: 10.1046/j.1464-410X.2000.00734.x, PubMed: 10971291)
96.	Masayuki Takahashi, Yasushi Kurokawa and Susumu Kagawa : Clinicopathological review of pediatric patients with a undescended testis, Japanese Journal of Pediatric Urology, Vol.9, No.2, 31(115)-39(123), 2000. (Keyword) undescended testis / mean tubular diameter / tubular fertility index (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570291225297161856 (CiNii: 1570291225297161856)

Academic Paper (Unrefereed Paper):

1.	塩﨑啓登, 堀克仁, Yutaro Sasaki, Kei Daizumoto, Tomoya Fukawa, 中西良一, Kunihisa Yamaguchi, Yasuyo Yamamoto, Kazuta Yamashita, Koichi Tomita, Hirofumi Izaki and Masayuki Takahashi : 未固定新鮮凍結遺体を用いたECIRSでの職業被曝低減についての検討, 日本尿路結石症学会学術集会プログラム・抄録集, 80, 2023.
2.	Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 【ここだけは押さえておきたい間質性膀胱炎・膀胱痛症候群診療のポイント】<治療>膀胱水圧拡張術, Japanese Journal of Clinical Urology, Vol.77, No.6, 460-464, 2023.
3.	Kunihisa Yamaguchi, Yutaro Sasaki, Tomoya Fukawa and Masayuki Takahashi : 腎移植後のリンパ漏にリンパ管造成が効果的であった3例, 日本臨床腎移植学会雑誌, Vol.9, No.1, 118-121, 2021.
4.	Masayuki Takahashi and Hiro-omi Kanayama : Injury of spleen, pancreas, and bowel during laparoscopic adrenalectomy or nephrectomy, Japanese Journal of Clinical Urology, Vol.70, No.11, 868-874, 2016. (Keyword) pancreatic injury / 腸管損傷 (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413205799 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390846634843361024 ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413205799 (DOI: 10.11477/mf.1413205799, CiNii: 1390846634843361024)
5.	井内俊輔, Hidehisa Mori, 大豆本圭, 津田恵, Yoshito Kusuhara, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 徳島大学泌尿器科におけるBCG膀胱内注入療法の臨床検討, 泌尿器外科, Vol.28, No.3, 330-331, 2015.
6.	Masahiko Takemura, Hirofumi Izaki, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 子宮頸癌副腎転移との識別が困難であった18F-FDG PET/CT陽性副腎皮質線種の1例, 泌尿紀要, Vol.59, 91-95, 2013.
7.	Tomoharu Fukumori, Shunsuke Furutani, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 泌尿器外科, Vol.27, No.8, 1651-1654, 2012.
8.	Tomoteru Kishimoto, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Susumu Kagawa : 射精障害を契機に発見されたトルコ鞍空洞症を伴う汎下垂体機能低下症の1例, The Japanese Journal of Sexual Medicine, Vol.26, No.1, 21-26, 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543024868809472 (CiNii: 1572543024868809472)
9.	津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : BCG膀胱内注入療法後に生じたReiter症候群の1例, The Nishinihon Journal of Urology, Vol.73, No.10, 559-561, 2011. (Keyword) *BCGワクチン(治療的利用,毒性・副作用) (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-82055207262 (Elsevier: Scopus)
10.	Tomoharu Fukumori, Takahiro Koizumi, 山本洋之, 湯浅明人, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Training system of laparoscopic surgery for young urologists in the university of Tokushima, The Nishinihon Journal of Urology, Vol.72, No.6, 285-288, 2010. (Keyword) laparoscopic surgery / training / 腎臓摘出術 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520009408512732416 ● Summary page in Scopus @ Elsevier: 2-s2.0-77954345645 (CiNii: 1520009408512732416, Elsevier: Scopus)
11.	Hirofumi Izaki, Masayuki Takahashi, Avirmed Shiirevnyamba, Ryuichi Taue, Hiroyuki Furumoto, Yoshimi Bando, Yoshihide Murakami, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : Long-term recurrence-free survivor after laparoscopic removal of solitary adrenal metastasis from endometrial adenocarcinoma., The Journal of Medical Investigation : JMI, Vol.57, No.1-2, 174-177, 2010. (Summary) Solitary adrenal metastasis from endometrial adenocarcinoma is extremely rare. We report herein the case of a laparoscopically resected solitary adrenal metastasis originating from endometrial adenocarcinoma. The patient was a 55-year-old woman who had undergone total abdominal hysterectomy for stage IIIc endometrial carcinoma, followed by 7 courses of adjuvant chemotherapy comprising carboplatin and paclitaxel. However, the patient developed an isolated right adrenal metastasis 15 months postoperatively. The solitary adrenal metastasis (diameter, 5.7 cm) was removed laparoscopically. The patient has now been in good health without recurrence for 5 years and 7 months after laparoscopic surgery. To the best of our knowledge, this is the first case of solitary adrenal metastasis originating from endometrial adenocarcinoma that is controlled for the long term by successful laparoscopic resection. (Keyword) Adenocarcinoma / Adrenal Gland Neoplasms / Endometrial Neoplasms / Female / Humans / Laparoscopy / Middle Aged / Survivors / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 77529 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.57.174 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20299759 ● Search Scopus @ Elsevier (PMID): 20299759 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.57.174 (Tokushima University Institutional Repository: 77529, DOI: 10.2152/jmi.57.174, PubMed: 20299759)
12.	Takahiro Koizumi, Hiroyoshi Nakatsuji, Tomoya Fukawa, Shiirevnyamba Avirmed, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The role of actinin-4 in bladder cancer invasion., Urology, Vol.75, No.2, 357-364, 2009. (Summary) To examine actinin-4 expression levels in bladder cancer, in particular its levels during cellular growth and invasion. Actinin-4 is an actin-binding protein that is associated with cell motility and cancer metastasis. (Keyword) Actinin / Cell Proliferation / Humans / Neoplasm Invasiveness / RNA, Messenger / Tumor Cells, Cultured / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2009.09.037 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19969329 ● Search Scopus @ Elsevier (PMID): 19969329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2009.09.037 (DOI: 10.1016/j.urology.2009.09.037, PubMed: 19969329)

Review, Commentary:

1.	Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 排尿障害・女性泌尿器;Next 10 Years 尿失禁手術で女性の健康長寿を目指す(解説), The Nishinihon Journal of Urology, Vol.85, No.5, 277-283, Jun. 2023. (Summary) 尿失禁は女性の約50%が一生のうちに一度は経験するとされ，その半数は腹圧性尿失禁(SUI: Stress Urinary Incontinence)である．骨盤底筋トレーニングが第一選択であるが，中等症以上や軽症でもQOLが低下している場合には，中部尿道スリング手術(MUS: Mid Urethral Sling)がゴールドスタンダードとなる．MUSには，恥骨後式のTVT(Tension-free vaginal Tape)と経閉鎖孔式のTOT(Transobturator Tape)があり，ともに成功率は高い．手術手技は比較的容易だが，テープ張力の調整は手術の成否に関わり，注意を要する．QOL疾患であり，手術に対する患者の期待も大きく，術前からの適切な症例の選択，十分な説明が必要である．難治性の切迫性尿失禁(UUI: Urge Urinary Incontinence)に対しては，ボツリヌス毒素の膀胱壁内注入療法が2019年より保険適用となった．外来で実施可能であり，安全性も高く，治療成績も良好である．内因性括約筋不全(ISD: Intrinsic Sphincter Deficiency)症例に対する尿道周囲注入術は有効であるが，本邦では使用可能なbulking agent がない．海外で認可されているシリコン粒子やポリアクリルアミドゲル，男性患者に承認がある自己皮下脂肪組織由来再生幹細胞の実用化が期待される．今後10年で尿失禁患者の治療の選択肢が増加し，さらに高齢女性の健康長寿に貢献できることを切に願っている． (Keyword) 女性泌尿器 / 尿失禁手術 (Tokushima University Institutional Repository) ● Metadata: 118514 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050579134193026560 (Tokushima University Institutional Repository: 118514, CiNii: 1050579134193026560)
2.	Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 【ここだけは押さえておきたい間質性膀胱炎・膀胱痛症候群診療のポイント】<治療> 膀胱水圧拡張術(解説), Japanese Journal of Clinical Urology, Vol.77, No.6, 460-464, May 2023. (Keyword) 間質性膀胱炎・膀胱痛症候群 / 膀胱水圧拡張術 (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413207847 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390577519395728512 ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413207847 (DOI: 10.11477/mf.1413207847, CiNii: 1390577519395728512)
3.	Masayuki Takahashi and Hiro-omi Kanayama : 【腎臓症候群(第3版)-その他の腎臓疾患を含めて-】腫瘍性腎疾患腎細胞癌, Nihon Rinsho. Japanese Journal of Clinical Medicine, 340-348, Sep. 2022.
4.	Masayuki Takahashi and Hiro-omi Kanayama : 【高齢者の泌尿器疾患update-病態に基づく診断・治療上の問題点-】高齢者泌尿器疾患の特徴と問題点外科治療の実際と問題点, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.80, No.6, 932-941, Jun. 2022.
5.	Masayuki Takahashi and Hiro-omi Kanayama : 【ここまで進んだ鏡視下手術】泌尿器領域腎・副腎, The Japanese journal of clinical and experimental medicine, Vol.99, No.6, 720-726, Jun. 2022. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520292706214564992 (CiNii: 1520292706214564992)
6.	Masayuki Takahashi and Hiro-omi Kanayama : CHANGING ROLE OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA, The Nishinihon Journal of Urology, Vol.82, No.2, 224-233, Jun. 2020. (Keyword) 転移性腎癌 / 腫瘍縮小腎摘除術 / サイトカイン療法 / 分子標的治療 / 免疫チェックポイント阻害剤 / metastatic renal cell carcinoma / cytoreductive nephrectomy / cytokine therapy / molecular targeted therapy / immune checkpoint inhibitor (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853832939214080 ● Summary page in Scopus @ Elsevier: 2-s2.0-85096340463 (CiNii: 1520853832939214080, Elsevier: Scopus)
7.	Mototsugu Oya, Hiro-omi Kanayama, Norihiko Tsuchiya, Hiroshi Kitamura, Takashi Arakawa and Masayuki Takahashi : 地域包括ケアシステムの中での泌尿器科医のあり方, The Japanese Journal of Urology, Vol.109, No.Suppl, S64-S69, Nov. 2018.
8.	Masayuki Takahashi and Hiro-omi Kanayama : 【腎癌に対する薬物療法-最新エビデンスを実臨床に活かす】腎癌に対する二次薬物療法各薬剤の特徴とその選択指針, Japanese Journal of Clinical Urology, Vol.72, No.1, 26-33, Jan. 2018. (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413206167 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413206167 (DOI: 10.11477/mf.1413206167)
9.	Masayuki Takahashi and Hiro-omi Kanayama : 膀胱尿管逆流症に対する気膀胱下Cohen法の導入時期におけるトラブルシューティング, 泌尿器外科, Vol.30, No.11, 1635-1637, Nov. 2017.
10.	Masayuki Takahashi and Hiro-omi Kanayama : 【まるごと泌尿器がんの化学療法・分子標的療法・免疫療法】腎がんチロシンキナーゼ阻害薬の副作用コントロール, Uro-Lo: 泌尿器Care & Cure, Vol.22, No.5, 556-561, Oct. 2017.
11.	Masayuki Takahashi, Tomoya Fukawa and Hiro-omi Kanayama : 【新腎・泌尿器癌(上)-基礎・臨床研究の進歩-】腎癌腎癌の分子生物学と発癌機序遺伝子異常, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.75, No.6, 39-46, Aug. 2017.
12.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器がん疾患に関する投与のポイント副作用のマネージメント, 腎臓内科・泌尿器科, Vol.4, No.1, 97-108, Jul. 2016.
13.	Masayuki Takahashi and Hiro-omi Kanayama : 【進行性腎細胞癌に対する治療の最前線】高齢に左右される進行性腎癌の治療について, 泌尿器外科, Vol.29, No.6, 985-994, Jun. 2016.
14.	Masayuki Takahashi, Hiro-omi Kanayama and 田岡寛之 : 腎がんに用いる薬 (特集切り取って使える保存版泌尿器科薬剤ノート(2)泌尿器がんの薬), Urological Nursing, Vol.18, No.10, 1056-1060, Oct. 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522262180578132864 (CiNii: 1522262180578132864)
15.	Masayuki Takahashi and Hiro-omi Kanayama : 肺転移 (Topics of RCC : 転移巣に対する治療戦略), Year book of RCC, 65-77, 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1524232505867284864 (CiNii: 1524232505867284864)
16.	Masayuki Takahashi and Hiro-omi Kanayama : Topics of RCC 併存症のある患者に対する分子標的治療糖尿病・代謝障害, Year Book of RCC 2012, 127-136, Dec. 2012. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010381216654592 (CiNii: 1520010381216654592)
17.	Masayuki Takahashi and Hiro-omi Kanayama : 【ナースがかかわる泌尿器がん薬物療法の副作用対策】副作用の予防法と発症時の対応悪心・嘔吐, Vol.17, No.9, 930-931, Sep. 2012.
18.	Masayuki Takahashi and Hiro-omi Kanayama : 【ナースがかかわる泌尿器がん薬物療法の副作用対策】副作用の予防と発症時の対応下痢・便秘, 泌尿器ケア, Vol.17, No.9, 932-933, Sep. 2012.
19.	Masayuki Takahashi and Hiro-omi Kanayama : 【知っておきたい内科症候群】内分泌《性腺の症候群》ミューラー管遺残症候群, 内科, Vol.109, No.6, 1314-1315, Jun. 2012.
20.	Masayuki Takahashi and Hiro-omi Kanayama : 【進行性腎癌の臨床:分子標的治療薬 up-to-date】新規薬物(候補)について, 泌尿器外科, Vol.25, No.5, 1181-1188, May 2012.
21.	Masayuki Takahashi and Hiro-omi Kanayama : 【泌尿器科ベッドサイドマニュアル】全身合併症を有する患者の管理肺疾患の既往を有する患者の管理, 臨床泌尿器科, Vol.66, No.4, 310-315, Apr. 2012.
22.	Masayuki Takahashi and Hiro-omi Kanayama : 【ここが変わった，腎癌診療ガイドライン-改訂版について-】腎癌の手術療法の変遷, 泌尿器外科, Vol.25, No.2, 165-170, Feb. 2012.
23.	Masayuki Takahashi and Hiro-omi Kanayama : 【腎臓症候群(第2版)上-その他の腎臓疾患を含めて-】腫瘍性腎疾患腎細胞癌, Nihon Rinsho. Japanese Journal of Clinical Medicine, 639-645, Jan. 2012.
24.	Masayuki Takahashi and Hiro-omi Kanayama : 【小径腎腫瘍の診断と治療Update】多発小径腎腫瘍の生物学的特徴, Urology View, Vol.8, No.4, 88-93, Jul. 2010. (Keyword) von Hippel-Lindau病(遺伝学)
25.	Masayuki Takahashi and Hiro-omi Kanayama : Gene alterations of renal cell carcinoma, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.68, 17-24, Apr. 2010. (Keyword) 網羅的遺伝子解析 / マイクロアレイ / 予後 / pathway analysis (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521417754981288576 (CiNii: 1521417754981288576)
26.	Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : GENE EXPRESSION PROFILING OF RENAL CELL CARCINOMA, The Nishinihon Journal of Urology, Vol.64, No.12, 679-686, Dec. 2002. (Keyword) マイクロアレイ / 腎細胞癌 / 予後 / cDNA microarray / gene expression profiling / RCC / prognosis (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570572700592871936 (CiNii: 1570572700592871936)

Proceeding of International Conference:

1.	Kei Daizumoto, Naoka Osafune, Kohei Torii, Ryota Nishimura, Hisanori Uehara, Mitsuki Nishiyama, Saki Kobayashi, Yutaro Sasaki, Ryotaro Tomida, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi and Masayuki Takahashi : Deep learning-based depth prediction system for upper tract urothelial carcinoma, the 111th Annual Meeting of the Japanese Urological Association (JUA), PDA-36-05, Yokohama, Apr. 2024. (Keyword) medical image / deep learning
2.	Kei Daizumoto, Naoka Osafune, Kohei Torii, Ryota Nishimura, Hisanori Uehara, Mitsuki Nishiyama, Saki Kobayashi, Yutaro Sasaki, Ryotaro Tomida, Yoshiteru Ueno, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Junya Furukawa : Development of pT classification prediction system in UTUC using deep-learning, 39th Annual European Association of Urology Congress, A0130, Paris, Apr. 2024.
3.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Examination of Mid-Urethral Sling (MUS) for elderly patients over 75 years old, Athens, Oct. 2019.
4.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : The significance of insulin receptor expression to predict the resistance to VEGFR-TKIs and induce PD-L1 expression in advanced clear cell renal cell carcinoma, 2019 ASCO Genitourinary Cancers Symposium, Feb. 2019.
5.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Yoshihiro Tsuruo, Kei Daizumoto and Hidehisa Mori : Usefulness of Fresh Frozen Cadaver and Animal Models for Surgical Training in Laparoscopic Sacrocolpopexy, The 36th World Congress of Endourology, Paris, Sep. 2018.
6.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of the insulin receptor expression changes by the administration of VEGFR-TKI and the resistance to the VEGFR-TKI in clear cell renal cell carcinoma, 113th American Urological Association Annual meeting, May 2018.
7.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : What is an appropriate definition of IPSS resolution that correlates closely with QOL recovery after prostate brachytherapy?, The Journal of Urology, Vol.199, No.4, e274, San Francisco, May 2018. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.juro.2018.02.718 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.juro.2018.02.718 (DOI: 10.1016/j.juro.2018.02.718)
8.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Masayuki Takahashi : Long-term Administration of Mirabegron in the Treatment of Overactive Bladder, 37th Congress of the Societe Internationale d'Urologie, Lisbon, Oct. 2017.
9.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Safety and efficacy of low-dose-rate brachytherapy for localized prostate cancer in elderly patients, Lisbon, Oct. 2017.
10.	T Shintani, K Daizumoto, Tomoya Fukawa, H Nakatsuji, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : HGF-MET-MMP and VEGF-C signaling as a potential target for invasive bladder cancer therapy, 2017 European association of Urology, London, Mar. 2017.
11.	Tomoharu Fukumori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is involved in the progression of castration-resistant prostate cancer through the regulation of tumor invasion, angiogenesis and androgen receptor signaling., 2017 European association of Urology, London, Mar. 2017.
12.	Masayuki Takahashi : Second line treatment for metastatic or unresectable RCC with nivolumab -No-, European Association of Urology 17, Mar. 2017.
13.	Masayuki Takahashi, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of insulin receptor expression with efficacy of axitinib in patients with advanced renal cell carcinoma, 2017 Genitourinary Cancers Symposium, Feb. 2017.
14.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Clinical characteristics differ in ulcerative and non-ulcerative subtypes of interstitial cystitis/ bladder pain syndrome, International Continence Society, Tokyo, Sep. 2016.
15.	Terumichi Shintani, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Low expression of Toll like receptor 4 is associated with squamous differentiation in bladder cancer., The American Urological Association, Inc. 111th Annual Meeting, May 2016.
16.	Tomoharu Fukumori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is implicated in the progression of castration-resistant prostate cancer through the regulation of angiogenesis and androgen receptor signaling., The American Urological Association, Inc. 111th Annual Meeting, San Diego, May 2016.
17.	Yasuyo Yamamoto, Hidehisa Mori, Terumichi Shintani, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Evaluation of Urinary tract inection after mid-urethral sling, International Continence Society, Oct. 2015.
18.	Tomoharu Fukumori, Dondoo Tsogt-Ochir, K Daizumoto, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is a therapeutic target for castration-resistant prostate cancer., The American Urological Association, Inc. 110th Annual Meeting, New Orleans, May 2015.
19.	Masayuki Takahashi : Management of adverse events by sunitinib in patients with renal cell carcinoma, The 12th KUOS Multidisciplinary Conference, Mar. 2014.
20.	Tomoharu Fukumori, Senzaki1 Tomoichi, Fukawa1 Tomoya, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Izaki Horofumi, Masayuki Takahashi and Hiro-omi Kanayama : Long-term outcomes of trimodality therapy with radical transurethral resection of the bladder tumor (TUR-Bt), intra-arterial chemotherapy, and concurrent radiotherapy for locally advanced bladder cancer., 33rd Congress of The Societe Internationale D'Urologie, Sep. 2013.
21.	Masayuki Takahashi, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : THE LOW TRANS-SCROTAL ORCHIDOPEXY FOR UNDESCENDED TESTES, The 32nd Congress of the Société Internationale dUrologie, Oct. 2012.
22.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Clinical significance of neoadjuvant combined androgen blockade before I-125 prostate brachytherapy in patients with localized prostate cancer., 32th Congress of the Societe Internationale dUrologie, Oct. 2012.
23.	Tomokazu Senzaki, Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Predictive factors for urinary morbidity after I-125 prostate brachytherapy, 32th Congress of the Societe Internationale dUrologie, Oct. 2012.
24.	Masayuki Takahashi, Yoshihiko Tomita, Robert Uzzo and Norihiko Tsuchiya : Case discussion 1: renal cell carcinoma, American Urological Association Annnual Meeting, May 2012.
25.	Masayuki Takahashi : Roundtable Discussion: Personalized Therapy for Asian mRCC Patients in Seoul, Japan-Korea Kidney Cancer Collaborative Group, Mar. 2012.
26.	T Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Clinical significance of neoadjuvant combined androgen blockade before I-125 prostate brachytherapy in patients with localized prostate cancer., 32th Congress of the Societe Internationale dUrologie, 2012.
27.	Masahiko Takemura, Hirofumi Izaki, Yasuyo Yamamoto, Masayuki Takahashi, Tomoharu Fukumori, Kunihisa Yamaguchi and Hiro-omi Kanayama : Laparoscopic adrenalectomy for adrenal metastases : Points of controversy, 国際泌尿器科学会ベルリン, Oct. 2011.
28.	Hirofumi Izaki, Masayuki Takahashi, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : The indication and limit of laparoscopic adrenalectomy for pheochromocytoma, 国際泌尿器科学会, Berlin, Oct. 2011.
29.	Yasuyo Yamamoto, Hiro-omi Kanayama, Hirofumi Izaki, Masayuki Takahashi, Masahiko Takemura, Hiroyoshi Nakatsuji and Tomoharu Fukumori : Clinical experience of Interstitial cystitis treated with hydrodistension, 国際泌尿器科学会, Berlin, Oct. 2011.
30.	Masayuki Takahashi, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : A multi-center randomized Phase II study of the second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT®) for prostate cancer with relapse after initial hormonal therapy, 2011 Annual Meeting of American Society of Clinical Oncology, Jun. 2011.
31.	Masayuki Takahashi, Kanayama Hiroomi, Kato Tomoyuki and Tomita Yoshihiko : Role of Neoadjuvant/Adjuvant Targeted Therapy for locally advanced RCC, 25th Anniversary EAU Congress Programme Book, Barcelona, Apr. 2010.

Proceeding of Domestic Conference:

1.	Yasuyo Yamamoto, Yutaro Sasaki, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Junya Furukawa, Kunihisa Yamaguchi and Masayuki Takahashi : 女性膀胱癌患者におけるRARC後のPOP発症を予防する腟再建の工夫, 日本排尿機能学会誌,
2.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Yutaro Sasaki, Masayuki Takahashi, Hiro-omi Kanayama, Kei Daizumoto, Yoshito Kusuhara and Kunihisa Yamaguchi : RASCにおけるPSS(Patient Side Surgeon)の役割, 日本女性骨盤底医学会,
3.	塩﨑啓登, 堀克仁, Yutaro Sasaki, Kei Daizumoto, Kazuta Yamashita, Tomoya Fukawa, 中西良一, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Koichi Tomita : 未固定新鮮凍結遺体を用いたECIRSでの職業被曝低減についての検討, 第33回日本尿路結石学会, Aug. 2024.
4.	Yutaro Sasaki, Ryotaro Tomida, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi, Hiro-omi Kanayama and Koichi Tomita : ロボット支援手術時代においても，腹腔鏡手術の教育・経験の重要性は揺るがない, 第36回日本内視鏡外科学会総会, Dec. 2023.
5.	Keito Shiozaki, 堀克仁, Yutaro Sasaki, Kei Daizumoto, Tomoya Fukawa, 中西良一, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hiro-omi Kanayama and Koichi Tomita : Cadaver surgical trainingにおける内シャント造設の試み, 第53回徳島透析療法研究会, Dec. 2023.
6.	塩﨑啓登, 堀克仁, Yutaro Sasaki, Tomoya Fukawa, 中西良一, 山下太一, Koichi Tomita, 伊﨑博文 and Masayuki Takahashi : 未固定新鮮凍結遺体を用いたECIRSでの職業被曝低減についての検討, 第37回日本泌尿器内視鏡・ロボティクス学会総会, Nov. 2023.
7.	Masayuki Takahashi : 腎癌に対する術後補助療法の現況と実際, 第75回西日本泌尿器科学会総会, Nov. 2023.
8.	Masayuki Takahashi : 腎癌に対する術後補助療法の現況と実際, 西日本泌尿器科学会総会, Nov. 2023.
9.	Masayuki Takahashi, Yutaro Sasaki, 西山美月 and 小林早紀 : 「ワークショップ5: 手術のPitfalls and Tips，共有しませんか?」停留精巣・遊走精巣固定術, 第32回日本小児泌尿器科学会総会・学術集会, Jul. 2023.
10.	Takashi Kaji, Aya Shirakawa, Ayuka Mineda, Atsuko Yoshida, Ken-ichi Suga, Ryuji Nakagawa, Masayuki Takahashi and Takeshi Iwasa : 胎児期の一過性の陰茎先端部の狭窄により片側腎臓の低形成を来した1例, 第32回日本小児泌尿器科学会総会・学術集会, Jul. 2023.
11.	Masayuki Takahashi, Yutaro Sasaki, 西山美月, 小林早紀 and 塩崎啓登 : 膀胱尿管逆流症に対する気膀胱下Cohen法の臨床的検討, 第32回日本小児泌尿器科学会総会・学術集会, Jul. 2023.
12.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 80歳以上の間質性膀胱炎患者に対するDMSO膀胱内注入療法, 日本老年泌尿器科学会誌, May 2023.
13.	Masayuki Takahashi, Yutaro Sasaki and Hiro-omi Kanayama : Key to the success of transvesical laparoscopic cross-trigonal ureteral reimplantation for vesicoureteral reflux, 第110回日本泌尿器科学会総会, Apr. 2023.
14.	Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Approaches for Benign Prostate Hyperplasia with detrusor underactivity, The Japanese Journal of Urology, Apr. 2023. (Keyword) Benign Prostate Hyperplasia / detrusor underactivity
15.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 当院におけるロボット支援下仙骨腟固定術の現況, 骨盤臓器脱手術手技研究会, Mar. 2023.
16.	ISHIHARA Reo, Kei Daizumoto, 堀克仁, Fumiya Kadoriku, Yutaro Sasaki, TOMIDA Ryotaro, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama and Ryota Nishimura : Deep-learningを用いた尿管癌についての検討, 第266会徳島医学会学術集会(令和4年度冬期), No.A-25, 266, Feb. 2023. (Summary) Although diagnostic imaging techniques have evolved in recent years, the accuracy of ureteral cancer detection and depth is still low. In particular, ureteral cancer depth diagnosis technology is important before drug therapy, and its early development is required. In this study, we conducted a pilot study to construct a system to predict the depth of ureteral cancer from CT images using AI (artificial intelligence) based on deep learning (deep learning). Methods: We evaluated the learning rate of the system by classifying CT images of 30 cases of lower ureteral cancer out of 157 cases of ureteral cancer treated by total nephroureteral resection from 2009 to 2020 at the University of Tokushima Hospital. The location of cancer was determined by comparing the location of cancer in the macro image of the resected specimen with the location of cancer in the CT image, and each CT slice was classified as "containing cancer" or "not containing cancer". The correct rate of lower ureteral cancer determination in CT images by the AI was 99.94% when tested with trained data at the time of 100 training cycles, and 99.15% when tested with un-trained data. No over-learning was observed in this study. [Conclusion] We evaluated lower ureteral cancer in CT images using AI. It was considered possible to learn to determine the presence or absence of cancer from CT images in this setting. In the future, we will use AI to identify the location and predict the depth of ureteral cancer from CT images, and aim to establish an evaluation model that can be applied in actual clinical practice.
17.	Masayuki Takahashi and Hiro-omi Kanayama : 進行性腎細胞癌に対する薬物療法のNext 10 Years, 第74回西日本泌尿器科学会, Nov. 2022.
18.	Masayuki Takahashi, Kei Daizumoto, 福田喬太郎, 安宅祐一朗, 泉和良, Yoshito Kusuhara, Tomoya Fukawa and Hiro-omi Kanayama : 進行性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の検討: 多施設共同後ろ向き研究, 日本泌尿器腫瘍学会第8回, Oct. 2022.
19.	Masayuki Takahashi and Hiro-omi Kanayama : Current sequential therapy for advanced non-clear renal cell carcinoma, 第60回日本癌治療学会, Oct. 2022.
20.	Yutaro Sasaki, 小林早紀, Keito Shiozaki, Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 小児精巣腫瘍の1例, 日本小児泌尿器科学会総会・学術集会, Jul. 2022.
21.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshiteru Ueno, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 女性神経因性膀胱患者に対するボツリヌス毒素膀胱壁内注入療法の経験, 日本女性骨盤底医学会, Jul. 2022. (Keyword) female / 神経因性膀胱 / ボツリヌス毒素膀胱壁内注入療法
22.	堀克仁, Yutaro Sasaki, 角陸文哉, Keito Shiozaki, Kei Daizumoto, 冨田諒太郎, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 当院での未固定遺体を用いた内シャント造設術トレーニングの試み ∼生体との違いについて∼, 日本泌尿器科学会四国地方会, Jul. 2022.
23.	Yutaro Sasaki, 堀克仁, 角陸文哉, Kei Daizumoto, 上野恵輝, 冨田諒太郎, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 多診療科で行うロボット支援手術 ∼後方骨盤内臓全摘除術の1例∼, 日本泌尿器科学会四国地方会, Jul. 2022.
24.	Masayuki Takahashi : 進行性腎細胞癌に対する二次治療の変遷と現状, 第37回腎移植・血管外科研究会, Jun. 2022.
25.	Yasuyo Yamamoto, Megumi Tsuda, 安宅真利花, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 当院における難治性過活動膀胱に対するボツリヌス毒素膀胱壁内注入療法の臨床的検討, 日本老年泌尿器科学会誌, Vol.35, No.1, 144, Jun. 2022. (Keyword) 難治性過活動膀胱 / ボツリヌス毒素膀胱壁内注入療法
26.	Yutaro Sasaki, 橋本啓佑, Keito Shiozaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 女性のRARCにおける膣再建の新たな手法 ∼Benz closure technique∼, 泌尿器科再建再生研究会, Jun. 2022.
27.	橋本啓佑, Yutaro Sasaki, 安宅真利花, 多田航生, 中西亮太, 吉岡拓哉, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援体腔内回腸導管造設術においてストマ造設を円滑に行うための工夫, 日本ロボット外科学会学術集会, Feb. 2022.
28.	Masayuki Takahashi : 進行性腎細胞癌に対する一次治療の選択と副作用マネージメント, 第203回日本泌尿器科学会信州地方会, Feb. 2022.
29.	Yutaro Sasaki, 福田喬太郎, Kei Daizumoto, Keito Shiozaki, Yoshito Kusuhara, Tomoya Fukawa, 中西良一, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, 神田和哉 and Hiro-omi Kanayama : 高齢患者(≧75歳)のロボット支援膀胱全摘除術における体腔内回腸導管造設術と尿管皮膚瘻造設術の比較, 日本泌尿器科学会総会, Dec. 2021.
30.	Yutaro Sasaki, Hirofumi Izaki, Masayuki Takahashi, 神田和哉 and Hiro-omi Kanayama : ICUDによる回腸導管造設術のピットフォール:回避するためにはPatient side surgeonの役割が重要である, 日本泌尿器科学会総会, Dec. 2021.
31.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 当院における外来排尿自立指導の臨床的検討, The Japanese Journal of Urology, Dec. 2021.
32.	Masayuki Takahashi : 腎癌に対する薬物療法の副作用マネージメントと今後の治療アルゴリズムの展望, 第109回日本泌尿器科学会総会, Dec. 2021.
33.	Masayuki Takahashi and Hiro-omi Kanayama : 転移性腎細胞癌に対し，術前薬物療法が優先される, 第109回日本泌尿器科学会総会, Dec. 2021.
34.	Yutaro Sasaki, Kei Daizumoto, Keito Shiozaki, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, 神田和哉 and Hiro-omi Kanayama : 「アシステントガイド」の開発体腔内回腸導管造設時の尿管ステント留置を円滑に, 日本泌尿器内視鏡学会総会, Nov. 2021.
35.	Masayuki Takahashi : 転移性腎細胞癌に対する Pembrolizumab+Axitinibの選択とその役割について, 第73回西日本泌尿器科学会総会, Nov. 2021.
36.	Masayuki Takahashi : 小児泌尿器疾患に対する腹腔鏡手術, 第73回西日本泌尿器科学会総会, Nov. 2021.
37.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 憩室口が遠位に存在する尿道憩室摘除術における工夫, The Nishinihon Journal of Urology, Vol.83, Nov. 2021.
38.	Yasuyo Yamamoto, Kei Daizumoto, Yutaro Sasaki, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 夜間頻尿に対するデスモプレシンの使用経験, 日本排尿機能学会誌, Vol.32, No.1, Sep. 2021.
39.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱に対し膣閉鎖術を行った症例の検討, 日本女性骨盤底医学会, Jul. 2021.
40.	Masayuki Takahashi : IO併用療法後の2nd-lineの選択について, 第51回腎癌研究会, Jul. 2021.
41.	Yutaro Sasaki, 小林早紀, Keito Shiozaki, Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 会陰部異所性精巣の2例, 日本小児泌尿器科学会総会・学術集会, Jul. 2021.
42.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 難治性過活動膀胱に対するボツリヌス毒素膀胱壁内注入療法の初期治療経験, 日本老年泌尿器科学会誌, Vol.34, No.1, 109, May 2021.
43.	Masayuki Takahashi, Yoshito Kusuhara, Yutaro Sasaki, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : ロボット支援下腎盂形成術-温故創新成人水腎症に対するロボット支援腎盂形成術の初期経験, 第33回日本内視鏡外科学会総会, Mar. 2021.
44.	Yasuyo Yamamoto, Tomoya Fukawa, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱患者に対する腹腔鏡下仙骨腟固定術前の下部尿路症状の変化, 第33回日本内視鏡外科学会総会, Mar. 2021.
45.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Tomoya Fukawa and Yoshito Kusuhara : 腎移植後のリンパ漏にリンパ管造影が効果的であった3例, 日本臨床腎移植学会, Feb. 2021.
46.	Masayuki Takahashi : 進行性腎細胞癌に対する一次治療の新たな展開, 第108回日本泌尿器科学会総会, Dec. 2020.
47.	Masayuki Takahashi, Tetsuhiro Yano, Kei Daizumoto, Yutaroh Sasaki, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : 転移性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の初期経験, 第108回日本泌尿器科学会総会, Dec. 2020.
48.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 腹腔鏡下仙骨腟固定術前後で比較した下部尿路機能症状とQOLの変化, 第108回日本泌尿器科学会総会, Dec. 2020.
49.	Masayuki Takahashi and Hiro-omi Kanayama : 転移性腎癌の治療 Cytoreductive nephrectomyの適応とタイミング, 第72回西日本泌尿器科学会総会, Nov. 2020.
50.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱患者に対する腹腔鏡下仙骨腟固定術前後での下部尿路症状の変化, 第82回西日本泌尿器科学会総会, Nov. 2020.
51.	Masayuki Takahashi : 進行性腎細胞癌に対する一次治療の新たな展開, 令和2年度福岡泌尿器科医会, Oct. 2020.
52.	Masayuki Takahashi : Oligomets泌尿器がんへの治療戦略, 日本泌尿器腫瘍学会第六回学術集会, Oct. 2020.
53.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : TOT手術時のヘガールを用いたテープ調整の有用性, 第27回日本排尿機能学会, Oct. 2020.
54.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa and Hiro-omi Kanayama : 転移性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の初期経験, 第24回日本がん分子標的治療学会学術集会, Oct. 2020.
55.	Kei Daizumoto, Yayoi Fukuhara, Tomoya Fukawa, Toyomasa Katagiri, Hisanori Uehara, Masayuki Takahashi and Hiro-omi Kanayama : 尿路上皮癌に対するDDX31/NCL相互作用阻害による抗腫瘍効果の検討, 第79回日本癌学会学術総会, Oct. 2020.
56.	尾崎啓介, Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi and Tomoya Fukawa : -, Journal of Japanese Society for Dialysis Therapy, Vol.53, 813, Oct. 2020.
57.	Megumi Tsuda, Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器科疾患以外の患者に対する排尿ケアチーム介入の臨床的検討, 第33回日本老年泌尿器科学会総会, Sep. 2020.
58.	Masayuki Takahashi : 進行性腎細胞癌に対する一次治療の新たな展開, 第33回日本老年泌尿器科学会総会, Sep. 2020.
59.	Masayuki Takahashi : 腎癌薬物療法のこれまでと今後の展望, 第33回日本泌尿器内視鏡学会総会, Nov. 2019.
60.	Masayuki Takahashi : 進行性腎細胞癌に対するこれまでの外科的アプローチは妥当か? 薬物療法の中心的な役割の再考, 日本泌尿器腫瘍学会第5回学術集会, Oct. 2019.
61.	Masayuki Takahashi, Kei Daizumoto, 佐々木雄太郎, 尾﨑啓介, 上野恵輝, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Case report of four patients with metastatic renal cell carcinoma who received nivolumab and ipilimumab combination therapy, Oct. 2019.
62.	Yasuyo Yamamoto, Tomoya Fukawa, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : RARPにおける術前残尿量と術後尿禁制の関連, 第26回日本排尿機能学会, Sep. 2019.
63.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱と膀胱憩室を同時に治療した1例, 第21回女性骨盤底医学会, Jul. 2019.
64.	Masayuki Takahashi, Kei Daizumoto, 尾﨑啓介, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 高齢腎癌患者に対する根治的腎摘除術/腎部分切除術の臨床的検討, 第50回腎癌研究会記念大会, Jul. 2019.
65.	Masayuki Takahashi, 佐々木雄太郎, 須藤泰史 and Hiro-omi Kanayama : 膀胱尿管逆流症術後にアセトアミノフェンにて急性腎不全，麻痺性イレウスをきたした1例, 第28回日本小児泌尿器科学会総会, Jul. 2019.
66.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Megumi Tsuda, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 排尿ケアチームが複数回介入した症例の検討, The Japanese Journal of Urology, Apr. 2019.
67.	Masayuki Takahashi, 西山美月, 福田喬太郎, Kei Daizumoto, 尾﨑啓介, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 小児膀胱尿管逆流症に対する気膀胱下Cohen法の初期治療経験, 第107回日本泌尿器科学会総会, Apr. 2019.
68.	Masayuki Takahashi : 腎癌，膀胱癌の診断と最新治療, 平成30年度徳島臨床細胞学会総会ならびに学術集会, Mar. 2019.
69.	尾崎啓介, Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi and Tomoya Fukawa : -, 日本臨床腎移植学会抄録集, 249, Feb. 2019.
70.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Yoshihiro Tsuruo : 腹腔鏡下仙骨膣固定術(LSC: Laparoscopic Sacrocollpopexy)導入にむけたトレーニング, 第31回日本内視鏡外科学会, Dec. 2018.
71.	Masayuki Takahashi : 腎癌・膀胱癌, 徳島県がん登録研修会, Dec. 2018.
72.	Masayuki Takahashi : 進行性尿路上皮癌に対する薬物療法のこれまでと今後, 第70回西日本泌尿器科学会総会, Nov. 2018.
73.	Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Kei Daizumoto, Yoshito Kusuhara and Hidehisa Mori : 排尿ケアチーム設立時の現況と課題, 第70回西日本泌尿器科学会総会, Nov. 2018.
74.	Masayuki Takahashi, Kei Daizumoto, Ozaki Keisuke, Tsuda Megumi, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Clinicopathological study of the elderly patients with renal cell carcinoma who underwent radical/partial nephrectomy, 第56回日本癌治療学会学術集会, Oct. 2018.
75.	Masayuki Takahashi : 有転移腎癌1st line治療におけるTKIの今後の役割を再考する, 第83回日本泌尿器科学会東部総会, Oct. 2018.
76.	Masayuki Takahashi, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : CAPDカテーテル大網嵌入に対し腹腔鏡下に大網除去，カテーテル腹壁固定した小児の1症例, 第24回腹膜透析医学会学術集会・総会, Oct. 2018.
77.	Masayuki Takahashi : 進行性腎細胞癌に対するこれまでの薬物療法と今後の治療選択, 第6回泌尿器画像診断・治療技術研究会, Sep. 2018.
78.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Minoru Kowada, Yoshimi Bando, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : The significance of insulin receptor expression in vascular endothelial cells of clear cell renal cell carcinoma, 第77回日本癌学会学術集会, Sep. 2018.
79.	Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 排尿ケアチーム設立時の現況と課題, 第25回日本排尿機能学会, Sep. 2018.
80.	Masayuki Takahashi : 腎がんはどのように見つかりますか?, 腎癌研究会第11回市民公開講座, Sep. 2018.
81.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器科領域でのロボット手術の経験, 第18回日本VR医学会学術大会, Sep. 2018.
82.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Yasuyo Yamamoto and Tomoya Fukawa : タクロリムスの血中濃度上昇に術後疼痛に対するフェンタニルの影響が示唆された3例, Japanese Journal of Transplantation, Vol.53, 479, Sep. 2018.
83.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Yoshihiro Tsuruo : 腹腔鏡下仙骨膣固定術導入にむけたトレーニング, 第20回日本女性骨盤底医学会, Jul. 2018.
84.	Masayuki Takahashi, Kei Daizumoto, Keisuke Ozaki, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : ニボルマブ投与中にhyper-progressionが疑われた淡明細胞型腎細胞癌の1例, 第49回腎癌研究会, Jul. 2018.
85.	Masayuki Takahashi, Keisuke Ozaki, Yoshito Kusuhara, 福田喬太郎, 西山美月, Kei Daizumoto, Megumi Tsuda, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 高齢の腎癌患者に対する手術, 第31回日本老年泌尿器科学会, May 2018.
86.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT術後の過活動膀胱(OAB)治療に関する検討, 第106回日本泌尿器科学会総会, Apr. 2018.
87.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : IPSS resolution, Apr. 2018.
88.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of the insulin receptor expression changes by the administration of VEGFR-TKI and the resistance to the VEGFR-TKI in clear cell renal cell carcinoma, 第106回日本泌尿器科学会総会, Apr. 2018.
89.	Masayuki Takahashi : 排尿障害の見方と治療, 名西郡医師会訪問看護ステーション講演会, Mar. 2018.
90.	Kei Daizumoto, Masayuki Takahashi, Taishi Miyazaki, Yayoi Fukuhara, Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : 淡明細胞型腎細胞癌・周囲血管におけるインスリンレセプターの発現とVEGFR阻害薬の治療効果との関連性, The 27th Japanese Society for Mollecular and Cellular Urology, Feb. 2018.
91.	Masayuki Takahashi : 筋層非浸潤性膀胱癌の診断と治療, 第67回日本泌尿器科学会中部総会, Nov. 2017.
92.	Masayuki Takahashi, 大豆本圭, 尾崎啓介, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 新規導入施設における気膀胱下Cohen法の問題点と工夫, 第31回日本泌尿器内視鏡学会総会, Nov. 2017.
93.	Masayuki Takahashi, 大豆本圭, 尾崎啓介, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : アキシチニブ抵抗性バイオマーカーとしての腎癌組織中インスリンレセプター発現, 第55回日本癌治療学会学術集会, Oct. 2017.
94.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 高リスク限局性前立腺癌に対する I-125 密封小線源療法の治療成績と生化学的再発予測因子の検討, 第55回日本癌治療学会学術集会, Oct. 2017.
95.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT術後の過活動膀胱(OAB)治療に関する検討, 第24回日本排尿機能学会, Sep. 2017.
96.	Masayuki Takahashi : IO Drug導入後の転移性腎細胞癌に対する逐次療法を考える, 第82回日本泌尿器科学会東部総会, Sep. 2017.
97.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Tomoharu Fukumori and Yasuyo Yamamoto : 徳島大学における腎移植後サイトメガロウイルス感染に関する検討, The Nishinihon Journal of Urology, Vol.79, No.6, 203, Jun. 2017.
98.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 排尿障害から診断を得た多系統萎縮症症例, The Japanese Journal of Urology, Apr. 2017.
99.	Kei Daizumoto, Yuichiro Atagi, Chizuru Kotoh, Minoru Kowada, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援前立腺全摘術後の尿失禁と内閉鎖筋体積の関連性の検討, The 105th Annual Meeting of the Japanese Urological Association, Apr. 2017.
100.	Masayuki Takahashi, 安宅祐一郎, 宇都宮聖也, 大豆本圭, 津田恵, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : アキシチニブ投与患者における腎癌組織中のインスリンレセプター発現のバイオマーカーとしての意義, 第105回日本泌尿器科学会総会, Apr. 2017.
101.	Tomoharu Fukumori, Tomoya Fukawa, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : The mechanism of tumor progression in prostate cancer by galectin-3 based on the gene profile, 第105回日本泌尿器科学会総会, Apr. 2017.
102.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Tomoharu Fukumori, Masayuki Takahashi and Yasuyo Yamamoto : 当院における腎移植後サイトメガロウイルス感染の検討, 臨床腎移植学会総会, Feb. 2017.
103.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 地方での泌尿器科医療の魅力を上げるには?四国内でのsubspecialty獲得への大学を超えた連携の提言, 第100回四国地方会, Vol.79, No.6, 202, Jan. 2017.
104.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Hidehisa Mori, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 麻酔下膀胱水圧拡張術を施行した間質性膀胱炎の検討, 第16回間質性膀胱炎研究会, Jan. 2017.
105.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 当院で加療した高齢者陰唇癒着症の検討, 第23回日本排尿機能学会, Dec. 2016.
106.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT手術後に再手術を施行した3症例, 第68回西日本泌尿器科学会総会, Nov. 2016.
107.	Tomoharu Fukumori, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Tomoharu Fukumori : ロボット支援手術でのシステムトラブルの検討, 第30回日本泌尿器内視鏡学会, Nov. 2016.
108.	Masayuki Takahashi and Hiro-omi Kanayama : 小児腹腔内精巣どう扱うか? 腹腔内精巣に対する腹腔鏡下二期的Fowler-Stephens法, 第30回日本泌尿器内視鏡学会総会, Nov. 2016.
109.	Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : I-125, 第54回癌治療学会学術集会, Oct. 2016.
110.	Masayuki Takahashi, 大豆本圭, Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : 腎がん分子標的治療の解析進行性腎細胞癌におけるアキシチニブの有効性とインスリンレセプター発現の関連性, 第54回日本癌治療学会学術集会, Oct. 2016.
111.	Masayuki Takahashi, 大豆本圭, Yoshito Kusuhara, Tomoharu Fukumori and Hiro-omi Kanayama : 進行性腎細胞癌におけるアキシチニブの腫瘍縮小率と生存期間の関連性の検討, 第47回腎癌研究会, Jul. 2016.
112.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 小児膀胱尿管逆流症に対する気膀胱下Cohen法の初期経験, 第25回日本小児泌尿器科学会総会・学術集会, Jun. 2016.
113.	Tomoharu Fukumori, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Terumichi Shintani, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 去勢抵抗性前立腺癌患者に対する新規薬剤(アビラテロン，エンザルタミド)の初期使用経験, 第104回日本泌尿器科学会総会, Apr. 2016.
114.	Tomoharu Fukumori, Tomoya Fukawa, 大豆本圭, 津田恵, 井内俊輔, Yoshito Kusuhara, Hidehisa Mori, Jun-ichiro Kagawa, Masatsugu Komori, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 去勢抵抗性前立腺癌患者におけるエンザルタミドの初期使用経験, 第103回日本泌尿器科学会総会, Apr. 2016.
115.	Masayuki Takahashi and Hiro-omi Kanayama : 最新支持療法から学ぶ，泌尿器癌化学療法を安全に完遂する極意腎癌分子標的薬使用時の支持療法, 第104回日本泌尿器科学会総会, Apr. 2016.
116.	Kunihisa Yamaguchi, Yoshito Kusuhara, Hidehisa Mori, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 生体腎移植後PMLに対しミルタザピンとメフロキンが奏功した1例, 第49回日本臨床腎移植学会, Mar. 2016.
117.	Masayuki Takahashi : 手術の落とし穴ー術前・術中にこれを見落とすな!鏡視下手術における隣接臓器(膵・脾・腸管)の術中損傷回避のためのポイントと対策, 第29回日本泌尿器内視鏡学会総会, Nov. 2015.
118.	Tomoharu Fukumori, Hidehisa Mori, 赤沢早紀, 大豆本圭, 津田恵, Yoshito Kusuhara, Terumichi Shintani, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後のPSA再発予測因子の検討, 第67回西日本泌尿器科学会総会, Nov. 2015.
119.	Kunihisa Yamaguchi, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱全摘+回腸を利用した尿路変更術後のイレウスに対する大建中湯早期内服の有効性の検討, 西日本泌尿器科学会総会, Nov. 2015.
120.	Kunihisa Yamaguchi, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱全摘+回腸を利用した尿路変更術後のイレウスに対する大建中湯早期内服の有効性の検討, 西日本泌尿器科学会総会, Nov. 2015.
121.	Masayuki Takahashi and Hiro-omi Kanayama : 腎細胞癌治療ー手術から薬物療法までー分子標的薬に対し反応性の異なる腎転移に対し転移巣切除術を施行した1例, 第67回西日本泌尿器科学会総会ケーススタディ, Nov. 2015.
122.	Masayuki Takahashi : 転移性腎細胞癌に対する分子標的薬治療法のアプローチー7年間の使用経験を踏まえて腎癌に対する薬物療法の治療アルゴリズムー徳島大学の使用経験を踏まえてー, 第67回西日本泌尿器科学会総会教育セミナー, Nov. 2015.
123.	Masayuki Takahashi and Hiro-omi Kanayama : 小児泌尿器科イノベーションエンドウロロジーの進歩小児に対する腹腔鏡下腎盂形成術, 第67回西日本泌尿器科学会総会, Nov. 2015.
124.	Kunihisa Yamaguchi, Yoshito Kusuhara, Hidehisa Mori, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 生体腎移植御早期に肺非結核性抗酸菌症を発症した1例, Japanese Journal of Transplantation, Vol.50, No.6, 660, Nov. 2015.
125.	Masayuki Takahashi, 赤澤早紀, 大豆本圭, 津田恵, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における進行性腎細胞癌に対するアキシチニブの治療成績, 第53回日本癌治療学会学術総会, Oct. 2015.
126.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 大豆本圭, 津田恵, Yoshito Kusuhara, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : I-125密封小線源療法のPSA再発症例の臨床的検討, 第53回日本癌治療学会学術集会, Oct. 2015.
127.	Tomoharu Fukumori, Hidehisa Mori, 赤沢早紀, 大豆本圭, 津田恵, Yoshito Kusuhara, Terumichi Shintani, Jun-ichiro Kagawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺密封小線源療法後の排尿障害予測因子の検討, 第22回日本排尿機能学会, Sep. 2015.
128.	Yasuyo Yamamoto, Hidehisa Mori, Terumichi Shintani, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 家族性片麻痺性片頭痛が疑われ，間歇的自己導尿を行っている1姉妹例, 第22回日本排尿機能学会, Sep. 2015.
129.	Yasuyo Yamamoto, Hidehisa Mori, Terumichi Shintani, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT手術後の尿路感染症に関する検討, 日本女性骨盤底医学会, Aug. 2015.
130.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 小児泌尿器科医療，こんな局面，あなたならどうする? 低位停留精巣へのアプローチは? 陰嚢切開アプローチ, 第24回日本小児泌尿器科学会総会・学術集会, Jul. 2015.
131.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : CAPDカテーテル大網嵌入に対し腹腔鏡下に大網除去，カテーテル腹壁固定した1例, 第24回日本小児泌尿器科学会総会・学術集会, Jul. 2015.
132.	Yasuyo Yamamoto, Hidehisa Mori, Terumichi Shintani, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 75歳以上の高齢者に対する間欠導尿の導入に関する検討, 第28回日本老年泌尿器科学会, May 2015.
133.	Tomoharu Fukumori, 湊亮詠, 大豆本圭, 井内俊輔, 津田恵, Yoshito Kusuhara, Hidehisa Mori, Jun-ichiro Kagawa, Masatsugu Komori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 去勢抵抗性前立腺癌患者におけるエンザルタミドの初期使用経験, 第103回日本泌尿器科学会, Apr. 2015.
134.	Masayuki Takahashi : 腎細胞癌に対する腎部分切除術の適応 T3a腎癌の部分切除術はするべきではない, 第103回日本泌尿器科学会総会ディベートセッション, Apr. 2015.
135.	Yasuyo Yamamoto, Hidehisa Mori, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 徳島大学病院におけるフェソテロジンの使用経験, 第103回日本泌尿器科学会, Apr. 2015.
136.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Tomoharu Fukumori and Yasuyo Yamamoto : 腎移植におけるHLA one way match症例, Japanese Journal of Transplantation, Vol.49, No.4-5, 378, Nov. 2014.
137.	Masayuki Takahashi, 大豆本圭, Masatsugu Komori, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : ドセタキセル70サイクル以上の投与により長期生存が得られた進行性前立腺癌の2例, 第52回日本癌治療学会学術集会, Aug. 2014.
138.	Hisaya Takahashi, 大豆本圭, Jun-ichiro Kagawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援腹腔鏡下腎部分切除術の初期経験, The Nishinihon Journal of Urology, Vol.76, No.8, 293, Aug. 2014.
139.	Masayuki Takahashi and Hiro-omi Kanayama : 進行性腎細胞癌の集学的治療 ~手術，放射線治療等~, 第102回日本泌尿器科学会総会卒後教育プログラム17, Apr. 2014.
140.	Masayuki Takahashi and Hiro-omi Kanayama : 進行腎がんのsequential therapy 三次治療以降のSequential therapyを考慮した治療戦略, 第102回日本泌尿器科学会総会, Apr. 2014.
141.	大豆本圭, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 両側腎腫瘍症例を発端者としたBirt-Hogg-Dube症候群の一家系, 日本泌尿器科総会, Apr. 2014.
142.	今田久美子, 永井隆, Maki Urushihara, Shuji Kondo, Masayuki Takahashi, 庄野実希, 藤野修司, 山上貴司, 松岡優 and Shoji Kagami : 精神運動発達遅滞と右多趾症を合併した常染色体劣性多発性嚢胞腎(ARPKD)と考えられた1例, 第30回中国四国小児腎臓病学会, Nov. 2013.
143.	Masayuki Takahashi : ディベート 12 2. 腹腔鏡下左腎盂形成術, 第27回日本泌尿器内視鏡学会, Nov. 2013.
144.	Masayuki Takahashi : 有転移腎癌のより良い薬物治療を目指して∼分子標的治療薬を長く投与するための管理と工夫∼, 第65回西日本泌尿器科学会, Nov. 2013.
145.	Masayuki Takahashi, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 分子標的薬投与中に腸管穿孔をおこした有転移腎癌の2例, 第51回日本癌治療学会学術集会, Oct. 2013.
146.	Yasuyo Yamamoto, Tomoharu Fukumori, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺肥大症に伴う蓄尿症状に対するシロドシン単独およびシロドシン・塩酸プロピベリン併用療法の検討, 第20回日本排尿機能学会, Vol.24, No.1, 198, Sep. 2013.
147.	Tomoharu Fukumori, Tomokazu Senzaki, Takashi Kawanaka, Akiko Kubo, Jun-ichiro Kagawa, Masatsugu Komori, Hisaya Takahashi, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対するI-125密封小線源療法のPSA再発予測因子の検討, 第48回日本がん治療学会学術集会, Sep. 2013.
148.	Masayuki Takahashi : 泌尿器がんの薬物療法∼腎がん・前立腺がんを中心に∼, 第247回徳島医学会, Aug. 2013.
149.	Masayuki Takahashi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 分子標的薬投与中に腸管穿孔をきたした2例, 第44回腎癌研究会, Jul. 2013.
150.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 尿管ポリープを伴った間欠性水腎症の1例, 第22回日本小児泌尿器科学会, Jul. 2013.
151.	Masayuki Takahashi : 小児泌尿器科腎疾患の診断と治療, 第7回香川小児腎疾患研究会, May 2013.
152.	Yasuyo Yamamoto, Tomoharu Fukumori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 第25回日本老年泌尿器科学会市民公開講座「おしっこの悩みに答えます∼出ない・漏れる・溜まらない∼」のアンケート結果, 日本老年泌尿器科学会誌, Vol.26, No.1, 88, May 2013.
153.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Masatsugu Komori, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢(75歳以上)前立腺癌の診断および治療戦略を考える∼放射線治療の適応と照射方法∼, 第26回日本老年泌尿器科学会, May 2013.
154.	Masayuki Takahashi and Hiro-omi Kanayama : 新しい治療戦略シリーズ転移を有する腎癌新たな治療薬として何が期待されるか?, 第101回日本泌尿器科学会総会, Apr. 2013.
155.	Tomoharu Fukumori, Jun-ichiro Kagawa, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺肥大症に対するデュタステリド投与1年の臨床的検討∼早期の治療効果について∼, 日本泌尿器科学会総会, Apr. 2013.
156.	Masayuki Takahashi, 小森正嗣, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 小児低形成腎/無機能腎に対する腹腔鏡下腎摘除術の検討, 日本泌尿器内視鏡学会, Nov. 2012.
157.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器癌の薬物療法近未来予測腎細胞癌治療アルゴリズムの近未来予測, 日本泌尿器科学会西日本総会, Nov. 2012.
158.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器癌の薬物療法近未来予測腎細胞癌治療アルゴリズムの近未来予測, 日本泌尿器科学会西日本総会, Nov. 2012.
159.	Tomoharu Fukumori, Tomokazu Senzaki, 小森正嗣, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Efficacy and safety of dose escalation in I-125 prostate, 第26回日本泌尿器内視鏡学会総会, Nov. 2012.
160.	川端留美, 大家真治, Masayuki Takahashi and Hiro-omi Kanayama : Up-regulation of IGFBP3 by 5-FU suppress the growth of androgen-independent human prostate cancer cells, 日本癌学会総会, Sep. 2012.
161.	Masayuki Takahashi and Hiro-omi Kanayama : 腎癌の網羅的遺伝子発現解析, 日本臨床分子形態学会, Sep. 2012.
162.	Hiroyoshi Nakatsuji, アビルメードシーレンヤンバ, Tomoya Fukawa, Masayuki Takahashi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The involvement of Plakophilin in bladder cancer invasion, 日本癌学会総会, Sep. 2012.
163.	Kunihisa Yamaguchi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, 悦子李, 菅政治 and 岡本賢二郎 : 徳島大学における生体腎移植初回例の報告, Japanese Journal of Transplantation, Vol.46, No.6, 696, Aug. 2012. (Keyword) *腎臓移植
164.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 精索静脈瘤手術の臨床的検討, 日本小児泌尿器科学会総会, Jul. 2012.
165.	Masayuki Takahashi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : エベロリムスを投与した進行性/転移性腎腫瘍患者の臨床的検討, 腎癌研究会, Jul. 2012.
166.	Yasuyo Yamamoto, Tomoharu Fukumori, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢者に対する尿失禁手術(TOT手術)の臨床的検討, 日本老年泌尿器科学会, Jun. 2012.
167.	Masayuki Takahashi, 瀬戸公介, 津田恵, Tomokazu Senzaki, 小森政嗣, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 低形成腎/無機能腎に対する腹腔鏡下腎摘除術の臨床的検討, 日本泌尿器科学会総会, Apr. 2012.
168.	Souji Kakiuchi, Masaki Hanibuchi, Hisatsugu Goto, Yuko Toyoda, Atsuro Saijo, Toshifumi Tezuka, Takashige Taoka, Masayuki Takahashi, Hiro-omi Kanayama and Yasuhiko Nishioka : mTOR阻害剤投与症例における間質性肺障害の臨床的特徴, 第109回日本内科学会講演会, Apr. 2012.
169.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後の排尿障害予測因子の検討, 第100回日本泌尿器科学会総会, Apr. 2012.
170.	Tomoharu Fukumori, Shunsuke Furutani, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 第27回前立腺シンポジウム, Dec. 2011.
171.	津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, 岸本大輝, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : MIBG療法を施行した悪性褐色細胞腫の1例, The Nishinihon Journal of Urology, Vol.73, No.9, 503, Nov. 2011. (Keyword) *褐色細胞腫(薬物療法,外科的療法)
172.	Masayuki Takahashi, 辻岡卓也, 中島英, 津田恵, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 進行性腎細胞癌に対する薬物療法いつ，何を，どう使う? 進行性腎癌に対する分子標的薬のsequential therapy, The Nishinihon Journal of Urology, Vol.73, 86, Nov. 2011. (Keyword) *腎細胞癌(薬物療法)
173.	辻岡卓也, 上野恵輝, Masahiko Takemura, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Masa-aki Nishitani : 血液透析患者に対してGemcitabine/Carboplatin併用療法を施行した浸潤性膀胱癌の一例, The Nishinihon Journal of Urology, Vol.73, 127, Nov. 2011. (Keyword) *Carboplatin(治療的利用)
174.	瀬戸公介, Masahiko Takemura, Hirofumi Izaki, 冨田諒太郎, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, Teruyoshi Kageji and Shinji Nagahiro : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, The Nishinihon Journal of Urology, Vol.73, 139, Nov. 2011. (Keyword) *von Hippel-Lindau病(合併症,外科的療法)
175.	Masahiko Takemura, 中島英, 富田諒太郎, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and 三浦浩康 : 不完全重複腎盂尿管に合併した上部尿路結石に対してf-TULを施行した2例, The Nishinihon Journal of Urology, Vol.73, 143, Nov. 2011. (Keyword) *砕石術
176.	Hirofumi Izaki, Masahiko Takemura, Masayuki Takahashi, 中辻弘能, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoya Fukawa, 津田恵, Tomoteru Kishimoto, 上野恵輝, Tomoharu Fukumori, Hiro-omi Kanayama and 三浦浩康 : 徳島大学におけるf-TULの試み導入期に注意したいこと, The Nishinihon Journal of Urology, Vol.73, 143, Nov. 2011. (Keyword) 病的狭窄(治療)
177.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Shunsuke Furutani, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 前立腺密封小線源療法前のcombined androgen blockade(CAB)療法の臨床的検討, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 677, Oct. 2011. (Keyword) *Androgen Antagonists(治療的利用)
178.	Masayuki Takahashi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における進行性/転移性腎腫瘍患者に対するエべロリムスの使用経験, 第49回日本癌治療学会学術集会, Oct. 2011.
179.	柴田恵理子, Kojiro Nagai, Taichi Murakami, 山田諭, Seiji Kishi, Motokazu Matsuura, Hideharu Abe, Toshio Doi, 板東良美, 津田恵, Masayuki Takahashi and Hiro-omi Kanayama : 腎細胞癌に対する受容体チロシンキナーゼ阻害薬Sunitinib投与にてThrombotic microangiopathyを来した一例, 日本腎臓学会雑誌, Vol.53, No.6, 794, Aug. 2011.
180.	Takashige Taoka, Masami Kishi, Akio Takezaki, Katsuhiro Kinoshita, Yuko Toyoda, Souji Kakiuchi, Masaki Hanibuchi, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Yasuhiko Nishioka : 当院におけるmTOR阻害薬投与患者に発症した間質性肺炎の臨床的検討, 第46回日本呼吸器学会中国・四国地方会, Jul. 2011.
181.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 当科における低形成腎/無機能腎に対する腹腔鏡下腎摘除術の臨床的検討, 日本小児泌尿器科学会総会, Jul. 2011.
182.	Yasuyo Yamamoto, 津田恵, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 頻尿・尿失禁を主訴に女性泌尿器科外来を受診した患者の検討, 日本女性骨盤底医学会学術集会, Jul. 2011.
183.	中島英, 上野恵輝, Masahiko Takemura, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Masa-aki Nishitani : 血液透析患者に対してGemcitabine/Carboplatin併用療法を施行した浸潤性膀胱癌の一例, 日本泌尿器科学会四国地方会, Jul. 2011.
184.	冨田諒太郎, Kunihisa Yamaguchi, 上野恵輝, 中島英, 瀬戸公介, 辻岡卓也, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Masahiko Takemura, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 肉眼的血尿から貧血をきたした悪性黒色腫の膀胱転移に対するTURの経験, 日本泌尿器科学会四国地方会, Jul. 2011.
185.	アビルメドシーレンヤンバ, Hiroyoshi Nakatsuji, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : Participation of N-caderin in bladder cancer, 日本泌尿器科学会総会, Apr. 2011.
186.	Masahiko Takemura, 瀬戸公介, 辻岡拓也, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, The Japanese Journal of Urology, Vol.103, No.2, 369, Apr. 2011. (Keyword) *血液透析
187.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 津田恵, Masahiko Takemura, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後のPSA failure 症例の臨床的検討, 日本泌尿器科学会総会, Apr. 2011.
188.	Yasuyo Yamamoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Tomohiko Miyatani and Kyoko Nishi : 徳島大学病院卒後臨床研修センターの取り組み∼若手医師・研修医・医学生への教育から泌尿器科医の増員にむけて, 日本泌尿器科学会総会, Apr. 2011.
189.	Hirofumi Izaki, Masayuki Takahashi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : いかに泌尿器科入局者を増やすか!地方大学の卒前教育の取り組み, 日本泌尿器科学会総会, Apr. 2011.
190.	Hiroyoshi Nakatsuji, シーレンヤンバアビルメド, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : HGFによる膀胱がん浸潤亢進におけるToll like receptor 4 (TLR4) の関与, 日本泌尿器科学会総会, Apr. 2011.
191.	Masayuki Takahashi, Hiroaki Kawano, 村上佳秀, 須藤泰史, 稲井徹, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 去勢抵抗性前立腺癌に対する抗アンドロゲン剤抗体療法とUFT併用療法の有効性と安全性に関する無作為化第Ⅱ相臨床試験, 日本泌尿器科学会総会, Apr. 2011.
192.	Tomoteru Kishimoto, 上野恵輝, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : 非虚血性持続勃起症の1例, 日本性機能学会東部総会, Mar. 2011.
193.	Kunihisa Yamaguchi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori and 金山博文 : 前立腺癌長期分泌療法施行術における治療中止後のPSAおよびテストステロン値の検討, 中国四国前立腺疾患研究会, Feb. 2011.
194.	Hirofumi Izaki, Kunihisa Yamaguchi, Masayuki Takahashi, Tomoharu Fukumori and 金山博文 : 転移性副腎腫瘍に対する腹腔鏡下副腎摘除術の検討, 中国四国泌尿器科悪性腫瘍研究会, Feb. 2011.
195.	Masahiko Takemura, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 2010年徳島大学病院泌尿器科臨床統計, 日本泌尿器科学会四国地方会, Jan. 2011.
196.	上野恵輝, Tomoteru Kishimoto, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 非虚血性持続勃起症の一例, 日本泌尿器科学会四国地方会, Jan. 2011.
197.	Kunihisa Yamaguchi, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, 岸本大輝, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, 須藤泰史, 上間建造, 河野明 and 濱尾巧 : 前立腺癌に対する長期内分泌療法中止に関する検討, 第62回日本泌尿器科学会西日本総会, Nov. 2010. (Keyword) Androgen Antagonists(治療的利用)
198.	Kunihisa Yamaguchi, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, 須藤泰史, 上間建造, 河野明 and 濱尾巧 : 前立腺癌に対する長期内分泌療法中止に関する検討, The Nishinihon Journal of Urology, Vol.72, 113, Nov. 2010. (Keyword) Androgen Antagonists(治療的利用)
199.	津田恵, Tomoteru Kishimoto, Masahiko Takemura, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 射精障害を契機に発見された汎下垂体機能低下症の1例, The Nishinihon Journal of Urology, Vol.72, 121, Nov. 2010. (Keyword) Cortisone(治療的利用)
200.	Yasuyo Yamamoto, 津田恵, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Ryuichi Taue and Masa-aki Nishitani : 徳島大学病院における膀胱水圧拡張術を施行した間質性膀胱炎の検討, The Nishinihon Journal of Urology, Vol.72, 169, Nov. 2010. (Keyword) 拡張法
201.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 二宮郁, 白戸玲臣, 橋根勝義, Shunsuke Furutani, Hitoshi Ikushima, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 早期前立腺がんの治療戦略早期前立腺癌に対する密封小線源療法の臨床的検討, 第48回日本癌治療学会学術集会, Oct. 2010. (Keyword) *近距離照射治療法
202.	Masayuki Takahashi, 川端留美, 河野明, 村上佳秀, 須藤泰史, 稲井徹, 赤澤誠二, 浜尾巧, 林秀樹, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : ホルモン再燃前立腺癌に対する抗アンドロゲン剤交替療法とUFTの併用療法, 第48回日本癌治療学会学術集会, Oct. 2010. (Keyword) *Androgen Antagonists(治療的利用)
203.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 二宮郁, 白戸玲臣, 橋根勝義, 古谷俊介, 生島仁史, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 早期前立腺がんの治療戦略早期前立腺癌に対する密封小線源療法の臨床的検討, The Journal of Japan Society for Cancer Therapy, Vol.45, No.2, 491, Oct. 2010. (Keyword) 近距離照射治療法
204.	Masayuki Takahashi, 川端留美, 河野明, 村上佳秀, 須藤泰史, 稲井徹, 赤澤誠二, 浜尾巧, 林秀樹, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : ホルモン再燃前立腺癌に対する抗アンドロゲン剤交替療法とUFTの併用療法, The Journal of Japan Society for Cancer Therapy, Vol.45, No.2, 595, Oct. 2010.
205.	Masahiko Takemura, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 206, Oct. 2010.
206.	Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 248, Oct. 2010. (Keyword) 血液透析
207.	Tomoteru Kishimoto, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 精嚢嚢胞状拡張を伴った射精管閉塞の1例, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 249, Oct. 2010.
208.	Hirofumi Izaki, Masayuki Takahashi, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : 転移性副腎腫瘍に対する腹腔鏡手術議論のポイント, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 162, Oct. 2010. (Keyword) 腎細胞癌(転移性,外科的療法)
209.	Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, 24 Endourology ESWL, Vol.23, No.3, 248, Oct. 2010. (Keyword) *血液透析
210.	岸本大輝, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 精嚢嚢胞状拡張を伴った射精管閉塞の1例, 24 Endourology ESWL, Oct. 2010. (Keyword) 精嚢
211.	Hiroyoshi Nakatsuji, シーレンヤンバアビルメード, Tomoya Fukawa, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した一例, 日本癌学会学術総会, Sep. 2010.
212.	津田恵, Tomoya Fukawa, Masahiko Takemura, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : BCG膀胱内注入療法後に生じたReiter症候群の1例, 日本泌尿器科学会四国地方会, Jul. 2010.
213.	Masahiko Takemura, 津田恵, Tomoya Fukawa, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, 日本泌尿器科学会四国地方会, Jul. 2010.
214.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した1例, 第19回日本小児泌尿器科学会総会, Jul. 2010.
215.	Hirofumi Izaki, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori, Takushi Naroda, 木内慎一郎, 高橋久弥, 赤沢誠二, Masahiko Takemura, 林秀樹, 水田耕司, 橋本寛文, 榊学, 浜尾巧 and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, Journal of Japanese Society for Dialysis Therapy, Vol.43, No.Suppl.1, 370, Jun. 2010.
216.	寺田知正, Kazuhiro Mori, 西岡理恵, 山上貴司, 松岡優, 村上桂秀, Masayuki Takahashi and Shoji Kagami : 重症尿路感染症の超早期診断における腹部超音波検査の有用性, 第134回日本小児科学会徳島地方会, Jun. 2010.
217.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢者に対する前立腺癌密封小線源療法の臨床的検討, 日本老年泌尿器科学会誌, Vol.23, 75, May 2010. (Keyword) *近距離照射治療法
218.	Masayuki Takahashi, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における80歳以上の腎腫瘍患者の臨床的検討, 第23回日本老年泌尿器科学会, May 2010.
219.	Masayuki Takahashi, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 進行性腎癌に対するNeoadjuvant療法進行性腎癌に対するNeoadjuvant療法のUpdate, The Japanese Journal of Urology, Vol.101, No.2, 152, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205072211840 (CiNii: 1390001205072211840)
220.	Masayuki Takahashi, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : DOUBLE-PHASE HELICAL CTによる腎腫瘍組織型予測, The Japanese Journal of Urology, Vol.101, No.2, 214, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205073840256 (CiNii: 1390001205073840256)
221.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : I-125前立腺癌密封小線源療法後の排尿障害の予測因子の検討, The Japanese Journal of Urology, Vol.101, No.2, 242, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680048519296 (CiNii: 1390282680048519296)
222.	アビルメッドシーレブニヤンバ, Hisanori Uehara, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Keisuke Izumi and Hiro-omi Kanayama : Change of Gene Expressions of Prostate Cancer Cells by Direct Contact with Osteoblasts, The Japanese Journal of Urology, Vol.101, No.2, 369, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205072421504 (CiNii: 1390001205072421504)
223.	Takahiro Koizumi, 山本洋之, 湯浅明人, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 転移を有さない再燃前立腺癌に対する放射線療法の検討, The Japanese Journal of Urology, Vol.101, No.2, 448, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680047830912 (CiNii: 1390282680047830912)
224.	Yasuyo Yamamoto, Tomoharu Fukumori, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Hiro-omi Kanayama, 桜井紀嗣, 稲井徹, 斎木喬 and 上間健造 : 徳島県下の泌尿器科施設における過活動膀胱(OAB)の実態調査, The Japanese Journal of Urology, Vol.101, No.2, 481, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205071964672 (CiNii: 1390001205071964672)
225.	Hiroyoshi Nakatsuji, アビルメッドシーレブニヤンバ, 湯浅明人, 山本洋之, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱癌浸潤におけるプラコフィリン2の関与, The Japanese Journal of Urology, Vol.101, No.2, 527, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680050442240 (CiNii: 1390282680050442240)
226.	松浦里, Ken-ichi Suga, Shuji Kondo, Masayuki Takahashi, 市岡隆男 and Shoji Kagami : 後腹膜鏡下リンパ管遮断術を行った特発性乳び尿の1例, 第113回日本小児科学会学術集会, Apr. 2010.
227.	Hiroyoshi Nakatsuji, Avirmed Shiirevnyamba, 湯浅明人, 山本洋之, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱がん浸潤におけるプラコフィリン2の関与, 泌尿器科分子・細胞研究会, Feb. 2010.
228.	Hiroyoshi Nakatsuji, Avirmed Shiirevnyamba, 山本洋之, 湯浅明人, 布川智也, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱がん浸潤におけるプラコフィリンの関与, 中国四国泌尿器科悪性腫瘍研究会, Feb. 2010.
229.	Takahiro Koizumi, 山本洋之, 湯浅明人, 布川智也, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : ホルモン抵抗性局所進行前立腺癌に対する放射線治療の検討, 中国四国前立腺疾患研究会, Feb. 2010.
230.	山本洋之, Masayuki Takahashi, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した一例, 日本泌尿器科学会四国地方会, Jan. 2010.
231.	湯浅智之, 小畑利之, 矢野聖二, 岡本英治, 西岡安彦, 久保宣明, Masayuki Takahashi, Hiroyoshi Nakatsuji, 長屋寿雄, Hiro-omi Kanayama, Seiji Arase, 曽根三郎 and 蛯名洋介 : 可溶化インスリン受容体細胞外ドメイン(sIR)は癌患者血清中で増加している, 日本分子腫瘍マーカー研究会誌, Vol.25, 53-54, 2010. (Keyword) 腫瘍
232.	Shunsuke Furutani, Hitoshi Ikushima, Seiji Iwamoto, Akiko Kubo, Takashi Kawanaka, Kyosuke Osaki, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Hiromu Nishitani : 膀胱温存を目的とした浸潤性膀胱癌に対するTUR-Bt+動注化学放射線療法の治療成績, 第47回日本癌治療学会学術集会, Oct. 2009.

Products:

1.	Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : A case that suffered an accidental bleeding from a tumor vessel flowing into an inferior vena cava after treating with a sealing device, Audio-Visual Journal of JUA, Vol.Vol.21, No.No.1, Jan. 2015.

Et cetera, Workshop:

1.	Yoshito Kusuhara, 大豆本圭, 尾崎啓介, 津田恵, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援腹腔鏡下腎盂形成術の初期経験, 第26回中国四国前立腺・腎尿路疾患研究会, Mar. 2018.
2.	Terumichi Shintani, Hidehisa Mori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱癌悪性化におけるToll like receptor 4の機能解析, 第25回泌尿器科分子・細胞研究会, Feb. 2016.
3.	Terumichi Shintani, Hidehisa Mori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱癌におけるToll like receptor 4の発現解析, 第67回西日本泌尿器科学会総会, Nov. 2015.
4.	今田久美子, 永井隆, Maki Urushihara, Shuji Kondo, Shoji Kagami, Masayuki Takahashi, 庄野実希, 藤野修司, 山上貴司 and 松岡優 : 精神発達遅滞と右多趾症を合併した常染色体劣性多発性嚢胞腎と考えられた1例, 第141回日本小児科学会徳島地方会, Dec. 2013.
5.	永井隆, Yoshihiro Touda, Hiromichi Ito, Maki Urushihara, Shuji Kondo, Shoji Kagami and Masayuki Takahashi : 末期腎不全をきたし腹膜透析を導入した伊藤白斑の一例, 第140回日本小児科学会徳島地方会, Jun. 2013.
6.	Tomoyuki Yuasa, Seiji Yano, Yasuhiko Nishioka, Yoshiaki Kubo, Masayuki Takahashi, Hiroyoshi Nakatsuji, Hisao Nagaya, Hiro-omi Kanayama, Seiji Arase, Saburo Sone and Yousuke Ebina : Soluble insulin receptor ectodomain in the plasma is a possible broad-spectrum tumor marker, 第68回日本癌学会学術総会記事, 450, Oct. 2009.
7.	Tomoyuki Yuasa, Toshiyuki Obata, Seiji Yano, 岡本英治, Yasuhiko Nishioka, Yoshiaki Kubo, Masayuki Takahashi, Hiroyoshi Nakatsuji, Hisao Nagaya, Hiro-omi Kanayama, Seiji Arase, Saburo Sone and Yousuke Ebina : Soluble insulin receptor ectodomain level was elevated in the plasma of cancer patients, 第29回日本分子腫瘍マーカー研究会プログラム, 70-71, Sep. 2009.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

A randomized controlled trial to verify the synergistic effect of nivolumab and radiotherapy in metastatic renal cell carcinoma (Project/Area Number: 24K02397 )
Mutant p53 - Cancer Immunology Research from the DDX31 axis (Project/Area Number: 23K08758 )
RCC Precision Medicine Project using PDX models (Project/Area Number: 23K08736 )
Elucidation of the molecular mechanism of galectin-3 in the progression of urological cancer (Project/Area Number: 18K09136 )
Elucidation of tumor regulation mechanism of galectin-3 against castration-resistant prostate cancer and clinical application (Project/Area Number: 15K10592 )
The tumor control mechanism of galectin-3 in prostate cancer bone metastasis (Project/Area Number: 24592394 )
Effect of highsalt intake onpenile corpus cavernosum (Project/Area Number: 23659760 )
A study to examine the renal protective effect and the remote effect of ischemic preconditioning for renal ischemia/reperfusion injury (Project/Area Number: 23592380 )
Mechanism of tumor regulation by galactose-binding protein in hormone refractory prostate cancer (Project/Area Number: 21592048 )
The interaction of cancer cell and stromal cell in urinary cancer-The approach of stromal therapy- (Project/Area Number: 21390442 )
The molecular mechanism of Actinin-4 in proliferation, invasion and metastasis of cancer (Project/Area Number: 20591857 )
Application of galectin-3 in combined therapy of urogenital cancer (Project/Area Number: 19591854 )
The tumor control mechanism of galectin-3 in urological cancer invasion and metastasis (Project/Area Number: 18591756 )
Tumor control mechanism of galactoside-binding lectin in metastasis of urogenital cancer (Project/Area Number: 17591681 )
腎細胞癌におけるcDNA microarrayにより得られた予後予測遺伝子群の検定 (Project/Area Number: 15790853 )
Interaction between interstitial and genitourinary cancer cells detected by microarray (Project/Area Number: 15390493 )
Search by Researcher Number (50325255)

Associate Professor : Takahashi, Masayuki

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Products:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)